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3.3 Over-expression and knockdown of LEMD3 using pFLAG-LEMD3-
V5 and siRNA. A and B, representative western blots and quantification
from plasmid over-expression (A) and siRNA knockdown experiments (B).
pFLAG-LEMD3-V5 electroporation significantly increases full length LEMD3
(p=0.0018 for HFF vs. 1 µg pFLAG-LEMD3-V5, p=0.0012 for Neon Only
vs. 1 µg pFLAG-LEMD3-V5, ANOVA with Tukey post-test). siLEMD3
delivered by Lipofectamine 2000 (L2K) significantly decreases LEMD3
expression relative to siGFP control (p=0.0248, Student’s T-test). . . . . . . 88
3.4 LEMD3 negatively regulates Smad3 phosphorylation. A, Phospho-Smad3
to Smad3 ratios were measured by western blot in HFFs on tissue culture
plastic. HFFs treated with 100 pg/mL TGFβ for 90 minutes had an in-
creased pSmad3/Smad3 ratio relative to untreated fibroblasts (p=0.0506).
HFFs treated with 100 pg/mL TGFβ and 25nM or 200nM siRNA against
LEMD3 (“siLEMD3”) had a higher pSmad3/Smad3 ratio than cells treated
with a concentration matched siRNA against GFP (“siGFP”; p=0.1103 and
p=0.0057 for 25nM and 200nM, respectively, Student’s T-test). TGFβ
dosed HFFs electroporated with pFLAG-LEMD3-V5 (“FL-OE”) or pFLAG-
LEMD3p.∆21-669-V5 (“CTF-OE”) had diminished pSmad3/Smad3 ratios
relative to TGFβ treated HFFs (p=0.0124 and p=0.2116 for CTF-OE and
FL-OE, respectively) but were not statistically different from the electroporation-
only (“Neon Only”) control. B, representative blots for Smad2/3 and phospho-
Smad2/3. Smad3 is the lower band at ≈ 50 kDa. . . . . . . . . . . . . . . . 89
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3.5 LEMD3-Smad2/3 interactions are inversely correlated to substrate stiff-
ness and occur in the nucleus and cytoplasm. A, micrographs of LEMD3-
Smad2/3 PLA interactions on soft (top row, 1 kPa) and stiff (bottom row,
25 kPa) matrices (PLA in green, f-actin in blue, nucleus in white). B, quan-
tification of PLA interactions grouped by substrate stiffness and by TGFβ
dose. Total LEMD3-Smad2/3 interactions are negatively correlated to sub-
strate stiffness (p<0.0001 for 1 kPa vs 25 kPa for both 0 pg/mL and 50
pg/mL TGFβ) but are not correlated to TGFβ dose. Cytoplasmic (p=0.0164
for 0 pg/mL TGFβ, p=0.0087 for 50 pg/mL TGFβ) and nuclear compart-
ment (p = 0.0428 for 0 pg/mL TGFβ, p=0.1228 for 50 pg/mL TGFβ) inter-
actions are also negatively correlated to substrate stiffness. C, total HFFs
and CCL210s LEMD3-Smad2/3 interactions by PLA normalized to 0.5 kPa
on surfaces with stiffness of 0.5, 1, 4, 8, 25 kPa and glass. Each fibroblast
population shows a biphasic trend, centered around a peak of LEMD3-
Smad2/3 interactions at 1kPa. CCL210 demonstrate greater dynamic range
in interaction frequency and a slower loss of interactions on stiffer sub-
strates than HFFs. D, subcellular location of LEMD3-Smad2/3 PLA inter-
actions in HFFs and CCL210s from (C). Each cell line demonstrates a cyto-
plasmic shift in location with increasing substrate stiffness (p<0.0001 and
p=0.0199 for HFFs and CCL210s, respectively; ANOVA - Test for trend).
E, micrographs of V5-Smad2/3 PLA interactions with pFLAG-LEMD3-
V5 on soft (top row) and stiff (bottom row) matrices (PLA in green, f-actin
in blue, FLAG in red, nucleus in white). F, V5-Smad2/3 PLA interac-
tions are also negatively correlated with substrate stiffness (for 1 kPa vs 25
kPa: Total PLA - p<0.0001, Cytoplasmic PLA - p<0.0001, Nuclear PLA
- p=0.0018) and also occur in the cytoplasm. G, V5-Smad2/3 PLA interac-
tions are significantly higher on soft substrates independent of the degree
of pFLAG-LEMD3-V5 expression (difference in linear regression slopes
- p<0.0001). All PLA groups were statistically compared using a 2-way
ANOVA with Tukey post-test unless noted. All scale bars are 10 µm. . . . . 90
3.6 LEMD3 binds phospho-Smad2/3 in a stiffness-dependent fashion. PLA
interactions between phospho-Smad2/3 and LEMD3, normalized to HFFs
on glass without TGFβ treatment, are stiffness- and TGFβ dose-dependent.
Fibroblasts on glass treated with 100 pg/mL TGFβ have significantly more
LEMD3-phospho-Smad2/3 interactions than cells without TGFβ treatment.
(p=0.0333, Student’s T-test). There is also a significant decrease in interac-
tions with increasing stiffness (p=0.0305, ANOVA-Test for trends). . . . . . 91
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3.7 Lamin B1-LEMD3 PLA interactions are compartmentalized to the nu-
cleus. To assess whether PLA and our analysis methods could localize
interactions to particular subcellular compartments, we performed PLA be-
tween lamin B1, an integral element of the nuclear lamina, and LEMD3 on
glass. A, micrographs of PLA interactions between lamin B1 and LEMD3.
B, quantification of the subcellular (nuclear) localization of these interac-
tions per cell. Across all biological replicates, 94.34 ± 0.005% of all lamin
B1-LEMD3 interactions were compartmentalized to the nucleus. There
were no significant deviations in nuclear PLA frequency across groups (all
inter-group comparisons p≥ 0.48, ANOVA). . . . . . . . . . . . . . . . . . 92
3.8 The C-terminal end of LEMD3 is sufficient for binding Smad2/3 in a
stiffness-dependent fashion. A, PLA interactions between the V5 tag of a
C-terminal fragment (“CTF”) of LEMD3 (pFLAG-LEMD3p.∆21-669-V5)
and Smad2/3, normalized to the total interactions observed on 1 kPa hydro-
gels. HFFs on 1 kPa hydrogels have significantly more interactions overall
(p<0.0001), in the cytosol (p<0.0001), and in the nucleus (p=0.0082) rel-
ative to fibroblasts on 25 kPa hydrogels. All transfected cells had more PLA
interactions than electroporation-only (”Neon”) populations (p<0.0001 and
p<0.0227 for 1 kPa and 25 kPa hydrogels, respectively). B, the higher V5-
Smad2/3 PLA frequencies observed in fibroblasts on 1 kPa hydrogels is
independent of the degree of V5 expression. The slopes of individual cells’
PLA vs. V5 staining intensity were higher for cells on 1 kPa hydrogels than
on 25 kPa hydrogels (p=0.1476, difference in slopes). All PLA groups were
statistically compared using a 2-way ANOVA with Tukey post-test unless
noted. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
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3.9 LEMD3-Smad2/3 interactions are negatively associated with actin poly-
merization but not nucleus-cytoplasm coupling or LEMD3-lamin cou-
pling. A, micrographs of LEMD3-Smad2/3 PLA in electroporated cells
(top row), mCherry-DN LEM expressing cells (2nd row), mCherry-DN
Kash expressing cells (3rd row), or mCherry only expressing cells (bottom
row), all on glass (PLA in green, f-actin in blue, mCherry in red, nucleus
in white). B, no significant differences in PLA frequency are seen in the
nucleus or cytoplasm of cells expressing either DN LEM or DN Kash rel-
ative to mCherry control cells. C, no correlation between DN LEM or DN
Kash expression and PLA frequency in transfected cells. D, micrographs
of LEMD3-Smad2/3 PLA in cells treated with cytochalasin D (top rows, g-
actin stabilizer) on glass or jasplakinolide (bottom rows, f-actin stabilizer)
on 1 kPa gels (PLA in green, f-actin in blue, nucleus in white). E, cytocha-
lasin D treatment significantly increases the total frequency (p=0.0089) of
PLA interactions per cell on glass. F, jasplakinolide (“Jas”) treatment sig-
nificantly decreases the total frequency of LEMD3-Smad2/3 interactions in
a dose-dependent fashion (p<0.0001 for DMSO vs. 100nM Jas or 200nM
Jas, p=0.0312 for 100nM Jas vs. 200nM Jas), and decreases the cytoplas-
mic (p<0.0001 for DMSO vs. 100nM Jas or 200nM Jas) and nuclear fre-
quencies (p=0.002 for DMSO vs. 200nM Jas, p=0.0466 for DMSO vs.
100nM Jas) of LEMD3-Smad2/3 interactions on 1 kPa surfaces. All groups
were statistically compared using a 2-way ANOVA with Tukey post-test.
All scale bars are 10 µm. . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
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3.10 YAP and TAZ KDs by siRNA antagonize LEMD3-Smad2/3 interac-
tions and shift interactions towards the nucleus. A, representative mi-
crographs of LEMD3-Smad2/3 PLA interactions in HFFs on 1 kPa fibronectin
hydrogels treated with 25nM siRNA against YAP (“siYAP”, top row), 25nM
siRNA against TAZ (“siTAZ”, middle row), or L2K vehicle treatment (“L2K”,
bottom row). B, quantification of PLA puncta per cell, normalized to
L2K condition, from at least two biological replicates per group. Signif-
icant loss of LEMD3-Smad2/3 interactions are observed with either siTAZ
(p=0.0005) or siYAP (p<0.0001) treatment. SiTAZ treated samples also
had significantly more LEMD3-Smad2/3 interactions than siYAP samples
(p=0.0094). C, loss of YAP (siYAP, p=0.0039) or TAZ (siTAZ, p=0.0716)
shifted remaining LEMD3-Smad2/3 interactions towards the nucleus. All
comparisons made using Kruskal-Wallis test with Dunn’s test for multiple
comparisons. D, representative western blots demonstrated YAP and TAZ
KD by siRNA using GAPDH as a loading control. E, quantification of YAP
(left graph) and TAZ (right graph) KD by siRNA from (D). Treatment with
25nM siYAP or 25nM siYAP and 25nM siTAZ (“siYAPTAZ”) significantly
reduced YAP levels relative to untreated HFFs (siYAP p=0.0044, siYAP-
TAZ p=0.008). Similarly, 25nM siTAZ or 25nM siYAPTAZ reduced levels
of TAZ (siTAZ p=0.0081, siYAPTAZ p=0.0145). No significant reductions
in either protein are observed with vehicle alone (L2K), or siRNA against
GFP (“siGFP”). All testing done using ANOVA with Dunnett’s multiple
comparison correction. All scale bars are 10µm. . . . . . . . . . . . . . . . 95
3.11 Full length LEMD3 is localized to the nucleus, but a 46kDa fragment
is localized to the cytoplasm. A, representative western blots of cytosolic
(GAPDH) and nuclear (LaminA/C) compartment markers from a fraction-
ated lysate are shown. Cytosolic markers are observed in the nucleus but
no nuclear markers are observed in the cytosol. B, LEMD3 western blot
on whole cell lysate or enriched lysates for the cytoplasmic or nuclear frac-
tions. An ≈ 50 kDa native LEMD3 fragment is found in the cytoplasm and
possibly the nucleus, while full length LEMD3 is only found in the nucleus. 96
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3.12 LEMD3 is proteolytically modified by a serine protease. A, Peptide
spectral matches (PSMs) were normalized from a 60kDa FLAG fragment
of LEMD3 by PSM frequencies measured in full length LEMD3. Nor-
malized PSM frequency revealed three distinct zones: over-enriched (left
shaded region), under-enriched (unshaded region), and absent (right shaded
region). B, LEMD3 cartoon showing relative position of the two deletion
mutants and known protein domains: LEM, transmemebrane (TMs 1&2),
and RRM domains, and FLAG and V5 epitope tags. C, western blots from
full length and each deletion mutant using N-terminal FLAG tag (top two
blots) and C-terminal V5 tag (bottom two blots) at 12 and 24 hours af-
ter electroporation. FLAG blots consistently produce a 60 kDa fragment,
while V5 blots produce 85 kDa, 60kDa, and 46 kDa fragments. D, rep-
resentative western blots for protease and cell cycle inhibitor experiments
using N-terminal FLAG tag (top two blots) and C-terminal V5 tag (bottom
two blots). E, quantification of blots from (D), showing that 60 kDa FLAG
fragment is significantly reduced relative to the full-length protein when
cells are treated with DCI (p=0.0153), MG-132 (p=0.0238), Cathepsin-G
inhibitor (p=0.0075), or roscovitine (p=0.0051). V5-tagged 46 kDa frag-
ment are similar in that DCI (p<0.0001) and MG-132 (p=0.0238) treat-
ments decrease its abundance, but dissimilar in that roscovitine increases
its abundance (p<0.0001). V5-tagged 85kDa fragment is increased with
MMP inhibitor treatment (p=0.0004) and E64D treatment (p=0.0044). All
treatment groups, except MG-132, were tested statistically using ANOVA -
Test for Trends with a correction for multiple hypotheses using a False Dis-
covery Rate (FDR) of α=0.05. MG-132 was compared to DMSO treated
lysates with a Mann-Whitney test and then also corrected using the FDR
approach above. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
3.13 LEMD3 C-terminal fragments are not significantly differentially abun-
dant in HFFs cultured on 1 and 25 kPa hydrogels. A, Fibroblasts trans-
fected with pFLAG-LEMD3-V5 were assayed by western blot for the rel-
ative abundance (fraction of total V5 signal in that lane) of the full length
protein or of the 85 kDa, 60 kDa, or 45 kDa fragments after 24 hours on
1 kPa, 25 kPa hydrogels or tissue culture plastic. Fibroblasts cultured on 1
kPa and 25 kPa hydrogels have significantly less full length LEMD3 than
cells cultured on tissue culture plastic (p=0.0062 and p=0.0031 for 1 kPa
and 25 kPa hydrogels, respectively) but do not vary significantly in the
abundance of any identified fragment. Cells on 25 kPa hydrogels have
nearly twice as much of the 45 kDa fragment than cells from 1 kPa hy-
drogels (p=0.5196). B, representative blots of the experimental lysates.
All stiffness in a given protein mass group were statistically compared us-
ing ANOVA with Tukey post-test. Data point represented by ”#” in Full
Length, 1 kPa was determined to be an outlier (Grubb’s method, α=0.05)
and is plotted for completeness but excluded from analysis. . . . . . . . . . 98
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3.14 LEMD3 is not directly regulated by substrate stiffness at the mRNA or
protein level. A, representative western blots and quantification of LEMD3
protein from soft (2 kPa) and stiff (25 kPa) hydrogels using GAPDH as a
loading control. No significant difference is observed between stiffness
conditions. B, LEMD3 mRNA quantification from cells on soft (2 kPa) or
stiff (25 kPa) hydrogels using 18S as a house-keeping gene. No significant
difference is observed between stiffness conditions. . . . . . . . . . . . . . 99
3.15 LEMD3-Smad2/3 PLA interactions are more cytoplasmic and more
varied in frequency in IPF vs. non-IPF human lung tissue. A and
B, LEMD3-Smad2/3 PLA frequency imaged at high-magnification (63X)
(A) and low-magnification (20X) (B) in non-IPF (top row) and IPF (bottom
row) tissue (PLA in green, f-actin in blue, autofluorescence in red, nuclei in
white). C, quantification of sub-cellular localization of LEMD3-Smad2/3
PLA events from (A) showing cytoplasmic shift in PLA interactions in IPF
patients (p=0.0307, Mann-Whitney test), mirroring in vitro trends seen in
Figure 3.5c. D, quantification of total LEMD3-Smad2/3 PLA frequency
from (B) showing similar frequency of interactions between IPF and non-
IPF patients (p=0.5783, Mann-Whitney test). IPF tissue had a higher intra-
patient variability (Coeff. of Variance = 67% and 30% for IPF and non-
IPF patients, respectively) and more extreme dispersion overall (kurtosis =
4.765 and -0.1391 for IPF and non-IPF patients, respectively). 22% of IPF
tissue areas sampled formed a unique low-interaction “tail” (<25% of the
mean IPF interaction frequency, denoted by dotted line), which is absent in
non-IPF tissues. All scale bars are 10 µM. Bars in (C) and (D) represent
grand medians. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
3.16 Summary Cartoon Mechanical cues from the extracellular matrix potenti-
ate TGFβ activation, which forms and translocates Smad2/3/4 complexes to
Smad Response Elements in the nucleus. LEMD3 antagonizes this TGFβ/Smad2/3
signaling by complexing with Smad2/3 both in the nucleus and in the cy-
tosol and shifts the mechanical response of cells to TGFβ. Cytosolic LEMD3
fragments are post-translationally generated at two sites, which separate
the nuclear localizing LEM domain and the Smad2/3 interacting RRM do-
main. Processing at the nucleoplasmic site (bottom red star) generates a
LEM- and RRM-containing fragment, which is inhibited by serine pro-
tease inhibitors, but has differential responses to lamin phosphorylation in-
hibitors. Both nuclear and cytosolic LEMD3-Smad2/3 complexes are in-
hibited by actin polymerization, which is driven by mechanical cues from
the matrix, thereby connecting ECM mechanics to inhibition of an inhibitor
of Smad2/3. Inhibitory interactions are shown with red block-end arrows
while activating signals are denoted with green arrows. Black arrows indi-
cate translocation. Abbreviations: Cat G: Cathepsin G; RRM: RNA Recog-
nition Motif; LEM: Lap2b-Emerin-MAN1 domain; TGFβ-R: TGFβ receptor.101
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4.1 Translocation of MRTF to the Nucleus at 4 Hours is Driven by Sub-
strate Stiffness but Not Modulated Consistently by TGFβ Treatment or
ROCK Inhibition. A, Representative micrographs of fibroblasts on soft,
physiologic-representative (0.5 kPa) hydrogels, on stiff, fibrotic-representative
(25kPa) hydrogels, and on glass. Cells on glass were treated with Latru-
culin B. MRTF and Smad2/3 subcellular localization was probed by im-
munofluorescence in the presence or absence of 50pg/mL TGFβ or 50pg/mL
TGFβ and 10µM Y-27632. B, Quantification of cellular volume (top right),
nuclear volume (top left), nuclear MRTF fraction (bottom right), and nu-
clear Smad2/3 fraction (bottom left). Treatment of the cells with 2µM La-
truculin B produced a reduction in measured cell volume (p=0.035, p=0.074,
p<0.0001 for Latruculin B vs. 0pg/mL TGFβ, vs. 50pg/mL TGFβ, and vs.
50pg/mL TGFβ + 10µM Y-27632, respectively, ANOVA - Tukey post-test),
a reduction in measured nuclear volume (p=0.0177, p=0.1215, p<0.0001
for Latruculin B vs. 0pg/mL TGFβ, vs. 50pg/mL TGFβ, and vs. 50pg/mL
TGFβ + 10µM Y-27632, respectively, ANOVA - Tukey post-test), and a
reduction in nuclear MRTF (p=0.0089, p=0.0166, p=0.3615 for Latruculin
B vs. 0pg/mL TGFβ, vs. 50pg/mL TGFβ, and vs. 50pg/mL TGFβ +
10µM Y-27632, respectively, ANOVA - Tukey post-test). TGFβ treatment
was associated with statistically increased nuclear localization of Smad2/3
(p<0.0001 for any TGFβ treatment relative to TGFβ untreated fibroblasts
at any stiffness, except between 50pg/mL TGFβ treated and untreated fi-
broblasts at 8kPa, two-way ANOVA, simple column effect, Tukey post-
test). Stiffness was associated with increased nuclear MRTF in all treatment
conditions (p<0.0001 for all groups, ANOVA - Test for trends); addition-
ally, treatment with TGFβ or TGFβ and Y-27632 did not produce consis-
tent, statistically significant alterations in MRTF nuclear localization. All
scale bars are 18µm. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
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4.2 CHIP-peak and Sequence Based Characterization of the Endogenous
Murine CArGome A, Summary of CHIP-peak/gene level data from Es-
nault et al. (2014) motivating the potential for SRF-MRTF based stiffness-
driven transgenes. Panel i-iii) Correlation plots of SRF (i), MRTF-A (ii),
and MRTF-B (iii) occupancy at a given CHIP-seq peak and the RNA reads
associated with the annotated gene(s) of that peak in low serum (0.2%) and
high serum (15%), cultured fibroblasts. There was a statistically signif-
icant correlation between SRF and RNA reads (r=0.1361 and r=0.1940,
p<0.0001 for low and high serum, respectively, Pearson’s correlation),
MRTF-A and RNA reads (r=0.08515 and r=0.1953 with p=0.0004 and
p<0.0001 for low and high serum, respectively, Pearson’s correlation) and
MRTF-B (r=0.1085 and r=0.2172, p<0.0001 for low and high serum, re-
spectively, Pearson’s correlation). Panel iv) Frequency distribution of SRF
peaks against annotated genes demonstrated that ≈ 95% of all endogenous
genes were associated with two or fewer independent SRF peaks. Panel
v) Correlation between the number of SRF peaks associated with a given
gene and the occupancy of SRF at those particular loci demonstrated that
increasing numbers of independent SRF peaks statistically increased the
relative abundance of SRF occupancy at a given gene (r=0.4901, p<0.0001,
Pearson’s correlation). B, Individual CArG box identification and charac-
terization by number and quality in Esnault et al. (2014) CHIP-seq SRF
peaks. Panel i) Frequency distribution of individual CArG elements (up
to double mismatch CArG boxes were analyzed) demonstrated that the av-
erage number of CArG box elements per SRF peak was 8±4, with some
SRF peaks containing over 30 individual CArG boxes. There was a statis-
tically significant correlation between CArG box number in a CHIP-seq
peak and SRF residency at that peak averaged across serum conditions
(r=0.222, p<0.0001, Pearson’s correlation). Panel ii) Decreasing quality,
as indicated by number of mismatches from the canonical CArG box se-
quence, of the highest quality CArG box in a given SRF peak was signif-
icantly inversely correlated with occupancy of SRF in that CHIP-seq peak
(r=-0.2850, p<0.0001, Pearson’s correlation) . Collectively, the annota-
tion of CArG box number and characterization of box quality up to two
mismatches (and beyond) described the thermodynamic architecture of the
murine CArGome as only 7 SRF CHIP peaks lack at least a double mis-
match CArG box. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
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4.3 Characterization of the Delivery of CArG Probes by Electroporation
and Lipofectamine by Absolute qPCR, Flow Cytometry, and Confo-
cal Microscopy A, pico-mole loads of CArG sinks delivered CArG sink
copies per cell on the order of magnitude of the endogenous CArGome.
Panel i) Representative qPCR amplification traces for the quantification of
probe delivery to cells. Panel ii) Standard curve of known input CArG
box load demonstrating the linearity of the measurement over multiple or-
ders of magnitude (r2=0.9975). Panel iii) Delivery of 1.4 pmol of an 120
bp double stranded CArG sink by electroporation to fibroblasts delivered
≈ 25,000 CArG sinks per cell, which is slightly greater than the ≈ 20,000
CArG boxes present in the endogenous murine CArGome. There was a sta-
tistically significant increase in CArG box delivery per cell with increasing
input CArG box load (p = 0.0053, Student’s T-Test). B, relative quantifi-
cation of CArG boxes probes by flow cytometry correlated strongly with
qPCR derived results with single cell resolution. Panels i and ii) Normal-
ized flow histograms showed a single population shift in the median fluo-
rescent signal per cell in fibroblasts electroporated with 1.4 pmol (Panel i)
or 140 fmol (Panel ii) of labeled CArG sinks. Panel iii) Quantification of
the shift in per-cell median fluorescence as a function of CArG box load
demonstrated a statistically significant increase in fluorescence with in-
creasing CArG box load (p<0.0001, ANOVA - Test for Trends). Panel iv)
Flow cytometry and qPCR quantification of delivered CArG probes were
significantly correlated (r = 0.9823 with p = 0.0005, Pearson’s correlation).
C, representative confocal micrographs demonstrating the subcellular com-
partmentalization of CArG sinks delivered by electroporation (top row) or
Lipofectamine3000 (bottom row). The XY/XZ/YZ profile are shown in
the right column, while the middle and left columns highlight the cellu-
larly constrained probe and the nuclearly localized probe, respectively. D,
quantification of subcellular delivery of CArG probes by electroporation
or Lipofectamine3000. Panel i) Relative nuclear delivery of CArG probes
demonstrated that electroporation was more efficient in delivering nucle-
arly localized probes than Lipofectamine (p<0.0001, Student’s T-Test).
Panel ii) Lipofectamine delivered greater abundances of cellular and nu-
clear probes (p<0.0001 for both total and nuclear probes, Student’s T-test)
than electroporation based on relative quantification of probe fluorescent
signal. Panel iii) Scatter plot of nuclear probe signal versus total probe
signal per cell demonstrated greater efficiency of electroporation based de-
livery of CArG probes relative to Lipofectamine. . . . . . . . . . . . . . . 131
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4.4 CArG Sink Delivery by Electroporation Did Not Alter the Subcellu-
lar Localization of SRF Nor Antagonized SRF Transcripts Relevant
to Pulmonary Fibrosis A, Representative confocal microscopy images
demonstrating the subcellular localization of SRF after delivery of a 120
bp double stranded, linear probe containing a CArG box based on the
murine cFOS promoter. Panel i) Confocal images presented in XY/YZ/XZ
planes. Panel ii) Algorithmic detection of SRF based masked by the actin
cytoskeleton and nucleus. Panel iii) Algorithmic detection of nuclearly re-
stricted SRF using a nuclear mask. B, Quantification of SRF localization
following 1.4pmol of a 120 bp cFOS CArG probe relative to blank electro-
poration. There was no statistical difference or trend between the localiza-
tion of SRF in cells with and without CArG probe delivery (p = 0.98 for
Delivery 1 vs. Blank and p = 0.3523 for Delivery 2 vs. Blank, ANOVA with
Dunnett’s post test). C, CArG sinks of varying dose and CArG box quality
did not significantly vary the transcription of disease relevant genes rela-
tive to “anti-CArG” (CArG boxes with a purine/pyrimidines substitution)
sinks. cFos CArG boxes were 120 bp double stranded, linear probe contain-
ing a CArG box based on the murine cFOS promoter, while αSMA probes
were analogously based on the αSMA promoter, centered on the CArG-B
box. All electroporated conditions were plated in 15% serum. There was
a statically significant decrease in XIAP transcripts in electroporation only
control fibroblasts relative to fibroblasts in 1% serum (p = 0.0364, ANOVA
with Dunnett’s post-test), indicating that electroporation itself may have a
confounding effect on SRF transcription at short time-scales. . . . . . . . . 132
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4.5 Synthetic or Naturally-Derived Probe Shift in EMSA was Dependent
on CArG Integrity and SRF A, Synthetic and naturally-derived Cy3b-
labelled CArG box probes only demonstrated a mobility shift in the pres-
ence of HEK lystate enriched for SRF. Lanes 2, 4, 6, and 8 did not contain
any HEK lysate while lanes 3, 5, 7, and 9 contained HFFs transfected with
pCN-SRF. Lanes 2 and 3 use a ≈ 430 bp double stranded, linear sequence
containing 16 CArG boxes designed synthetically. Lanes 4 and 5 contained
a 300bp double stranded, linear sequence containing CArG boxes from the
murine cFOS promoter, centered on the CArG box, while lanes 6 and 7
contained analogously constructed probes centered on the αSMA CArG-B
box. Lanes 8 and 9 contained a 120 bp double stranded, linear sequence
containing the CArG box from the cFOS promoter, centered on the CArG
box. Lane 1 was blank while Lane 10 was the DNA ladder. Gel shifts
were observed with all synthetic and naturally-derived probes, at all probe
lengths between ≈ 100-400 bp and with canonical and single mis-match
CArG elements. No multiple binding events were detected. B, Probe shift
was specific to the integrity of the probe’s CArG box. Lanes 2-4 did not
contain 2µg recombinant human SRF while lanes 5-8 did. Lanes 2 and 6
contained an 120 bp double stranded, linear “anti-CArG” probe wherein
the purines and pyrimidines from the murine cFOS promoter’s CArG box
have been swapped. The surround sequences remained unmodified. Lanes
3 and 7 contained a 120 bp double stranded, linear CArG probe based on
the murine αSMA promoter and centered on the CArG-B box. Lanes 4
and 8 contained a 120 bp double stranded, linear CArG probe based on the
murine cFOS promoter and centered on its CArG box. Lane 5 contained
SRF alone and Lane 1 was the DNA ladder. These results demonstrated the
specificity of the gel-shift response to the integrity of the probe’s CArG box. 133
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SUMMARY
Over the past decade and a half, scientific research into pulmonary fibrosis has come full
circle. The fibrotic matrix, a disorganized, stiff accumulation of extracellular proteins, has
gone from being the unfortunate product of pathological fibroblast activation to being a key
driver of its own accumulation through mechanical cues to the cells. Important mechanical
regulation by the matrix occurs in distinct spatial domains throughout the cell (e.g. at the
cell-ECM interface, in the mechanical machinery of the cytosol, and through the genome),
which all contribute to the long-term disease phenotype. While the importance and ther-
apeutic promise of understanding this pathologic mechanotransduction has been explored
in the scientific literature, there are still no therapies to reverse pulmonary fibrosis, and life
expectancy with this condition has been largely unchanged even after the advent of new
medical management. The identification and demonstration of novel matrix-responsive
therapies represents a new frontier in the medical approach to pulmonary fibrosis, which
could directly address the disease feature (i.e. the matrix itself) responsible for the dyspnea
and eventual asphyxiation that kills patients.
This thesis focuses on the application of genetics and nucleic acids to directly treating
and to identifying novel therapeutic targets that break this deadly feedback cycle. Each
Chapter of this thesis is dedicated to applying genetics to a particular domain/step in patho-
logic mechanotransduction: Chapter 2 demonstrates the delivery of mRNA-based thera-
peutics to modulate cell-ECM interactions; Chapter 3 illustrates how the fibrotic matrix
perverts the cell’s innate mechanosensing machinery to potentiate pathologic TGFβ-driven
transcription factor biology; and, Chapter 4 explores the structure and activation of a me-
chanically regulated transcription factor system, the MRTF/SRF axis, to allow for the ra-
tional exploitation of mechanical genetic.
In Chapter 2, I have demonstrated the mRNA-based delivery and efficacy of two cell-
tethered, conformationally sensitive fibronectin binding single chain antibody fragment
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variants, H5-CD8 and H5-GPI. I have shown that H5 expression alters the focal adhe-
sion profile of fibroblasts in a linker dependent fashion and characterized the resultant
mechanotransductive phenotypes of fibroblasts expressing these variants. Furthermore I
have shown that these mRNA-based therapies can be translated in vivo in anticipation of
efficacy testing in a bleomycin model of pulmonary fibrosis in mice. In Chapter 3, I have
discovered a unique mechanism by which the fibrotic matrix sensitizes cells to TGFβ tran-
scription through stiffness-dependent inhibition of a TGFβ inhibitor, LEMD3. I have found
and characterized unique, cytosolic elements of LEMD3 biology and extended these find-
ing into ex vivo human tissues. Finally, in Chapter 4, I have mapped the stiffness-based
translocation of MRTF with and without TGFβ treatment in initial mechanosensing by
fibroblasts. I have also characterized the genomic space that activated MRTF and its cofac-
tor SRF act over by profiling the number and sequence characteristics of CArG elements
in the murine genome. Finally, I have developed the tools necessary to complete a thermo-
dynamic survey of this system in anticipation of the construction of models to predict the
stiffness-dependent behavior of therapeutic CArG-based transgenes.
These three particular, individual stories follow the path of mechanical information as
it weaves from the matrix, into the cell and ultimately back into the matrix. Each Chapter
suggests unique approaches to pathologic mechanosensing, and the integration of these





This thesis represents the work I undertook to understand the intersection of cellular mechano-
sensing in fibrosis and genetics through 1) the therapeutic application of nucleic acids
to modulating the rigidity-dependent intergin-ECM binding, 2) the mechano-biology of
Transforming Growth Factor β a transcription factor relevant to pulmonary fibrosis, and
3) the organization of the murine CArGome, a set of mechanically regulated elements in
the genome. This global introduction focuses on the critical clinical features of pulmonary
fibrosis that motivated these works collectively and the organization of these projects in-
side a framework of bi-lateral cell-matrix communication. The review of the literature and
necessary biological background for each Chapter is embedded in that Chapter to maintain
the clarity of presentation across these diverse projects.
1.2 Pulmonary Fibrosis
1.2.1 Pulmonary Fibrosis is a Heterogeneously Presenting, Deadly Sclerosis
Pulmonary fibrosis (PF) is a progressive scarring of the lung parenchyma with a median
survival-rate of 3-5 years post diagnosis and which kills 16,200 Americans each year. [1,
2] While lung transplantation is often curative, it is, itself, an overly morbid process, is
unavailable to overly frail patients, and has median survival rates for single lung transplan-
tation at 4.6 years and 6.6 years for a double organ transplant. [3] Fibrotic regions in the
PF lung present heterogeneously with a general basal to apical progression, are largely col-
lagen dominated, are significantly stiffer than healthy regions (median stiffness of 1.96 kPa
and 16.52 kPa respectively), and are marked an irreversible loss of lung compliance arising
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from alveolar collapse during injury. [4, 5] Interstitial fibrosis also impairs gas exchange as
evidenced by decreased diffusion of hyperpolarized Xe and carbon monoxide studies in PF
patients. [6] Medical management of PF is an historically fraught business with numerous
failed phase III clinical trials along multiple therapeutic axes (e.g. N-acetyl cysteine, Etan-
ercept, interferon-gamma 1b, prednisone, azathioprine, tyrosine kinase inhibitor imatinib
mesylate, JNK inhibitor CC-930, anti-IL13 antibody QAX576, etc.). [7] However, in 2015,
the FDA approved two agents, pirfenidone (an “anti-fibrotic” agent) and nintedanib (tyro-
sine kinase inhibitor affecting CTGF, FGF, PDGF) for the treatment of mild-to-moderate
PF after both showed statistically significant decreases in the rate of loss of forced vital
capacity (≈50% reductions in annual loss). Moreover, meta-analysis of the CAPACITY
and ASCEND pirfenidone trials demonstrated a reduction in trial participant mortality to
all causes and to IPF-related causes not seen with nintedanib. [8, 9, 10, 11] While these
drugs mark an important turning point in the management of PF, they do not offer a cure or
a means to deal with crippling dyspnea present in clinically evident patients.
1.2.2 Matrix Mechanics is a Pathologic Driver in Pulmonary Fibrosis
Recent scientific and translational attention has focused on the role on the fibrotic ma-
trix itself. In addition to being the central pathological symptom of the disease process,
the fibrotic matrix appears sufficient to drive myofibroblastic differentiation and potenti-
ates important soluble factors, like TGFβ. Liu et al. demonstrated that matrix stiffness
alone was able to initiate a fibrotic program in naive fibroblasts. [12] These findings have
subsequently been reproduced using 3D, acellular matrices derived from healthy and dis-
eased human lung tissue [4]; and, mechanistically, mechanosensitive transcription factor
families, like transforming growth factor β (“TGFβ”), the myocardin-related transcription
factor family (commonly MRTF A/B or MKL1/2) and yes-associated protein/ transcrip-
tional coactivator with PDZ-binding motif (YAP/TAZ) have been implicated in convey-
ing this matrix-derived phenotype. [13, 14, 15] The fibrotic matrix, as a nexus of both
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pathological cause of effect, has become a target for therapeutic intervention as recognized
by NHLBI. [16] However, there are currently not many investigations into matrix-driven
therapy: a recent matrix-focused clinical trial, simtuzumab, an anti-lysyl oxidase therapy,
failed Phase II trials in 2016 due to a lack of efficacy. [7, 17] There are still cellular-
focused, Rho/ROCK [18, 19, 20] and MRTF specific therapeutics [21] under investigation;
however, these therapeutics often elicit pleiotropic effects in multiple organ systems since
these kinases/transcription factors regulate basic cell processes, like motility, polarity and
cell-cell junctions. [22] Because the matrix and the cell’s ability to sense the mechanical
cues of the matrix are so central to the pathology of fibrosis, there is a clinical need for
understanding pathologic mechano-transduction to identify new potential therapeutic in-
terventions. The Chapters of this thesis are dedicated to uncovering novel approaches to
pathological mechano-transduction through genetic tools and investigation.
1.3 Conceptual Organization of This Thesis
These chapters fall neatly into two organizational frameworks - one spatial and one con-
ceptual. Spatially, this thesis is organized ”outside-in” - starting with biology of the cell-
matrix interface, traversing the intra-cellular machinery that transduces biophysical signals
into the biochemical language of the cell and working towards the heart of the nucleus.
Conceptually, this work mirrors this spatial organization and mimics the biological feed-
back that exists between genetics and matrix mechanics. The cell senses mechanical forces
thought ligand-matrix binding events at the cell-ECM interface (Chapter 2), which the cell
then transduces into biochemical signals using a variety of tools including actin polymer-
ization and post-translational modifications to a variety of kinases and transcription factors
(Chapter 3), which filter through the particular decision matrix of the genome (Chapter 4)
and become reactions that update the mechanical environment and the state of the cells as
it evolves in time.
The ultimate goal of this thesis is to enable coupling of the insights and tools from each
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Chapter to rationally antagonize or hijack the cell’s innate mechanosensing systems to pro-
vide novel therapeutics that complement the existing clinical management for PF. In Chap-
ter 2, I described the use of nucleic acids to modulate cell-ECM interactions by mRNA-
based expression a conformationally specific single chain antibody fragment (“scFV”) to
fibronectin. I hypothesized that scFV expression would antagonize pathologic αVβ3 in-
tegrin tone in fibrosis and demonstrated that: (1) cell linked scFv retained their ability to
bind strain-mimic fibronectin fragments; (2) that these scFVs modulated focal adhesions in
a linker-dependent fashion; (3) that these changes in focal adhesion biology did not fully
predict the effects of these scFVs in mechanically-driven cell spreading assays; and, (4) that
these scFVs can be expressed in vivo out to 8 days post instillation. In Chapter 3, I explored
the mechanical regulation of TGFβ biology through LEMD3, an inner nuclear membrane
protein, and LEMD3’s role in the substrate stiffness-driven sensitization of fibroblasts to
TGFβ signaling. I hypothesized that LEMD3’s known inhibition of TGFβ signaling would
itself be inhibited in a cellular stress dependent fashion. I found that: (1) that LEMD3’s
inhibitory interactions were inversely correlated to substrate stiffness; (2) that these inter-
actions were not dependent on cellular stress to the nucleus, but were negatively correlated
to both actin polymerization and YAP/TAZ knockdown; (3) that LEMD3 interactions were
throughout the cell; (4) that LEMD3 was proteolytically modified in two locations and that
cytoplasmic fragments resembling endogenous LEMD3 fragments were regulated by a ser-
ine protease, possibly cathepsin G; and, (5) that biopsies from pulmonary fibrosis patients
recapitulated these in vitro phenotypes and demonstrated extra-nuclear LEMD3 interac-
tions. Finally, in Chapter 4, I dissected the genomic architecture of the myocardin related
transcription factor family (“MRTF”) and serum response factor (“SRF”) axis, a mechani-
cally regulated transcription factor family, and characterized the development of tools nec-
essary to understand its thermodynamic structure. I hypothesized that understanding the
thermodynamic landscape for MRTF/SRF would permit for the development of stiffness-
specific promoter elements from a rational design perspective. In this Chapter I showed:
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(1) that the translocation of MRTF to the nucleus was stiffness-dependent but largely inde-
pendent of fibrosis-relevant growth factor signaling from TGFβ at short time-scale; (2) that
the murine CArGome was comprised of ≈ 20,000 individual CArG boxes, distributed over
≈ 2,000 individual sites, and that RNA transcription, MRTF/SRF occupancy, and the num-
ber and quality of CArG boxes in a particular peak were all correlated with one another;
(3) that decoy CArG sequences were delivered to the cell on the scale of the endogenous
CArGome in vitro; and (4) that a broad range of CArG probes from both endogenous and




CONTEXTUAL ANTAGONISM OF αVβ3 INTEGRIN WITH A FN-STRAIN
SPECIFIC SCFV, H5
2.1 Introduction
2.1.1 Importance of Fibronectin to Pulmonary Fibrosis
Fibronectin (“FN”) is a key component of the provisional matrix deposited during wound
healing and in tissue regeneration/fibrosis, which helps to pattern the collagen matrix of the
new tissue and bind regenerative growth factors. [23, 24] Chronic lung injury through occu-
pational and environmental exposures are key risk factors in the development of pulmonary
fibrosis [25, 26] and much of the fibrotic program is derived from wound-associated my-
ofibroblasts, which become constitutively active. [14, 27, 28, 29, 30] Given the central role
of wound healing in pulmonary fibrosis and direct experimental evidence indicating that
fibronectin’s and particular fibronectin splice-variants’ deposition is increased in fibrotic
pathology [31, 32, 33], understanding the ability of this matrix molecule to drive cellular
phenotype is of translational significance.
2.1.2 Fibronectin Mechano-sensing at the Matrix-Cell Interface
Many important mechano-transductive events occur at the interface between cells and the
extra-cellular matrix (“ECM”) as this space is the physical connection between the cell
and its environment. This introduction focuses on fibronectin and focal adhesion biology
that could be exploited to alter the cell’s ability to sense its mechanical environment and
to antagonize stiffness-driven fibrotic phenotypes. Specifically, this section motivates the
therapeutic delivery of “H5”, a strained-fibronectin specific single chain antibody fragment
(scFv) by mRNA to antagonize excessive αvβ3 integrin signaling.
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Integrin Switch in Fibronectin Between αvβ3 and α5β1
Physical Distention of Fibronectin’s Integrin Binding Domain Drives the Integrin Switch
The integrin binding domain, located in the 9th and 10th type III repeats of fibronectin
(”III9” and ”III10”, respectively), is engaged by both αv and α5 integrins. [34, 35, 36, 37]
While αv integrins typically only require the RGD loop present in FN’s III10 domain, α5
integrin’s affinity for FN is strongly potentiated by the PHSRN sequence in FN III9. [35,
34] Because FN’s type III repeats are not stabilized by intra-repeat disulfide bridges, the
relative position between the III9 and III10 domains (and the PHSRN and RGD peptide
sequences) can be strained by pico-newton levels of stress provided by cellular contraction.
[38, 39, 40] This physical decoupling of the III9 and III10 domains allows for mechanical
forces applied to FN to dictate the relative balance of αv and α5 integrin binding, the so-
called “integrin-switch,” which has now been verified ex vivo in fibrotic and developing
tissues. [38, 41, 29]
Cellular Phenotypes Associated with the Integrin Switch
The use of protein mimetic or fragments of fibronectin III9 and III10 provide strong in vitro
evidence that a shift towards αvβ3 integrin engagement over α5β1 supports mesenchymal
and fibrotic phenotypes. [42, 43, 44] Epithelial cells exposed to biochemically decoupled
III9 and III10 domains were more likely to undergo epithelial-to-mesenchymal transforma-
tion and expressed myofibroblastic markers, like α-smooth muscle actin, than cells plated
on FN with stabilized III9 and III10 domains. [43, 44] In fibroblast, a fibronectin fragment
lacking the α5β1 necessary III9 domain strongly up-regulated matrix synthesis relative to
III8-III10 fragments. [45] Integrin selection through unfolded fibronectin has also been
shown to be important in regulating the levels of wound-healing associated growth factors
like VEGF. [46] These alternations in phenotype are likely due to changes in focal adhe-
sion composition and activity, such as focal adhesion kinase and the Src family of kinases,
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that accompany the switch between αv and α5 integrins when the III9 and III10 repeats are
decoupled. [47] The importance of these in vitro findings are corroborated by cre-knockout
of the αv integrin in vivo, which has proven to be strongly protective against fibrotic devel-
opment in multiple organs, including the lungs, liver and kidneys in mice. [48]
Targeting Strained Fibronectin to Inhibit αvβ3 Integrin Switching
The altered mechanics of fibrosis drive inappropriate αvβ3 tone through a conformational
distortion of fibronectin’s III9 and III10 integrin binding domains (IBDs). Targeting this
altered confirmation of fibronectin may have therapeutic value through antagonizing αvβ3
tone relative to α5β1 tone. Previously, the Barker lab discovered a single chain antibody
fragment (scFv) through phage display that specifically bound biochemically decoupled
(“strain mimic”) fibronectin IBD fragments relative to biochemically stabilized (“relaxed
mimic”) fibronectin IBD fragments. [49] This scFv, termed H5, has been shown to bind
physically strained fibronectin preferentially both in vitro and ex vivo, and inhibits αvβ3
signaling. [29] Moreover, this antibody’s accumulation in the lungs was correlated with
the progression and regression of a bleomycin-induced model of pulmonary fibrosis in
mice relative to a control, scrambled scFv, indicating that H5 is able to recognize fibrosis
associated distortions to the matrix. [49] These findings motivate the therapeutic use of
H5 in experimental models of fibrosis as an antagonist to pathologic, matrix-driven αvβ3
signaling.
2.1.3 Genetics as a Therapeutic Intervention at the Cell-Matrix Interface
While information from the physical environment filters through the cells and converges
on the genome of the cell to drive long-term alterations in mechanical phenotypes, genetics
and nucleic acids proper are not thought to play a direct role in stiffness sensing at ECM-
cell interface. However, using an innovative technique pioneered by the Santangelo lab,
I have chosen to deliver H5 as messenger RNA (“mRNA”), encoding membrane tethered
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forms of H5, thereby demonstrating the novel use of nucleic acids to modulate mechano-
sensing at the cell-ECM interface. In the following sections I describe the motivation for
delivering of H5 as mRNA and the motivation for the specific membrane linkers I chose to
explore.
Airway Delivery of H5 mRNA
mRNA as a vehicle for therapeutic delivery of proteins or as therapy in and of itself has
been demonstrated in a variety of in vivo application to the lung and beyond, including
the treatment of anemia, asthma, and lung surfactant deficiency. [50, 51, 52, 53] These
approaches different significantly from DNA- [54, 55], viral- [56, 57, 58] or recombinant
protein [59] based-therapies in terms of their safety (e.g. no risk of genomic incorpora-
tion), immunogenicity/repeatability (e.g. no antibodies develop against the viral delivery
vectors) and cost-effectiveness. Additionally, incorporation of modified chemical bases
into the sequence of synthetic mRNAs has been shown to decrease their recognition by the
innate immune system and prevent stress-granule formation, which can limit translation
of exogenous genetic therapeutics. [60] Finally, using an micro-spraying technique pio-
neered by the Santangelo Lab, the delivery of naked mRNA in a PBS-based aerosol has
been demonstrated (Personal Communication). This simple and safe formulation allows
mRNA-based therapeutics to be delivered specifically to the airspace, without systemic ex-
posure, and without the pharmacological and inflammatory complications associated with
chemical/liposomal or nano-/micro-particle delivery mechanisms. [61, 62, 63]
Motivation for Thy-1-inspired GPI Linker and CD8 Peptide Linkers
The necessity for cellular translation of mRNA-based therapy by cells affords unique op-
portunities to use cells themselves as a solid support for therapeutic protein expression.
Specifically, it restricts access of H5 to fibronectin that is necessarily accessible to cells,
potentially increasing the efficacy of the therapeutic targeting as H5 is not sequestered
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by cellularly inaccessible fibronectin. Additionally, tethering H5 proteins to cells avoids
many of the pharmco-kinetic difficulties encountered in delivering proteins and peptides
to the lungs including clearance by the muco-ciliary tract [64], absorbance and clearance
by the lymphatic and systemic routes [65, 66], and sequestration and degradation by air-
way macrophages. [67, 68] Previous characterization of the pulmonary half life of human
growth factor (≈ 22kDa, similar in size to H5) found its effective half-life was ≈ 10.5 hours
in rat lungs. [68] Tethering H5 to the surface of cells may alter these undesirable kinetics
without without the need for advanced pharmacological interventions to the protein, such
as Fc domain fusions [69, 70] or extensive PEG-ylation of the molecule. [71]
Furthermore, tethering H5 expression to the cells’ surfaces may allow for additional
functionality to be derived from the linker to the membrane itself. The glycosylphos-
phatidylinositol (“GPI”) linker derived from Thy-1, a cell-surface glyco-protein, is of par-
ticular interest to applications in pulmonary fibrosis because of Thy-1 innate role in the de-
velopment of pulmonary fibrosis and because of its role in modulating the biology of αVβ3
integrins. [72, 73, 74, 30] Specifically, the GPI-linker of Thy-1 has been shown to asso-
ciate with αVβ3 integrin in the plasma membrane. This association is lost with mutation of
Thy-1’s RLD domain or through substitution of the GPI linker for a canonical single-pass
peptide transmembrane domain from CD8’s α transmembrane domain. [75] This associa-
tion with αVβ3 integrin has been shown to be dependent on the GPI linker’s association
with cholesterol lipid rafts on the membrane’s surface. [76, 77] Furthermore, the associa-
tion of Thy-1’s GPI linker with lipid rafts allows for Thy-1 to coordinate the composition of
proteins in focal adhesions. Specifically, Thy-1 has been shown to precluster fyn, a member
of the Src Family Kinases (“SFK”) found in lipid rafts, within focal adhesions, modulating
the relative balance of focal adhesion kinase (“FAK”) and SFK signaling through integrins.
[78, 79, 80, 81] The experimental contrast between CD8- and GPI-based linkers led me to
incorporate these design features into my work with membrane-bound H5.
In this Chapter I present my work exploring the hypothesis that membrane-bound H5
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antagonizes αVβ3 integrin signaling both through H5’s innate function in binding strained
fibronectin and through modulation of focal adhesion signaling, and I demonstrate the abil-
ity to deliver these therapeutic mRNA constructs in vivo.
2.2 Methods
2.2.1 Cell Culture, Fibronectin Fragments and Transfection Protocol
Primary human foreskin fibroblasts (“HFFs”) were procured from ATCC (ATCC SCRC-
1041, ATCC, Manassas, VA) and routinely cultured in DMEM (ThermoFisher, Waltham,
MA) supplemented with 15% FBS and 1% penicillin/streptomycin (ThermoFisher, Waltham,
MA) in 5% CO2 at 37C in a humidified incubator to passage 13. Chinese Hampster Ovary
(“CHO”) cells were stably transfected to express either human αVβ3 integrin (“CHOB2”)
or human α5β1 integrins (“CHOK1”) and previously characterized and gifted to the Barker
lab. [82] These cells were routinely cultured in F-12K median (ThermoFisher, Waltham,
MA) supplemented with 10% FBS and 1% penicillin/streptomycin (ThermoFisher, Waltham,
MA) in a 5% CO2 in a humidified incubator till passage 25. Rat lung fibroblasts (“RFL-
6”) were procured from ATCC (ATCC CCL-192, ATCC, Manassas, VA) and routinely
cultured in DMEM (ThermoFisher, Waltham, MA) supplemented with 20% FBS and 1%
penicillin/streptomycin (ThermoFisher, Waltham, MA) in 5% CO2 at 37C in a humidified
incubator to passage 13.
Fibronectin fragments (fibronectin’s III9 and III10 domains) were a kind gift from Dr.
Haylee Bachman. The fragments contain either a stabilizing proline mutation, which rela-
tively fixes the domains’ positions (“9*10”) or a 4 glycine linker, which conformationally
destabilizes the two domains (“4G”). The production and purification of these fragments
are described in detail previously. [29] Fragments were stored at -80C until use and only
freeze-thawed 3 times.
All cells were transfected with mRNA using Lipofectamine 2000 (ThermoFisher, Waltham,
MA). Confluent or near confluent cultures of fibroblasts or CHO cells in 6 well plates
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were inoculated with 250 µL of OptiMEM containing 1µg of mRNA and 2uL of Lipofec-
tamine2000, formulated according to the manufacturer’s protocol. All transfections were
done in antibiotic free media or OptiMEM for at least 6 hours, at which point, the cells
were washed and cultured routinely.
2.2.2 mRNA Cloning and Production
DNA encoding the mRNA constructs were codon optimized and ordered as Gene Blocks
(IDT, Coralville, IA) and ligated into pMA-7 plasmid backbones using NotI/HindIII (New
England Biolabs, Ipswich, MA) digestion and ligation. Sequences for these constructs were
confirmed using Oligos from Table 2.2 by Sanger sequencing (Macrogen USA, Rockville,
MD). Subsequent incorporation of nano-luciferase fusions into these designs was accom-
plished by Gibson assembly using a HiFi Assembly Kit and NEBuilder tool (New England
Biolabs, Ipswich, MA) from stock nano-luciferase containing plasmids in the Santangelo
Lab, originally obtained from Addgene (Cambridge, MA). Oligos for Gibson assembly are
listed in Table 2.2. DNA plasmid stocks were purified using a DNA Midi Kit (Qiagen,
Hilden, Germany).
Plasmids encoding mRNA constructs were linearized with Not-I HF (New England Bi-
olabs, Ipswich, MA) overnight and PCR purified using PCR clean-up kit (Qiagen, Hilden,
Germany). In vitro transcription was performed using a T7 mScript Kit (Cellscript, Madi-
son WI) according to the manufacturer’s instructions with the following modifications: N1-
methylpseudouridine-5-triphosphate (TriLink, San Diego, CA) was used instead of uracil
with equimolar concentrations of other nucleotides (ATP, CTP, GTP, also TriLink). Con-
structs were capped with 2-O-Methytransferase followed by enzymatic addition of a poly-A
tail for 90 minutes. Finally, constructs were treated with Antarctic Phosphatase (New Eng-
land Biolabs, Ipswich, MA) for 1 hour (New England Biolabs, Ipswich, MA). Intermediate
and final purifications were performed using an RNeasy midi or maxi-kit (Qiagen, Hilden,
MA) according to the expected yield of mRNA. After final purification, RNA was recon-
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stituted in PBS, and the concentration was determined using 260nm/280nm module on a
NanoDrop spectrophotometer (ThermoFisher, Waltham, MA). The mRNA was stored at
-80◦C until use.
2.2.3 Dose and Time Course Assay
HFFs were transfected on glass coverslips as above in antibiotic free media at doses ranging
from 100ng to 1µg. All time course data cells were dosed with 1µg of mRNA. Time course
cells were fixed in 4% paraformaldehyde in PBS at the appointed time post-transfection.
All dose-response cells were cultured for one day and then fixed in 4% paraformaldehyde
in PBS. Coverslips were then permeabilized in 0.1% Triton X-100 in PBS. Following per-
meabilization, the cells were blocked in 5% BSA, 5% goat serum and 5% donkey serum
in PBS for one hour at room temperature. Cells were then incubated with primary anti-
V5, anti-αVβ3 antibodies from Table 2.1 overnight in a 1% goat serum solution of PBS at
4◦C. The following day, the coverslips were washed three times in PBS-T, and incubated
for an hour at room temperature with the 488, 657 secondary antibodies listed in Table
2.1 in PBS-T, counter-stained with 1:40 AlexaFluor546 conjugated phallodin and 1:1000
Hoescht 33342 (ThermoFisher, Waltham, MA) and washed three more times for 5 minutes
each in 1X PBS-T. Coverslips were then mounted to 25mm coverslips with Prolong Gold
(ThermoFisher, Waltham, MA). These coverslips were sealed to a microscope slide and
stored at -20◦C until imaged.
Coverslips were imaged using a Axiovert 200M microscope (Carl Zeiss Microscopy,
Jena, Germany) with an UltraVIEW spinning disk (PerkinElmer, Waltham, MA) and Flash
4.0v2 cMOS camera (Hamamatsu Photonics, Hamamatsu City, Japan). 40X images were
collected using a 1.4NA Plan-Apochromat objective (Carl Zeiss Microscopy, Jena, Ger-
many). Image acquisition and analysis of cell expression was performed in Volocity (PerkinElmer,
Waltham, MA). Cells’ expression data were exported and analyzed in Prism (Graphpad, La
Jolla, CA).
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2.2.4 CHO-Fibronectin Binding Assay
Clear bottom, 96 well plates were prepared by incubation at 37◦C for 1 hour with one
of four ligands: (1) fibronectin fragments that mimic the stabilized, mechanically relaxed
integrin binding domain (“9*10”); (2) fibronectin fragments that mimic a strained, desta-
bilized integrin binding domain (“4G”); (3) 10µg/mL human fibronectin; or (4) 1% BSA
passivated surfaces. All surfaces were then washed 3 times with PBS and blocked at 4◦C
with 1% BSA in PBS until use. After initial characterization of cell binding to the fi-
bronectin fragments with ligand concentrations between 250nM and 2µM, all subsequent
experiments with fragments were conducted at 250nM.
Stably transfected CHO cells expressing either human αVβ3 or α5β1 integrins were
harvested in 135mM potassium chloride with 1.5mM sodium citrate, spun down at 1000g
for 5 minutes, and resuspended to a concentration of 200,000 cells/mL in pre-warmed,
serum free media. For the standard curve, these cells were plated in a dilution series from
20,000 cells per well to 1000 cells per well in a constant volume of 100 µL in duplicate
for each CHO cell line on full length fibronectin surfaces. For experimental conditions,
20,000 cells were plated in 100 µL volumes on the experimental surfaces and incubated
for 20 minutes at 37◦C in a 5% CO2 incubator. The standard curve conditions were plated
first and then the experimental cells were plated. All plating and subsequent washing was
conducted using an 8-channel multi-well pipette to allow for minimal plating time. Fol-
lowing the incubation at 37◦C, the standard curve cells were fixed directly in the wells
through the addition of 10% glutaraldehyde in PBS. For experimental cells, the media was
removed, cells were washed once with ice-cold PBS, and then fixed in 5% glutaraldehyde
for 10 minutes. After fixation, wells were washed three times with PBS and then stained
with 0.1% crystal violet in water for one hour. After staining, well were washed 3 times
with PBS and allowed to air dry over night inverted. After drying, the remaining crystal
violet was solubilized with 100µL of 10% acetic acid and the absorbance of wells was
measured on a Synergy H4 with Hybrid Technology plate reader (BioTek, Winooski, VT)
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plate reader using a monochromoter at 570nm. Raw absorbance values were imported into
Prism (Graphpad, La Jolla, CA) for analysis. Each well’s absorbance was corrected for
background crystal violet staining using wells without cells plated and the final number of
adherent cells was interpolated from the standard curve from that plate.
2.2.5 RFL6 Mechanotransduction Assay
RFL-6 cells were plated at a concentration of 10,000 cells/cm2 in 6 well plates and allowed
to adhere for 4 hours. After the cells had adhered, the media was exchanged for OptiMEM
(ThermoFisher, Waltham, MA), and these fibroblasts were then transfected with 1µg of
mRNA or vehicle alone using 2 µL of Lipofectamine2000 (ThermoFisher, Waltham, MA)
in a 250 µL reaction in OptiMEM according to the manufacturer’s instructions. The fol-
lowing day, cells were harvested in 135mM potassium chloride with 1.5mM sodium citrate,
spun down at 1200g for 5 minutes and resuspended in serum free media. 3000 cells/cm2
were plated on 1kPa and 25 kPa hydrogel surfaces (Matrigen, Brea, CA) functionalized
with 10 µg/mL human fibronectin according to the manufacturer’s instructions. Cells were
allowed to spread on these surfaces at 37◦C in a 5& CO2 incubator for 4 hours.
After spreading, cells were washed in ice-cold PBS, fixed in 4% paraformaldehyde
in PBS for 10 minutes and then permeabilized in 0.1% Triton X-100 in PBS. Following
permeabilization, the cells were blocked in 5% BSA, 5% goat serum and 5% donkey serum
in PBS for one hour at room temperature. Cells were then incubated with primary anti-
V5 antibody from Table 2.1 overnight in a 1% goat serum solution of PBS at 4◦C. The
following day, the hydrogels were washed three times in PBS-T, and incubated for an hour
at room temperature with the 488 secondary antibody listed in Table 2.1 in PBS-T, counter-
stained with 1:40 AlexaFluor546 conjugated phallodin (ThermoFisher, Waltham, MA) and
washed three more times for 5 minutes each in 1X PBS-T. Hydrogels were then mounted to
25mm coverslips with PLA Mounting Media with DAPI (Sigma, Hilden, Germany). These
coverslips were sealed to a microscope slide and stored at -20◦C until imaged.
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Hydrogels were imaged using a Axiovert 200M microscope (Carl Zeiss Microscopy,
Jena, Germany) with an UltraVIEW spinning disk (PerkinElmer, Waltham, MA) and Flash
4.0v2 cMOS camera (Hamamatsu Photonics, Hamamatsu City, Japan). 40X images were
collected using a 1.4NA Plan-Apochromat objective (Carl Zeiss Microscopy, Jena, Ger-
many). Image acquisition and analysis of cell morphology was performed in Volocity
(PerkinElmer, Waltham, MA). Individual cell morphologies were exported and analyzed
in Prism (Graphpad, La Jolla, CA).
2.2.6 Focal Adhesion Phosphorylation by Western Blot
HFFs were transfected in 6 well plates at confluence in antibiotic free media with 1µg
of mRNA or vehicle alone using 2 µL of Lipofectamine2000 (ThermoFisher, Waltham,
MA) in a 250 µL reaction in OptiMEM according to the manufacturer’s instructions. After
overnight incubation, cells were collected using a solution of 135mM potassium chloride
and 1.5mM sodium citrate, spun at 1200g for 5 minutes and resuspended in warm serum
free media. 100,000 cells were plated into 6 well plates functionalized with 10µg/mL
human fibronectin in 1 mL total volume. These cells were incubated at 37◦C for 30 minutes
in a 5% CO2 incubator. After incubation, the surfaces media was aspirated and washed
with ice-cold PBS. The PBS was aspirated and the cells were directly lysed into 60µL
of 2X loading dye supplemented with Pierce protease and phosphatase inhibitors tablets
(ThermoFisher, Waltham, MA). This lysate was collected using a cell scraper and then
treated with 0.3 µL of benzonuclease (ThermoFisher, Waltham, MA) for 15 minutes at
room temperature with vigorous shaking. Samples were heated to 95◦C for 5 minutes and
20µL of the total solution was run on a 4-12% Bis-Tris gel in 1x MES buffer and run for
70 minutes at 150V. The gel was then transferred to a nitrocellulose membrane using the
XCell Blot Module (ThermoFisher, Waltham, MA) at 25V for 65 minutes. Membranes
were air-dried for an hour, and blocked with 5% BSA in 1X TBS for an hour at room
temperature. The blots were then incubated with primary antibodies as described in Table
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2.1 in 1X TBS-T with 1% BSA for 16-24 hours at 4◦C with shaking. Near-IR or HRP
conjugated secondaries as described in Table 2.1 were then incubated with the blot and
imaged subsequently on either an Odyssey CLx system (Licor, Lincoln, NE) Band analysis
was performed using the associated Licor software and exported to Prism (Graphpad, La
Jolla, CA) for analysis.
2.2.7 In vivo Delivery of mRNAs
Eight to 10-week old female BALB/c mice (Charles River Laboratories, Wilmington, MA)
were house in the Physiology Research Lab in the Engineering Biosciences Building and
cared for in accordance with Georgia Institute of Technology and National Institutes of
Health guidelines. Food and water was provided ad libitum. Animals were quarantined
for 6 days before any experiments were performed. All animals were euthanized with CO2
asphyxiation. Experimental review covering this work was provided by Georgia Institute of
Technology’s Institutional Animal Care and Use Committee (IACUC), protocol #A17015.
For mRNA instillation, mice were anesthetized using an IP injection of 87 mg/kg ke-
tamine and 16 mg/kg xylazine. The mice were intubated with 1.22 mm endotracheal tubing
(Hallowell EMC, Pittsfield, MA) on a 45◦ tilt table with a surgical lamp to provide visual-
ization of the trachea. Aerosol delivery was performed using a MicroSprayer Model 1A-1C
with a High Pressure Syringe Model FMJ-250 (PennCentury, Philadelphia, PA), which was
pumped using a custom Pump 11 Elite Nanomite handheld syringe pump (Harvard Appa-
ratus, Holliston, MA). 50 µL of mRNA were delivery for each animal and total mRNA
doses of V5-tagged and nano-luciferase fused mRNA constructs were 100 µg per animal
and 133 µg per animal, respectively. Animals were recovered from anesthesia under a heat
lamp and returned to housing until experimental sacrifice one and eight days after mRNA
instillation.
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2.2.8 Flow Cytometry and FACS of Single Cell Suspensions
Generation of Live/DEAD Stained, Single Cell Suspensions
Dissected lungs were washed in ice cold PBS and then digested into a single cell suspen-
sion using the Miltenyi Biotec Lung dissociation kit and protocol (Cat. # 130-095-927,
Miltenyi Biotec, Auburn, CA) with the following changes: (1) the amounts of enzyme D
and enzyme A were reduced by 40% to 60uL enzyme D and 9uL enzyme A per cell prep;
(2) the digestive enzymes were not added until after the initial tissue crush in the gen-
tleMACS device; and, (3) the samples were not incubated on a rotor during the digestion
by enzymes A and D but were shaken vigorously at 37◦C in a shaking water bath upright.
After the Miltenyi digestion protocol, the suspensions were pelleted at 4◦C for 10 minutes
at 300g and resuspended in 3mL of red cell lysis solution (Alfa Aesar, Haverhill, MA) for 5
minutes. The reaction was quenched by addition of at least 20 mL of ice-cold PBS to each
suspension. The cells were then pelleted at 4◦C for 10 minutes at 300g and counted using
a hemocytometer. 3 million cells were aliquoted per reaction and stained for 30 minutes
at 4◦C with Blue Live/DEAD fixable dye (ThermoFisher, Waltham, MA) according to the
manufacturer’s instructions. The cells were then pelleted at 4◦C for 10 minutes at 300g.
Flow Cytometry Protocol
After pelleting the cells following Live/DEAD staining, the cells were resuspended in PBS
with 2% FBS and then pelleted again at 4◦C for 10 minutes at 300g. The cell pellet was
resuspended in 500 µL of 2% paraformaldehyde and incubated for 10 minutes at room
temperature. From this point on, the cells were routinely pelleted at 4◦C for 5 minutes at
1200g. After pelleting the cells were washed once in 1mL of 2% FBS in PBS, pelleted
again and stained in 200 µL of antibody solution for 30 minutes shaking at 4◦C. The anti-
bodies used, along with their relative dilutions into 2% FBS in PBS, are listed in Table 2.1.
After antibody staining, the cells were pelleted and washed once in 2% FBS in PBS before
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being resuspended in 250 µL and strained into flow tubes through a 70µm filter. Cells
were stored on ice until run on the cytometer. Cells were analyzed using a LSRFortessa
running FACSDiva software (BD, Franklin Lanes, NJ). Exported FCS files were analyzed
and representative plots generated in FlowJo (BD, Franklin Lanes, NJ). Data exported from
FlowJo was analyzed and graphed in Prism (Graphpad, La Jolla, CA). Compensation and
gating by negative cell populations are described below.
FACS Protocol
Staining the cells in preparation for FACS is similar to the protocol used for flow cytometry
with the following changes: (1) cells were not fixed after Live/DEAD staining and were
instead resuspended and washed in 2% FBS in PBS; (2) all pelleting steps remained at
4◦C for 10 minutes at 300g; (3) the primary antibody solution did not contain the primary
V5-647 conjugate listed in Table 2.1 but did contain all the other primary antibodies; (4)
during their final resuspension, the cells were resuspended in FACS buffer (1mM EDTA,
25mM HEPES at pH 7, 1% FBS in 1X PBS). Cells were stored on ice until run on a custom
BD FACSAria Fusion sorter running FACSDiva software (BD, Franklin Lanes, NJ). Sorts
were conducted using a “4-way purity sort” until there were at least 10,000 cells in each
population. Cells were sorted into chilled FACS buffer. Exported FCS files were analyzed
and representative plots generated in FlowJo (BD, Franklin Lanes, NJ). Data exported from
FlowJo was analyzed and graphed in Prism (Graphpad, La Jolla, CA). Compensation and
gating by negative cell populations are described below.
Compensation and Fluorescence Minus One Controls for FACS and Flow Cytometry
Antibody compensation beads were prepared using AbC Total beads according to the man-
ufacturer’s protocol (ThermoFisher, Waltham, MA). One drop of beads was incubated with
1µL of each individual primary antibody for 30 minutes at 4◦C. A single drop of the kit’s
negative control beads was then added to each reaction, which was supplemented with 100
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µL of 2% FBS in PBS. Live/DEAD compensation beads were prepared in a similar fashion
using ArC beads and the associated ArC negative control beads instead of AbC beads (Ther-
moFisher, Waltham, MA). Fluorescence minus one (“FMO”) controls were prepared from
cell suspensions that were processed according to the FACS and flow cytometry staining
protocols above except a single primary antibody conjugate was omitted from the antibody
staining solution for each marker used in the panel.
Each cytometer’s detector voltage settings were calibrated using the compensation beads
to create at least a half log difference in fluorescent intensity between that bead’s channel
and any other detector used during the assay. A compensation matrix was generated and
algorithmically validated by the cytometer’s software. FMO samples were used to create
the gates discriminating positive and negative cell populations for each antibody/dye.
2.2.9 nanoLuciferase Assays
In vitro nano-luciferase assay: Transfected cells were harvested from culture or from FACS
and plated in a white 96-well plate microtiter plate (Corning, Corning, NY) in 100 µL
volumes. Nano-luciferase assays were performed on a Synergy H4 with Hybrid Tech-
nology plate reader (BioTek, Winooski, VT) according to the manufacturer’s instructions
(Promega, Madison, WI) with the following modifications: 100 µL of nano-luciferase as-
say buffer was injected using plate reader’s integrated pumps, luciferase integration times
were held to 1 second, and the plate reader’s detector voltages were adjusted by the software
based on brightest wells to maximize the dynamic range of the assay. Raw luminescence
values were exported to text files and analysis was performed in Prism (Graphpad, La Jolla,
CA).
In vivo nano-luciferase assay: Lungs harvested from experimental animals were washed
in ice-cold PBS and then incubated in 500 µL of a 1:40 nano-luciferase reagent in PBS
(Promega, Madison, WI) in black, 12 well plates (BioTek, Winooski, VT) and imaged
using an IVIS Spectrum CT (PerkinElmer, Waltham, MA). Images were acquired using
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an integration time of 60 seconds and a binning factor of 8. ROIs were fitted to each
well and the area and total luminescence for each ROI were exported to Prism for analysis
(Graphpad, La Jolla, CA).
2.2.10 Immunofluorescence in Cyrosectioned Lung Tissue
Dissected lungs were immersed in a 3:1 by volume solution of 30% sucrose and OCT
(ThermoFisher, Waltham, MA) on ice. These lungs were subjected to house vacuum for
an hour before being transferred to cyromolds filled with OCT. Molds were frozen in a
2-methyl-butane bath (Sigma, St. Louis, MO) cooled with dry ice. Embedded sections
were stored at -80◦C until sections. 10µm sections were cut on a CyroStar NX70 cyrostat
(ThermoFischer, Waltham, MA).
Following sectioning, tissue was isolated using a pap-pen, fixed for 10 minutes in 2%
paraformaldehyde in 1X PBS, permeabilized for 5 minutes in 0.1% Triton X-100 in PBS
and blocked in 5% BSA, 5% goat serum, and 5% donkey serum solution in 1X PBS for one
hour at room temperature. Samples were incubated in primary antibody solution overnight
at 4◦C using the V5 antibody listed in Table 2.1 in PBS-T with 1% goat serum. Tissues
were washed three times in PBS-T with 5 minute incubations before incubation for an
hour at room temperature with the 488 secondary antibody listed in Table 2.1 in PBS-T,
counter-stained with 1:40 AlexaFluor546 conjugated phallodin and 1:1000 Hoescht 33342
(ThermoFisher, Waltham, MA) and washed three more times for 5 minutes each in 1X
PBS-T. Samples were sealed with Prolong Gold (ThermoFisher, Waltham, MA) and stored
at -20◦C until imaged.
Tissues were imaged using an Axiovert 200M microscope (Carl Zeiss Microscopy,
Jena, Germany) with an UltraVIEW spinning disk (PerkinElmer, Waltham, MA) and Flash
4.0v2 cMOS camera (Hamamatsu Photonics, Hamamatsu City, Japan). High resolution
images (40X) were collected using a 1.4NA Plan-Apochromat objective (Carl Zeiss Mi-
croscopy, Jena, Germany). Whole tissue images were created by finding an ROI to encom-
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pass the entire tissue, fitting the ROI to a focus map to adjust for systemic focal bias, and
then stitching individual images together using 15% overlap between individual frames.
Image acquisition and analysis was performed in Volocity (PerkinElmer, Waltham, MA).
Table 2.1: Primary and Secondary Antibodies Used in this Chapter
Application
Target Clone Host Dye Conjugate IF FlowCyto FACS WB Vendor Cat #
Primary
V5 1036H Rabbit Alexa Fluor 647 1:50 R&D Biosystems FAB8926R
CD31 390 Rat PE-CF594 1:200 1:200 Biolegend 102429
CD45 30-F11 Rat Brilliant Violet 711 1:500 1:500 Biolegend 103147
CD326 G8.8 Rat APC/Cy7 1:50 1:50 Biolegend 118217
V5 Polyclonal Rabbit 1:1000 1:1000 Abcam ab9116
pFAK Polyclonal Rabbit 1:1000 Invitrogen 44-624G
pSFK Polyclonal Rabbit CST 2101
GAPDH D-6 Mouse 1:1000 Santa Cruz sc166545
Integrin LM609 Mouse 1:1000 EMD Millipore MAB1976
Secondary
Donkey anti-Rabbit IR680 Polyclonal Donkey 680 IR Dye 1:20000 Licor 926-68073
Donkey anti-Mouse CW800 Polyclonal Donkey 800 IR Dye 1:20000 Licor 926-32212
Goat anti-Rabbit Polyclonal Goat Alexa Fluor 488 1:500 Invitrogen A-11008
Goat anti-Mouse Polyclonal Goat Alexa Fluor 647 1:500 Invitrogen A-21245
Table 2.2: Oligos for Sequencing and Cloning Used in this Chapter
Oligo 5’-3’ Sequence Purpose Tm Concentration Vendor Cat. #
nanoLuc Adapter Forward gctgcccccgcctccTCTCTTGATTTCCACCTTG
Gibson Assembly of H5-CD8 & Thy-1 mRNA with nanoLuc
59.7 500nM
IDT Custom
nanoLuc Adapter Reverse gctGCTGCTGCTGCTCACGAG 59.7 500nM
H5-CD8-NanoLuc Forward ccaaggtggaaatcaagagaggaggcgggggcagcATGGTCTTCACACTCGAAGATTTCG
H5-CD8 Specific Gibson Primers
67.6 500nM
H5-CD8-NanoLuc Reverse gtctcgtgagcagcagcagcagcCGCCAGAATGCGTTCGCAC 67.6 500nM
Thy-1-NanoLuc Forward tcagagacaaactggtcaagggaggcgggggcagcATGGTCTTCACACTCGAAGATTTCG
Thy-1 Specific Gibson Primers
67.5 500nM
Thy-1-NanoLuc Reverse gtctcgtgagcagcagcagcagcCGCCAGAATGCGTTCGCAC 67.6 500nM
Interior Seqeuncing Primer TAAGCTGCTGATCTACGCTGCC Interior Sanger Sequencing Primer for Gibson Products 60 2uM
5’ mRNA Sequencing Primer TTTTAAGCTTTAATACGACTCACTATAGG 5’ Sanger Sequencing Primer for mRNA Constructs 60 2uM
3’ mRNA Sequencing Primer TTTTTGCGGCCGCCTTC 3’ Sanger Sequencing Primer for mRNA Constructs 60 2uM
2.3 Results
2.3.1 mRNA Constructs Expressed in a Dose-Dependent Fashion on the Surface of Fibroblasts
within 4 Hours of Transfection
The kinetics and dose-dependence of surface expressed mRNA constructs were assessed
by confocal microscopy. HFFs transfected with H5-mRNA constructs using Lipofec-
tamine 2000 demonstrated clustered surface expression of H5-GPI and H5-CD8 proteins
that was qualitatively distinct from the pattern of αVβ3 surface expression in these cells
(Figure 2.1A). Expression of mRNA constructs was linearly dose-dependent (r2=0.9377)
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with mRNA loads between 100ng and 1ug of mRNA one day after transfection (Figure
2.1B). HFFs began expressing mRNA constructs on their surface 4 hours after transfec-
tion (p=0.0106), and expression increased further during one day of culture (Figure 2.1C,
p=0.0054).
2.3.2 CD8- and GPI-linked H5 Constructs Specifically Increased Adherence to Strained
Fibronectin Fragments
In order to ascertain whether this surface expressed H5 protein was functional, adhesion
assays using CHO cells expressing a single human integrin pair (“CHOB2” cells expressed
αVβ3 while “CHOK1” cells expressed α5β1 integrins) were performed on previously es-
tablished fibronectin fragments that mimic the strain or relaxed forms of the integrin bind-
ing domain of fibronectin’s III9-III10 repeats (Figure 2.2). [44, 43, 29, 49] Untransfected
CHOK1 cells demonstrated a binding preference to relaxed-mimic fragments (“9*10”) rel-
ative to strain-mimic fragments (“4G”) at all fragment concentrations, though the difference
was greatest at 250nM concentration. CHOB2 cells did not have a preference for strain-
or relaxed-mimic fragments at any fragment concentration (Figure 2.2A&B). These data
were consistent with previous literature, which found that α5β1 integrins required both the
RGD motif on fibronectin’s III10 repeat and the close juxtaposition of the PHSRN sequence
on fibronectin’s III9 repeat, while αVβ3 integrins only required the RGD motif and were
insensitive to PHSRN’s relative position. [35, 34].
Experimentally treated CHOB2 and CHOK1 cells demonstrated greater binding to full
length fibronectin coated surfaces than BSA passivated surfaces after 30 minutes in serum
free media (Figure 2.2C, p=0.0141 and p=0.0058 for CHOK1 and CHOB2 binding to
fibronectin relative to BSA, respectively). Overall, the expression of either H5-CD8 or
H5-GPI linked proteins significantly shifted the balance of CHOK1 binding towards stain-
mimic fibronectin fragments (p=0.002 and p=0.0022 for CHOK1 cells treated with CD8-
and GPI-linked H5 mRNA). A similar, non-significant trend was observed in CHOB2 cells,
23
indicating potentially increased cellular avidity for these surfaces. These data indicated that
H5 expression imparted a fibronectin strain-specific affinity to cells’ interactions with their
surrounding matrices.
2.3.3 H5-GPI Expression Increased Global Src Family Kinase Phosphorylation in Fibroblasts
I hypothesized that the H5-GPI linker would specifically promote pre-clustering of mem-
bers of the Src Family Kinases (“SFK”) to focal adhesions and increase their activity via
phosphorylation, based on a previous established role for Thy-1’s GPI linker. [30] To test
this hypothesis and to determine if either mRNA construct had an effect on global focal
adhesion signaling as measured by alterations in focal adhesion kinase (“FAK”) phospho-
rylation, phospho-western blots on lysates from fibroblasts expressing H5-CD8 and H5-
GPI linked proteins were performed (Figure 2.3). H5-GPI linked constructs demonstrated
significantly increased levels of phospho-SFK relative to vehicle treated controls (Figure
2.3B, p=0.0088). A similar, statistically insignificant trend was observed in lysates from
H5-CD8 expressing fibroblasts. Interestingly, the degree of phospho-FAK and phospho-
SFK were strongly correlated to the degree of GPI-linked H5 expression in these lysates
(Figure 2.3C&D, r=0.9951 with p<0.0001 and r=0.9768 with p=0.0008 for H5-GPI vs.
pFAK and H5-GPI vs pSFK correlations, respectively). Similarly, less pronounced trends
were present in lysates from fibroblasts transfected with H5-CD8 constructs. These correla-
tions suggested that H5-GPI constructs, in particular, may be both pre-clustering elements
of the focal adhesion complex while also modulating focal adhesion signaling globally.
2.3.4 H5-CD8 Constructs Altered the Mechanotransductive Phenotype of Thy-1 Null
Fibroblasts
RFL6 mechanosensing on soft and stiff substrates through cell spreading and polariza-
tion was used to assess the phenotypic consequences of expression of H5-CD8 or H5-
GPI constructs. RFL6 cell spreading and polarization had previously been shown to be
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sensitive to αVβ3 modulation through expression of Thy-1. [30] Surprisingly, while all
cells, regardless of experimental group, showed increased cell spreading on stiff relative
to soft substrate (p<0.0001 for all groups), H5-CD8 treated cells were significantly more
spread than vehicle treated controls (Figure 2.4C, p=0.0012). Furthermore, RFL6 cells
on stiff substrates trended towards being less polarized, with a significant difference ob-
served in vehicle treated control fibroblasts (Figure 2.4B p=0.0005). These data indicated
that global alternations in focal adhesion protein activation observed in Figure 2.3 may not
have cleanly correlated to mechano-transductive phenotypes in fibroblasts. This discor-
dance may have arisen specifically because H5-CD8 proteins may not have co-clustered as
significantly with αVβ3 integrins and thus may have provided unique binding opportuni-
ties to fibroblasts. Further experimentation examining the focal adhesion more directly will
help resolve this particular discrepancy.
Additionally, the lack of polarization in RFL6 cells with increasing substrate stiffness
was surprising given that cell spread area and cell polarization are usually correlated. [30,
83] Phenotypically, cells on stiffer substrates demonstrated significant actin remodeling
consistent with previous literature, including the development of prominent actin stress
fibers. These observations supported the conclusion that the hydrogel surfaces in these as-
says were differentially presenting mechanical cues to RFL6 cells. However, it remained
possible for there to be differential ligand conjugation to the soft and stiff hydrogel sur-
faces, which could independently modulate cell polarity, resolving this apparent paradox
(specifically, these results are consistent with lower fibronectin conjugation to soft hydro-
gels with relatively higher conjugation on stiff hydrogels). [83] Importantly, both mRNA
treatments led cells towards being more polarized on stiff substrates, which is consistent
with the cell spreading data.
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2.3.5 H5-CD8 Constructs Expressed In Vivo
Flow Cytometry Did Not Detect V5-Tagged mRNA Constructs
Translation of the mRNA-based technology in vivo required characterization of the deliv-
ery of these constructs to the airspace. Flow cytometry is a high-throughput characteriza-
tion technique suitable to assay the effective delivery and expression of V5-tagged mRNA
constructs with single cell resolution and the ability to characterize the cellular tropism of
mRNA expression. [84] Mice were intubated and sprayed with a PBS-mRNA solution, and
their lungs, after digestion into a single cell suspension, were assayed for V5 expression
one day after mRNA instillation (Figure 2.5). Pooled analysis from 3 mice with and with-
out mRNA exposure did not reveal differential population shifts in the median fluorescent
intensity of the V5 signal at any antibody concentration (Figure 2.5A). While the fluores-
cent intensity was linearly correlated with the concentration of the V5 antibody used for
staining (r2=0.998 and r2=0.9721 for mRNA treated and untreated animals, respectively),
indicating the expected dose-response, the slopes of these responses were not significantly
different, indicating that there was not an antibody concentration dependence in the inabil-
ity to separate these two populations (Figure 2.5B, p=0.2396).
All mice, regardless of mRNA treatment, stained brightly with the V5 antibody rela-
tive to unstained controls, possibly indicating a high background to the antibody’s binding
profile. Complicating this interpretation, however, was the observation that decreasing anti-
body concentration led to a bi-modal movement of cells from the positive peak to a negative
peak, co-localized with unstained cells. This trend was qualitatively stronger in the mRNA
untreated population. These data were most consistent with the interpretation that the V5
detection system has a relatively low affinity profile towards the V5 epitope on these cells,
requiring strong electronic amplification in the cytometer’s detectors to discriminate the
signal - e.g. cells moved digitally from a ”stained” to ”unstained” population. The rel-
atively low affinity of this previously characterized antibody for the V5 epitope towards
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these constructs may be explained by the relative placement of the V5 epitope, between the
H5 protein and the membrane linker, as this location for the epitope could have high steric
hindrance associated with it, which could negatively impact surface detection by flow cy-
tometry. [85, 86] While this digital population shift could have been indicative of effective
delivery and expression of V5 to the air space, it was insufficient to determine the degree
of relative expression (due to a lack of shift in the positive population) and direct detection
of the V5 epitope by flow cytometry was not considered going forward.
FACS Isolated H5-Luciferase Fusion Constructs Were Inhibited by Tissue Preparation
To maintain the ability to characterize the relative cellular tropism of expression of H5
in the lungs of sprayed mice while avoiding steric/detection issues identified in the pre-
vious flow cytometry experiments, single cell preps from sprayed and unsprayed mice
were sorted using a FACS scheme previously validated to isolate hematopoietic, epithe-
lial, endothelial, and lineage negative cells. [84] Additionally, the fused V5 tag of these
mRNA constructs were replaced with a nano-luciferase enzyme, which would allow for
the antibody-free, enzymatically amplified detection of translated mRNAs.
This FACS work flow sorted cells into single, live cells populations before dividing
them into CD45+ and CD45- groups (Figure 2.6A-D). These two subpopulations were
each subsequently subdivided into CD31 and CD326 positive and negative populations.
Hematopoietic (Figure 2.6E, lower left quadrant, CD45+CD31-CD326-), epithelial (Fig-
ure 2.6F, lower right quadrant, CD326+CD45-CD31-), endothelial (Figure 2.6F, upper left
quadrant, CD31+CD45-CD326-), and lineage negative cell populations (Figure 2.6F, lower
left quadrant, CD31-CD45-CD326-) were then isolated in a 4 way purity sort.
Characterization of the nano-luciferase system in vitro revealed linear, sensitive detec-
tion of mRNA expressed in HFFs down to dilutions of a hundred transfected cells (Figure
2.7A, r2=0.9949 and r2=0.9969 for the cell number vs luciferase response of Thy-1 and
H5-CD8 constructs, respectively). Given that in vitro transfection is not perfectly efficient,
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these data suggested that the nano-Luciferase system was able to detect 10s of transfected
cells with a high signal-to-noise ratio relative to untransfected HFFs, which had a flat lu-
ciferase response to input cell number.
Following cell type isolation from FACS, individual cell populations from the right
lungs of mice were analyzed using a nano-luciferase assay one day after mRNA instillation
(Figure 2.6C). An independently prepared standard curve (Figure 2.7B) from in vitro trans-
fected HFFs demonstrated the same linear luciferase response previously observed (Figure
2.6A), down to abundances of 100 input cells. Unfortunately, no FACS isolated popula-
tion had luciferase readings within the interpolation range of the standard curve and were
similar to readings from wells without any cells. There were no statistical differences in
the luciferase readings in any cell population between mRNA exposed and unexposed ani-
mals except for the lineage negative (“Triple Negative”) population, which had significantly
higher luciferase readings in the mRNA untreated cells than in cells from either mRNA
treatment (p<0.0001). Given the previously demonstrated sensitivity of the nano-luciferase
system, I hypothesized that there may be tissue-derived inhibitors of the nano-luciferase re-
action which were preventing detection of the translated proteins. This hypothesis was sup-
ported by nano-luciferase assays in which single cell suspensions of mRNA treated animals
demonstrated a biphasic response to dilution in FACS buffer. Specifically, Thy-1 treated
single cell suspension showed a trend towards increasing luciferase signal with increasing
dilution in FACS buffer, which peaked around a ten-fold dilution and began to fall with
decreasing cellular input at one hundred fold dilutions. Single cell preps from control of
H5-CD8 mRNA treated animals did not show this same bi-phasic response (Figure 2.7D).
Subsequently, I tested whether single cell preps from animals without exposure to nano-
luciferase fused mRNA could inhibit the activity of nano-luciferase expressed in vitro. In
vitro treated HFFs, which demonstrated a linear dose-response in nano-luciferase assays
(Figure 2.7B), showed a clear loss of luciferase signal when mixed 1:1 by volume with cell
suspensions from control animals relative to 1:1 volume dilution in FACS buffer (Figure
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2.7E, p=0.0332 and p=0.0215 for H5-CD8 and Thy-1 expressing HFFs, respectively).
These data supported the conclusion that there were tissue-derived nano-luciferase in-
hibitors present in the single cell preparations, though the specific source of that inhibitor
was unclear. One noticeable difference between individual single cell lung preps from
different animals was the level of residual blood in the suspension. While red blood cells
(“RBC”) were lysed using osmotic treatment in the preparation of these lysates, differential
levels of RBC contamination could have been present in each prep, complicating the po-
tential downstream analysis. RBCs or RBC lysis products have not been previously shown
to inhibit nano-luciferase assays and these data may contribute a unique perspective on the
limitations of such studies ex vivo. [87]
Whole Lung Tissues Demonstrated mRNA-Dependent Luciferase Activity
While tissue digestion and processing seemed to produce a nano-luciferase inhibitor, sev-
eral groups have demonstrated the use of nano-luciferase as a reporter system in intact
tissues and living animals. [84] Right and left lungs, dissected from mice but otherwise
intact, were assayed for nano-luciferase activity using an IVIS imager 8 days after mRNA
instillation (Figure 2.8A). Kinetic measurements of the luciferase response from these tis-
sues showed a time-invariant trend, where Thy-1 mRNA treated animals demonstrated sig-
nificantly higher luciferase readings at 7 and 15 minutes relative to untreated animals’
lungs (Figure 2.8B, p=0.0414 and p=0.0078 for 7 and 15 minutes, respectively). H5-CD8
mRNA sprayed animals displayed a similar trend (Figure 2.8B, p=0.2292 and p=0.1295
for 7 and 15 minutes, respectively), though one H5-CD8 sprayed animal had luciferase
readings comparable to non-treated lungs. Single time-point analysis at 15 minutes of the
combined left and right lung luciferase response demonstrated this trend as well (Figure
2.8C, p=0.4494 and p=0.1645 for H5 and Thy-1 luciferase activity relative to untreated
lungs, respectively). The nano-luciferase assays also revealed a left-right lung expression
bias, with increased expression in the left lung, in all animals (Figure 2.8D). While the
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increased expression in the left lungs of mRNA treated animals could indicate delivery
bias (p=0.108 and p=0.14 for left vs right luciferase activity in Thy-1 and H5-CD8 mRNA
treated animals, respectively), the difference in untreated animals suggested that intrinsic
mass biases between the left and right lungs need to be accounted for in future studies.
Spatial Distribution and Heterogeneity of mRNA Expression in the Lung by Immunofluo-
rescence
In order to account for the spatial distribution of mRNA expression in the airspace, im-
munofluorescence on V5-tagged mRNA constructs was performed on cyrosectioned lung
tissue from mRNA exposed and unexposed animals. Whole lung imaging of these tissues
reveal millimeter sized variation in H5/V5 expression in mRNA treated animals (Figure
2.9A). Interestingly, certain cell populations inside the lungs of control animals demon-
strated exceptionally high staining background, specifically on the luminal surfaces of
structures that could plausibly be either arteries or bronchial airways. This heterogene-
ity in V5 staining background could have been a complicating factor which made analysis
of single cell suspensions derived from these tissues difficult to assay cleanly by flow cy-
tometry (Figure 2.5).
At higher resolution, areas of high V5 signal in mRNA exposed animals had quali-
tatively distinct patterns of V5 expression relative to areas of low V5 signal expression in
mRNA exposed animals and to control animals’ lungs. Control animals and low-expression
regions of mRNA treated animals demonstrated faint V5 staining, which appeared to be
colocalized with the nucleus. In contrast, high expression regions from mRNA exposed
animals, demonstrated a cellular dispersed V5 signal, indicating high levels of local trans-
fection of these tissue regions. These data demonstrated that profiling V5 expression by
immunofluorescence was a tractable way to address spatial heterogeneity in the delivery
and translation of mRNA to the lungs and could potentially be multiplexed with cell-type
markers in the future to characterize the relative cellular tropism of mRNA transfection.
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2.4 Discussion
2.4.1 αVβ3 Antagonism as a Therapy for Pulmonary Fibrosis
The ability of the fibrotic matrix to drive pathology has emerged as a frontier in the dis-
covery for treatments of pulmonary fibrosis. [16] This new focus has been driven by the
discovery of a variety of mechanisms through which the matrix and mechanical cues from
it drive fibrotic pathology. These matrix-driven factors include activation of the myocardin
related transcription factor family and YAP/TAZ transcription factors [12, 15, 14], potenti-
ation of TGFβ activation [13] and cellular-sensitization [88, 89, 90, 91] (discussed further
in Chapter 3 of this thesis), and alterations in integrin signaling, specifically focused on αV
and α5 integrins. [30, 49, 29]
Unfortunately, this scientific enthusiasm for the matrix and mechanical signaling to
cells has not translated yet into a bevy of new clinical trials to explore novel matrix-based
therapeutic avenues: of the current 19 clinical trials in Phase II or Phase III for pulmonary
fibrosis, only a single trial focuses on cell-ECM interactions, a monoclonal antibody ther-
apy directed against αVβ6 integrin by Biogen Pharmaceuticals. [92] Another matrix-based
therapy, simtuzumab, a monoclonal antibody against lysyl oxidase-like 2, recently failed
its Phase II clinical trial after it failed to demonstrate efficacy in progression-free survival
relative to placebo. [93] Other clinical trials in progress mainly focus on previous failed ap-
proaches in the setting of co-administration with pirfenidone or nintedanib, newly approved
drugs for pulmonary fibrosis. [10, 9]
The ability of H5 to recognize and contextually antagonize αVβ3 integrin signaling
through strained fibronectin matrices has been previously established. [29, 49] A H5-based
approach differs significantly from Biogen’s αVβ6 therapy in that H5’s antagonism of in-
tegrin is contextual - it specifically recognizes a mechanically-activated, fibrosis-associated
state of fibronectin. Indeed, in this Chapter, H5 has shown that the ability to discriminate
between fibronectin strain states was preserved when H5 was attached to cells by a GPI or
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CD8 peptide linker. This contextual antagonism of H5 may be especially important clin-
ically because of the physiological role played by αV integrins in various processes like
wound healing and regeneration. [94, 95, 96] Another important difference between a H5-
and αVβ6-based approach is the former’s ability to antagonize TGFβ activation in addition
to matrix-ECM contacts. [97, 98] αV integrins have been shown to be able to mechanically
activate TGFβ from matrix-bound latent complexes through binding of an RDG motif in
the latent-associated peptide. [13] Previous work in characterizing the binding of H5 has
established that RGD alone is not sufficient for engagement, and H5 likely recognizes a par-
ticular three-dimensional confirmation of the III9 and III10 domains of fibronectin. [29, 49]
These fundamental differences in the mechanisms of H5 and other matrix-focused therapies
underscores the novelty of work in this area and may present an opportunity for synergistic,
combination therapies in the future.
2.4.2 Role of Cell Linkers in Modulating the Function of Surface Expressed Proteins
Cell Tethering as a Modulator of Molecular Pharmacokinetics
The ability to conjugate H5 to the surface of cells is a novel approach to modulating cell-
ECM interactions. [29] Tethering to cells likely changes the pharmcodynamics of H5 resi-
dency in the lung by preventing rapid clearance into the lymphatic and systemic circulation
[65, 64] and by resident airway marcophages. [67, 68] Proteins of equivalent mass deliv-
ered to the airway in previous studies, like human growth factor, have demonstrated tissue
life-times on the order of 10 hours in previous studies [68]. These half-lives can be ex-
tended through various engineering solutions such as PEG-ylation of the molecule, which
provided PEG-lysine dendrimers tissue half-lives on the order of 1-2 days mostly by pre-
venting them from leaching into the systemic circulation [71]. Alternatively, groups have
also used Fc-fusions to proteins, which increased the therapeutic protection of IL-7 against
influenza infection in mice on the order of weeks [99], but which are also associated with
increased transcytosis of the proteins into the systemic circulation and directed associa-
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tion with immune cells in the lung, potentially increasing off-target effects for a H5-based
therapy. [69, 70] In contrast, cell surface expression of H5 affords straight-forward, cell-
implemented (i.e. not requiring external modification and subsequent characterization of
the proteins’ purity and function) strategy, which intrinsically focuses the therapeutic ac-
tivity of H5 on fibronectin which is cellularly accessible. Furthermore, data in this Chapter
suggests that H5-nano-luciferase fusions are present in the lung 8 days after instillation,
indicating a substantially improved half-life over similarly sized molecules. [68]
Cell Tethering as a Modulator of H5 Biology
The conjugation of H5 to the surface of cells also affords the opportunity to modulate
H5’s efficacy based on the innate biological regulation of the linker itself. Thy-1 and its
GPI linker have served as a biologically-inspired template for how to link H5 to cells be-
cause of Thy-1’s endogenous role in regulating mechano-transduction in fibrosis. [72, 100,
74] Specifically, Thy-1 has been shown to associate with αVβ3 integrins in a GPI and
cholesterol-dependent fashion, which is lost when Thy-1 is expressed with a single-pass
peptide transmembrane linker from CD8. [75, 76, 77, 30] This association is significant
both because of Thy-1’s ability to lock αVβ3 into a “bent”, inactive conformation through
cis-binding of Thy-1’s RLD domain [30] and because the GPI linker pre-clusters members
of the Scr Family Kinases, specifically fyn, into focal adhesions, which alters the mechan-
ical phenotype of the cell in a Rho- and cytoskeleton-dependent fashion. [81, 78, 79, 80]
Work in this Chapter has shown that GPI-linked H5 constructs are just as effective as
H5-CD8 constructs at binding strain-mimic fibronectin fragments while also significantly,
and differentially to H5-CD8, increasing global phospho-SFK signaling. Interestingly, in a
study of Thy-1 null fibroblast spreading on soft and stiff surfaces, H5-CD8 constructs led
to increased cell spreading relative to H5-GPI and vehicle treated controls, implying that
the ultimate effect on the mechano-transductive phenotype of the cells may not be fully
captured by the alterations in focal adhesion biology. Indeed, the pre-clustering of H5 with
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αVβ3 integrins may also modulate the kinetics of integrin-ECM interactions. Previous
studies of integrin-ECM binding have found that the cell’s glycocalyx creates an energy
barrier due to the relative extent of this mucin-layer and integrins from the cell’s surface.
[101] The consequence of this energy barrier is that single binding events, which necessar-
ily occur in regions where this energy and space barrier have been overcome, act as kinetic
funnels for the subsequent binding of other integrins. [102] In this context, non-associated
H5-CD8 constructs may actually serve as an unique nidus for cell-ECM interactions, apart
from H5-GPI/integrin clusters, which could ultimately potentiate the ability of αVβ3 inte-
grins to associate with the matrix. Studying the ability of H5-CD8 and H5-GPI integrins to
modulate the number and size of focal adhesions in the cell as well as the ability of these
H5 proteins to compete directly for matrix binding sites with integrin in pull-down assays
(both described below in Future Directions) will help to directly these questions.
Finally, the use of the GPI and CD8 linkers should be considered in the context of Thy-
1’s regulation in inflammatory and fibrotic settings. Thy-1 expression is lost in fibrotic
tissues both through epigenetic heterochromatinization of its promoter [73], and through
TNFα- and IL-1-driven activation of phospholipase C, which cleaves the GPI anchor. [72]
The effect of phospholipase C’s activity on H5-GPI constructs in the diseased setting has
not been considered here but could negatively impact the tissue residency of H5-GPI con-
structs and motivate the use of H5-CD8 designs. Interestingly, other groups have explored
the cleavage of various GPI-linked proteins by phospholipases in vitro and in vivo and
found evidence for discrimination in the enzymes’ activity. [103] Understanding the pro-
tein features associated with this discrimination may afford the ability to design cleavage
resistant H5-GPI constructs to avoid inflammation-driven loss of H5 from the cell’s surface.
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2.4.3 Role of Aerosol Spray For Delivering mRNA Therapeutics to the Lung
Direct Administration Via the Airspace Compared to Oral- or Injection-based Routes
The delivery of aerosolized mRNA without a secondary delivery scheme to the airspace is
a unique method of drug delivery pioneered by the Santangelo group. Direct therapeutic
administration to the lung has obvious advantages in targeting the therapy to the affected
organ and avoiding systemic side-effect. The approach in this chapter differs significantly
from most currently investigated therapeutics. All currently investigated therapies for pul-
monary fibrosis except the small molecules TD139, an inhibitor of inflammatory signaling
through galactin-3, and trepostinil, a prostacyclin, are currently administered orally or by
injection. [92] Previous work by the Barker group had focused on the vascular delivery of
H5 to the lung. [49, 29] This route of delivery exploits unique derangements of the vas-
cular permeability in fibrotic regions, likely driven by local inflammation. However, the
long-term accessibility to the lung through this vascular mechanisms has yet to be vali-
dated. An investigation of collagen-I PET probes, which used injection as a route to lon-
gitudinally study the progression of pulmonary fibrosis, demonstrated that efficient disease
tracking was only possible in an experimental model of fibrosis that combined bleomycin
with FTY720, a sphingosine-1-phosphate receptor modulator that increased vascular per-
meability to the lung. [104, 105] Further work with aerosolized mRNA should help to
establish the direct pharmacological benefits of this particular route of administration.
Effects of Gene Therapy Carriers and Vectors In Delivery to the Airspace
Remarkably, the spraying method used in this work allows for the expression of mRNA
constructs as demonstrated by immunofluorescence and nano-luciferase activity without
the need for a delivery vehicle. This is extremely advantageous as delivery vehicles for gene
therapy require additionally engineering controls to implement and often interact them-
selves with the biology of the lung. For instance, gene therapy approaches using adeno-
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viral vectors have been thwarted by the presence of endogenous antibodies against the
vectors themselves, raising questions about the efficacy of these treatments in adeno-virus
exposed populations and the repeatability of therapeutic intervention along this route. [58]
Additionally, several different cationic polymer-based approaches to gene delivery have
been employed in the lung, using both synthetic and naturally derived compounds. PEI,
in particular, has been used in several pre-clinical model of gene therapy to the airspace.
[106, 107] Analysis of these vehicles’ effects on gene regulation alone find that both PEI
and naturally derived polymer systems, such as chitosan, independently increased the tran-
scription of inflammatory genes, COX and HO-1, which may be especially disadvantageous
in the setting of diseased, frail tissues. [108] Indeed, the inflammatory activity of PEI, in
particular, seems critical to its ability to target genes to the lung when administered system-
ically. [109] Delivery of mRNA-based therapies without an additional carrier represents an
important and novel method to address these current limitations.
The lack of carriers for mRNA in this system also helps reduce the pharmacological
complexity of their delivery. Efficient delivery of macromolecules to the airspace is de-
pendent on a variety of factors including the relative size, charge, and particle-particle
interactions of the cargoes in an aerosol. [110] Previous studies of airway delivery have
found that micron-sized particles like those generated by the microsprayer in this work are
needed for efficient delivery of therapeutics to the alveolar airspace as larger particles re-
main entrapped in the upper airways and have difficult penetrating the mucus layer in the
lung.[110] I have demonstrated that naked mRNA droplets reached the distal airspace in
the immunofluorescent profiling of V5 expression in transfected lungs. This technique can
be employed in future studies exploring the spatial heterogeneity of mRNA delivery to the
airspace.
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Mechanism of mRNA Uptake Delivered by Aerosolized Particles
How does mRNA delivered to the distal airspaces get taken up by cells and become trans-
lated? Previous work in the Santangelo lab has extensively characterized the routes of
entry by exogenous mRNA to cells and found that polymer-based systems primarily em-
ploy a mixture of clathrin- and caveolin-mediated endocytosis to gain entry to the cells.
[60] Interesting, additional work studying the uptake of naked and nano-particle delivered
mRNA found that substrate mechanics significantly altered the endocytic route and release
of mRNA in the cytoplasm. [111] These mechanistic insights will be particularly impor-
tant in the delivery of therapeutics to the fibrotic lung where normal matrix mechanics have
been significantly deranged. While aerosolized DNA- and mRNA-based therapeutics have
been delivered to the lungs [112, 113] and the genital tract [114] in a variety of experimen-
tal models, these studies were always performed with the use of cationic polymers or viral
vectors, which confounded an understanding of the aerosol itself as a potential vector for
gene therapy. This lack of knowledge as to how the physical delivery of mRNA connected
to the endocytosis and translation of mRNA in tissues will be an important area of future
research to understand delivery of naked mRNAs by aerosols fully.
2.5 Future Directions
2.5.1 Experiments In Progress
Thy-1 Motivated Experiments
While Thy-1 has served as biological inspiration in this work through the use of its GPI
linker, I have planned to use delivery of Thy-1 itself as a positive control mRNA construct
in bleomycin models of fibrosis in Thy-1 null mice. The delivery of Thy-1 constructs in
vivo has been demonstrated in this Chatper. Experiments to validate the in vitro functional-
ity of Thy-1 constructs include proximity ligation assays (“PLA”) to assess its association
with αVβ3 integrins, and RFL-6 cell spreading assays to demonstrate Thy-1’s role in mod-
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ulating cellular mechanosensing. The data for both experiments have been collected, and
the data are in analysis currently. Additionally, I have used Thy-1 mRNA as a negative
control mRNA in the CHO fibronectin binding experiments. These experiments have also
been conducted and the data are being analyzed. Work in this Chapter has demonstrated
the in vivo delivery efforts I have undertaken to deliver Thy-1 to the lungs of mice along
side H5-CD8 constructs.
H5 Motivated Experiments
Experiments to demonstrate the GPI-dependent association of H5 mRNA constructs with
αVβ3 integrins by PLA have also been conducted and are currently in analysis. These
experiments have been conducted in two ways: with paxillin post-staining and with V5
post-staining. Paxillin post-staining will allow me to quantify global alterations in focal
adhesion number, size and placement in the cell with and without H5 expression. This data
may be especially useful in understanding the effects observed in the RFL-6 cell spread-
ing assays with H5-CD8 and H5-GPI linked constructs. PLA experiments with V5 post-
staining are an important methodological control that will allow me to control for the de-
gree of H5 expression in assessing its relative interaction frequency with αVβ3 integrins.
Additionally, there are a planned set of experiments using dSTORM super-resolution mi-
croscopy to analyze the clustering of αVβ3 integrins, fibronectin and the various mRNA
constructs used in this work. These experiments are in the data collection phase. Finally,
a set of “focal adhesion pull down” experiments have been performed and are currently
being blotted and analyzed based on methodology previous developed in the Barker lab.
[30] These experiments use magnetic beads coupled to fibronectin to assess the ability of
H5-CD8 and H5-GPI constructs to compete for matrix binding directly (i.e. does the ratio
of αV and α5 integrins bound to these matrix-coated beads vary with H5-CD8 or H5-GPI
treatment?) and to specifically assess the recruitment of fyn to focal adhesions. These data
will help validate claims concerning the competitive antagonism of αVβ3 integrin by H5-
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based constructs and validate global focal adhesion experiments already performed, which
show increased SFK phosphorylation with H5-GPI treatment.
In vivo Efficacy of mRNA Constructs
Finally, the efficacy of these mRNA constructs (both Thy-1 and H5-CD8) in vivo needs
to be assessed. The Barker lab at UVA is independently working to address bleomycin
optimization in this model to ensure a robust fibrotic response, and I have prepared the
materials and methods necessary to conduct these experiments once the model is in place.
2.5.2 Development of a Chimeric H5-Thy1 Construct, Thy-5
One future project inspired by this work would be the development and characterization of a
chimeric Thy-1/H5 construct that fully integrates the ability of both molecules to modulate
αVβ3 signaling. Currently, H5-GPI construct capture one important element of Thy-1
biology - the ability of the GPI anchor to associate with αVβ3 integrin and to pre-cluster
focal adhesion protein. [78, 79, 80, 30] However, Thy-1 is also able to antagonize αVβ3
by stabilizing the inactive, “bent” integrin conformation of the integrin through cis-binding
in the membrane to Thy-1’s RLD motif. [30] Incorporating the first 30 amino acids, which
include the RLD domain, of Thy-1’s mature sequence into the design of H5 is molecularly
straight-forward; however, because the binding interface of H5 and fibronectin has not
been firmly mapped beyond knowing that it is restricted to the III9 and III10 domains of
fibronectin, characterization of the chimeric protein will have to ensure that H5’s innate
ability to bind fibronectin is not compromised in the process.
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Figure 2.1: Dose and Temporal Response of Fibroblasts to mRNA Delivered in vitro A,
micrographs of HFFs transfected with 500ng of CD8- or GPI-linked H5 mRNA along with
vehicle treated control cells. H5 surface expression in unpermeablized cells qualitatively
showed clustering of both the CD8- and GPI-linked H5 constructs, which was distinct from
the punctate pattern of αVβ3 staining on the cells’ surfaces. B, HFFs demonstrated a linear,
dose-dependent increase in surface expressed V5-tagged proteins (r2=0.9377, linear regres-
sion) one day after transfection. C, significant increases in V5-tagged protein expression
was observed as early as 4 hours post-mRNA transfection (p=0.3203 and p=0.0106 for “0
hours vs 2 hours” comparison and “2 hours vs 4 hours” comparison, respectively, ANOVA,
Tukey post-test). V5-tagged protein surface expression grew significantly over the 24 hour
period (p=0.0054, ANOVA, Test for trends).
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Figure 2.2: H5 mRNAs Specifically Bound Strain Fibronectin Fragments A, integrin
null CHO cells expressing human α5β1 integrins (“CHOK1” cells) adhered to “relaxed-
mimic” fibronectin fragments (“9*10”) preferentially to “strain-mimic” fibronectin frag-
ments (“4G”). Integrin null CHO cells expressing human αVβ3 integrins (“CHOB2” cells)
did not discriminate between the two fibronectin fragment types. B, quantification of
fragment-concentration dependence from (A) for CHOK1 and CHOB2 cells showed the
greatest difference in cell adhesion at concentrations of 250nM of fibronectin fragments.
C, Raw absorbance values for CHO adhesion experiments to fibronectin fragments and con-
trol surfaces at 250nM concentrations. Both CHOK1 and CHOB2 cells adhered in greater
numbers to full length human fibronectin than to BSA passivated surfaces (p=0.0141 and
p=0.0058 for CHOK1 and CHOB2 relative binding, respectively, Student’s t-test). Addi-
tionally, each cell line trended towards higher binding to full length fibronectin than fi-
bronectin fragments in vehicle treated control cells. D, quantification of the relative “re-
laxed” to “strained” fragment binding in CHO cells demonstrated that H5 expression with
either a GPI or CD8 linker significantly increased adhesion of α5β1 expressing cells to
“strained” fibronectin fragments (p=0.002 and p=0.0022 for CHOK1 cell adhesion ratios
with CD8- or GPI-linked H5 transfection relative to vehicle treated controls, respectively,
2-way ANOVA, simple row effects with Tukey post-test). CHOB2 cells also demonstrated
the same mRNA-dependent trend. Vehicle treated CHOB1 cells statistically preferred
“strained” fragments for binding relative to vehicle treated CHOK1 cells (p=0.0002, Stu-
dent’s t-test).
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Figure 2.3: GPI-linked H5 mRNA Increased phospho-Src Family Kinases A, repre-
sentative blot for phospho-FAK (top row), phospho-Src Family Kinases (2nd row from
top), GAPDH (3rd row from top, and H5-V5 constructs (bottom row) from lysates trans-
fected with H5-GPI (left column) or H5-CD8 mRNAs (right column). B, quantification
of global changes in phospho-focal adhesion complex proteins normalized by GAPDH
expression. H5-GPI linked lysates had significantly higher levels of phospho-Src Fam-
ily Kinases (p=0.0088, 2-way ANVOA with simple row effects, Dunnett’s post-test). C,
phospho-FAK abundances were statistically correlated to the degree of H5/V5 expres-
sion in GPI but not CD8 expressing lysates (r=0.9951 with p<0.0001 and r=0.7154 with
p=0.1099 for GPI- and CD8-linked H5 mRNA lysates, respectively, Pearson’s correlation
coefficient). D, phospho-SFK levels were statistically correlated to the degree of H5/V5
expression in GPI but not CD8 expressing lysates (r=0.9768 with p=0.0008 and r=0.7069
with p=0.1163 for GPI- and CD8-linked H5 mRNA lysates, respectively, Pearson’s corre-
lation coefficient).
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Figure 2.4: H5-CD8 Altered the Cell-Spreading Phenotype of Thy-1 Null Fibroblasts
on Stiff Substrates A, micrographs of GPI- or CD8-linked H5 expressing RFL6 fibrob-
lasts on soft (1kPa) or stiff (25kPa) substrates after 4 hours in serum free media. mRNA
expression on stiff substrates seemed to be restricted mostly to nuclear staining. B, cell
polarization on soft and stiff substrates as measured by the ratio 4π×Area
Perimeter2
. Vehicle treated
RFL6 fibroblasts were significantly less polarized on stiff substrates relative to soft sub-
strates after 4 hours (p=0.0005, 2-way ANOVA with Sidak’s post-test). C, cell spread area
as a function of substrate stiffness and mRNA treatment in RFL6 fibroblasts. All mRNA
conditions had a significant increase in cell spread area between soft and stiff substrates
(p<0.0001 for all comparisons, 2-way ANOVA with Sidak’s post-test). H5-CD8 trans-
fected cells were significantly more spread on stiff substrates than vehicle treated controls
(p=0.0012, 2-way ANOVA, simple column effect, Tukey’s post-test). Scale bars are 17µm.
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Figure 2.5: V5 Surface Expression Was Insufficient for Identifying mRNA Trans-
fected Cells from Single Cell Lung Preps A, V5 antibody titration did not demonstrate
statistically meaningful population shift in fluorescent intensity of mRNA exposed (yel-
low histograms) single cell preps relative to untreated (blue histograms) single cells preps
one day after mRNA instillation. Antibody labeled cells were significantly and uniformly
brighter than unlabeled cells (unlabeled cells are shown with red histograms, p<0.0001 for
all mRNA conditions, all dilutions, 2-way ANOVA with Dunnett’s post-test). B, quantifi-
cation of median fluorescent intensity of various V5 antibody dilutions revealed a linear
antibody dose trend (r2=0.998 and r2=0.9721 for mRNA exposed and mRNA untreated cell
preps, respectively), which did not significantly vary in slope between mRNA-treated and
untreated cell preps (p=0.2396).
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Figure 2.6: Epithelial, Endothelial, Hematopoietic, and Lineage Negative Population
Isolation by FACS A, forward and side scatter gating identified the total population of
cells by relative size and internal complexity. B, single cell populations were gated by
restricting forward and side scatter area and height traces to a linear correlation. C, live cells
were isolated using an amine-reactive, cell-impermanent viability dye. D, live cells were
divided into CD45+ and CD45- populations, which were then subdivided in (E) and (F). E,
CD45+ cells were gated on CD31 and CD326 to isolate hematopoietic lineage cells (lower
left quadrant, “CD45+CD31-CD326-”). F, CD45- cells were gated on CD31 and CD326
to reveal endothelial lineage cells (upper left quadrant, “CD31+CD45-CD326-”), epithelial
lineage cells (lower right quadrant, “CD326+CD31-CD45-”) and lineage negative cells
(lower left quadrant, “CD31-CD45-CD326-”).
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Figure 2.7: FACS Isolation of Lung Populations Revealed Intrinsic Luciferase In-
hibitor in Lung Preps A, nanoLuciferase assays demonstrated a linear (r2=0.9949 and
r2=0.9969 for Thy-1 and H5 transfected HFFs, respectively) and sensitive dose-response to
transfected cell number. Each mRNA demonstrated a three orders of magnitude signal-
to-noise ratio at the 100 cell input level, which indicated sufficient power to detect 1-
10% transfected cells in isolations of thousands of cells from FACS. B, standard curve
with 10,000 transfected input cells used to normalize luciferase assay results from (C).
Both curves were linear over the input range (r2=0.9988 and r2=0.9991 for Thy-1 and H5-
transfected HFFs, respectively). C, luciferase activity of endothelial (“CD31”), hematopoi-
etic (“CD45”), epithelial (“CD326”), and lineage negative (“Triple Negative”) populations
from FACS. Absolute luciferase values were below range for standard curve interpola-
tion and did not vary significantly in any cell population with or without mRNA treatment
except in the lineage negative population (p<0.0001 for no-treatment vs. H5 or Thy-1
exposed lungs, 2-way ANOVA, Tukey post-test). D, dilution of single cell preps from
Thy-1 mRNA exposed lungs in BSA buffer demonstrated a bi-phasic luciferase response
with dilutions between one- and ten-fold increasing luciferase activity, which dropped with
hundred-fold dilution of input suspension. No apparent change in the luciferase activity of
diluted H5-treated cells was seen relative to non-treated lung preps. E, single cell suspen-
sion from non-treated lungs significantly inhibited luciferase activity from in vitro trans-
fected HFFs for both H5 (p=0.0332, 2-way ANOVA, Sidak post-test) and Thy-1 mRNAs
(p=0.0215, 2-way ANOVA, Sidak post-test) relative to BSA buffer.
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Figure 2.8: mRNA-sprayed Lungs Demonstrated Stronger Luciferase Activity than
Non-Sprayed Lungs 8 Days After mRNA Instillation A, representative image of lu-
ciferase activity from dissected lungs from Day 8 mice. B, Luciferase kinetics of ex vivo
right and left lungs demonstrated that Thy-1 sprayed lungs have significantly higher lu-
ciferase activity at 7 minutes and 15 minutes (p=0.0414 and p=0.0078, 2-way ANOVA,
Dunnett’s post-test, respectively) than non-exposed lungs. H5-sprayed lungs trended to-
wards higher expression at those time points as well (p=0.2992 and p=0.1295, 2-way
ANOVA, Dunnett’s post-test, respectively) but one H5-sprayed lung did not show increased
luciferase activity relative to control lungs. C, quantification of normalized luciferase ac-
tivity of right and left lungs at 15 minutes trended towards higher luciferase activity in
exposed lungs, relative to non-exposed lungs (p=0.4494 and p=0.1645 for H5 and Thy-1
mRNA-sprayed lungs, respectively, ANOVA with Dunnett’s post-test). D, quantification of
normalized luciferase activity at 15 minutes from right or left lungs demonstrated a trend
toward asymmetric delivery of mRNA to the left lung (p=0.108 and p=0.14 for Thy-1 and
H5-sprayed lungs, respectively, 2-way ANOVA with Holm-Sidak post-test). Difference in
luciferase activity in untreated lungs could indicate intrinsic mass-bias in measurement.
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Figure 2.9: Spatial Distribution of Aerosolized mRNA in the Lung A, whole mount,
cyrosectioned left lungs from mRNA sprayed (top row) and unsprayed (bottom row) lungs
revealed heterogeneous delivery to the lung parenchyma with millimeter-scale variation
in delivery. Additionally, cell-type specific, high backgrounds for the V5 antibodies were
revealed in control lungs, giving insight into the potential background issues seen in whole
tissue flow cytometry analysis. B, micron-scale resolution of inserts regions from (A).
Heterogeneity of the delivery of aerosolized mRNA was revealed by comparing the inserts
from the mRNA-exposed lung (top two rows) between high H5 protein-expressing region
(middle row in (B), left insert from top row in (A)) and low or non-expressing H5 region
(top row in (B), right insert from top row in (A)). These low or non-expression H5 regions
(middle row) were comparable in staining to mRNA unexposed section (bottom row in (B),




MATRIX-STIFFNESS REGULATION OF TRANSFORMING GROWTH
FACTOR-β BY INNER NUCLEAR MEMBRANE PROTEIN 3
3.1 Introduction
TGFβ in Pulmonary Fibrosis
Transforming Growth Factor β (“TGFβ”) and its intra-cellular transcription factor part-
ners, receptor-Mothers Against Decapentaplegic 2 & 3 (“Smad2/3”), are a growth fac-
tor/transcription factor system whose central role in wound healing, immunity, inflam-
mation, fibrosis and development has long been appreciated. [115, 116, 117, 118] The
connection between TGFβ and pulmonary fibrosis has been repeatedly underscored by
clinical studies that show increased TGFβ protein and mRNA in fibrotic tissues and lung
lavages relative to healthy tissues and secretions. [119, 120] Antagonism of TGFβ acti-
vation through inhibition or deletion of αv integrins generally [48], and αvβ6 integrins
specifically [98, 121], have been shown to be protective against experimental models of
pulmonary fibrosis and fibrosis in multiple other organ systems. Moreover, transgenic
Smad3 knockout mice have also been shown to be protected from fibrosis. [122, 123] In-
terestingly, TGFβ might also contribute to pulmonary fibrosis through its suppression of
the innate immune system, which allows for chronic and acute-on-chronic infections of the
lung that injure the tissue and drive further fibrosis. [118, 124, 125]
Clinically, pirfenidone has led to a slowing of disease progression, potentially through
antagonism of TGFβ. [10] Experimentally, pirfenidone has been shown to normalize TGFβ
expression and tissue stores in multiple organ models of fibrosis. [126, 127] Pirfenidone
has also been shown to inhibit TGFβ-driven myofibroblastic differentiation (e.g. fibroblast
activation) but did not inhibit epithelial mesenchymal transition. [128]
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3.1.1 Mechanical Regulation of Transforming Growth Factor β
One of the most interesting features of TGFβ signaling is that it is highly contextual, as it
seemingly imparts opposite phenotypes to cells based on the context of its activity. [129,
130] Understanding the molecular basis of TGFβ signaling regulation is key not only to
understanding its role in physiology and pathology, but in developing targeted, contextual
therapies. Given the focus on tissue fibrosis, this introduction to TGFβ biology focuses
on how micro-environmental mechanics regulates TGFβ activity both extra- and intra-
cellularly to drive Smad2/3 transcriptional decision in the cell.
Canonical TGFβ Signaling
The canonical features of TGFβ signaling are well understood - TGFβ is a 25 kDa homod-
imer, which activates intracellular signaling by ligating to a Type II Transforming Growth
Factor Receptor (“TβR”), which in turn forms a heterodimer of two Type II and two Type
I TβRs. This ligated TβRII activates the serine/theronine kinase activity of the TβRI re-
ceptor, which ultimately drives the phosphorylation of Smad2 and Smad3 on its C-terminal
S-S-X-S motif. [131, 132, 133, 134] Smad2 and Smad3, in complex with Smad4, translo-
cate to the nucleus in a sorting nexin 9- and importin 9/β-dependent fashion and act as
transcription factors and chromatin remodelers directly. [135, 129, 136, 137, 138, 139] In
the nucleus, Smads2/3 can also act in concert with a variety of other transcription factors
and these partners help to impart distinct transcription programs and signaling integration
(e.g. coordinating with Wnt [140] and Akt signaling [141]). Smad2/3’s nuclear residency
is closely tied to its phosphorylation state, and de-phosphorlyation, through a variety of
mechanisms, leads to its cytoplasmic sequestration. [142, 143]
Stiffness Driven Activation of Latent TGFβ
In tissues, TGFβ is stored in a latent complex, comprised of the latency-associated peptide
(“LAP”) and the latent TGFβ binding protein (“LTBP”), which physically connects to
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ECM proteins, like fibronectin and its splice variants and fibrillin-1. [144, 145] These
stores of TGFβ are quiescent until activated by cells or the environment, where after the
newly freed TGFβ acts in a paracrine fashion. There are a variety of TGFβ activation
mechanisms from the latent complex, including ROS production, low pH conditions, and
proteolysis. [146, 147, 148, 149]
One additional mechanism of liberating free TGFβ from the matrix is that cells may
physical pry open the latent complex through αv integrin’s engagement of LAP in the
latent complex. This mechanism is dependent on cellular contractility and is antagonized
by function blocking αv integrin antibodies. While mechanical activation by integrin was
found to be distinct from proteolytic activation of the latent complex [13], the ability of αv
integrins to help coordinate MT1-MMP activity against the latent complex has also been
demonstrated. [148] Genetic deletion of αv integrins or antagonism of αvβ6 particularly
has been shown to be protective against fibrosis in a variety of organ systems. [98, 121, 48]
Mechanical activation of TGFβ is potentiated by the underlying stiffness of the sub-
strate. The current physical model is that the matrix-bound latent TGFβ complexes is
stress/strain-shielded by the physically connected ECM, which acts as a spring in parallel
to the latent complex. In fibrotic matrices, this shielding is diminished and more physical
force is transmitted to the latent complex, ”popping” TGFβ out of its molecular prison.
[13, 150] Because matrix stiffness is correlated both to the sensitivity of the latent complex
to mechanical perturbation and to the force applied to the latent complex through cellular
contractility, mechanical activation of TGFβ is particularly insidious in the fibrotic setting.
Stiffness Potentiation of Receptor-Mothers Against Decapentaplegic (rSMADs)
A number of in vitro studies have indicated that matrix stiffness also potentiates the cellular
responses to free TGFβ. In particular, cells on increasingly stiff substrates have increased
TGFβ-targeted transcription, cellular contractility and matrix synthesis when exposed to
pre-activated, free TGFβ in vitro. [88, 89, 90, 91] These data strongly suggest that the
51
stiffness of the matrix imparts a “double-hit” in fibrosis - the increased stiffness not only
increases the available supply of free TGFβ, but also increases cellular sensitivity to any
free TGFβ.
The mechanism of this stiffness-dependent sensitivity to TGFβ signaling is unclear. It is
known that TGFβ’s intracellular signaling partners, Smad2/3, associate with mechanically
regulated proteins like Rho-Associated Protein Kinase (“ROCK”) and Yes Associated Pro-
tein/Transcriptional Co-activator with PDZ-binding motif (“YAP/TAZ”). These proteins
could provide mechanically contextual cues to Smad2/3 through post-translation modifi-
cations (“PTMs”) of the linker and MH1 domains of the Smads, respectively. [151, 91,
152] The PTMs by YAP/TAZ on Smad2/3 appear to influence the nuclear translocation of
Smads in response to TGFβ stimulus, potentiating pro-fibrotic signaling in a model of renal
fibrosis. This nuclear accumulation phenotype is particularly sensitive to small molecular
antagonism of YAP by verteporfin, which indicates that YAP and TAZ may play differential
roles in the mechanical regulation of Smad2/3. [91]
TGFβ also appears to acquire some of its mechano-sensitivity and to confer some of
the mechanical phenotypes associated with it through association with both the myocardin-
related transcription factors-A and -B (MRTF). Contrastingly, while YAP/TAZ appear to
have a potentiating effect on TGFβ signaling through Smad2/3 with increasing substrate
stiffness [91], Smad3 appears to impart a mechanical phenotype by inhibiting the activity
of MRTF-A at baseline but not during TGFβ stimulation in the pulmonary vasculature.
[153] There is also evidence that TGFβ exerts a mechanical phenotype through MRTF-A
in a Smad-independent fashion, though the molecular mechanism is not known. [154]
3.1.2 Inner Nuclear Membrane Protein 3
Inner nuclear membrane protein 3 (LEMD3), or MAN1, is a double-pass integral inner
nuclear membrane protein. The N- and C-terminal arms of LEMD3 are both nucleoplas-
mic, while the intra-transmembrane domain region lies in the peri-membrane space, be-
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tween the inner and outer nuclear membranes. LEMD3 is named, in part for its LEM
(LAPB2/Emerin/Man1) N-terminal domain, which is necessary for the nuclear targeting of
the mature protein through a kinetic trap with the nuclear lamina. [155, 156, 157, 158, 159,
160, 161] In addition to a localizing function, the LEM domain of LEMD3 helps organize
peripheral chromatin through binding with Barrier-to-Autointegration Factor (BAF) and
heterochromatin protein 1 (HP1). [155, 162] The functional overlap between the LEMD3
and other LEM containing proteins, specifically emerin, is unclear and LEMD3 and emerin
may have compensatory roles in nuclear organization. [157, 158, 163] Following its two
transmembrane domains, LEMD3 has two annotated protein domains: the RNA recogni-
tion motif (RRM), and its MSC (MAN1-Src1 C-Terminal) domain. The MSC domain of
LEMD3 has redundant chromatin/BAF binding functionality and appears to play a role in
chromosomal organization during mitosis. [164] The RRM domain, discussed below, is a
known Smad2/3 and Smad1 binding domain, which is necessary for LEMD3’s antagonism
of TGFβ superfamily signaling. [161, 165, 166, 167, 168, 169, 170, 171]
Inhibition of TGFβ Signaling by LEMD3
LEMD3 is a known inhibitor of TGFβ signaling. LEMD3 binds and inactivates the down-
stream transcription factor partners of both TGFβ and bone morphogenic protein (BMP),
Smads 2&3 and 1&5&8, respectively. [161, 165, 166, 167, 168, 169, 170, 171] LEMD3s
RNA recognition motif (RRM) domain competes with other transcription factors, such as
FAST/Forkhead Box Protein H1 and Runx, for binding to Smad2/3 and promotes Smad2/3
dephosphorylation and nuclear export by acting as a coordinating scaffold for protein phos-
phatase, Mg2+/Mn2+-dependent 1α (PPM1α). [142, 166]
In humans, heterozygous loss of LEMD3 is frequently, but not always [172], associ-
ated with the development of Buschke-Ollendorf syndrome (BOS), in which patients de-
velop some constellation of cutaneous collagenomas and elastomas (from aberrant TGFβ
signaling) and osteopoikilosis (from aberrant BMP signaling), hyperostic lesions in long
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bones, which can mimic osteoblastic metastatic lesions radiographically. [170, 173, 174,
175, 176, 177, 178, 179, 180, 181] Depending on the penetrance and specific genotype,
heterozygous loss of LEMD3 can also be associated with more severe ECM pathologies,
such as melorheostosis, a rare, progressive sclerosis frequently found in long bones that
may lead to disfigurement and joint destruction. [170, 173]
Biophysical Linkages of LEMD3
In addition to its clear role in antagonizing TGFβ signaling both in vitro and in vivo,
LEMD3 is retained in the inner nuclear membrane through its connection to the nuclear
lamin superstructure by the activity of its N-terminal LEM domain. [156, 157, 158, 159,
160, 161] This connection, in turn, creates a direct biophysical link to the cells actin mi-
crofilament network through the nesprin-sun Linker of Nucleus and Cytoskeleton (LINC)
complex, which has been shown to be necessary for the transmission of cytoplasmic and
substrate derived stresses to the nucleus. [182, 183, 184] The LINC complex has been an-
tagonized genetically using dominant negative constructs that competitively inhibit func-
tional nesprin-actin linkages on the cytoplasmic side of the nucleus or nesprin-sun linkages
in the perinuclear membrane space. These constructs allow for a functional decoupling of
nuclear and cytoplasmic mechanics, without obviously compromising cell-ECM coupling
and mechanics. [184]
3.1.3 Hypothesis and Summary
Given LEMD3s role in antagonizing Smad2/3 and its biophysical connection to the cells
cytoskeleton, I hypothesized that LEMD3s inhibition of Smad2/3 would be reduced by
cytoskeletal stress, thereby potentiating TGFβ signaling in an ECM stiffness-dependent
fashion. In this thesis, dermal fibroblasts displayed ECM stiffness- and actin-dependent
TGFβ responsiveness, and LEMD3 knockdown or over-expression modulated this stiffness
responsiveness. This modulation was correlated to trends in Smad3 phosphorylation we ob-
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served with LEMD3 over-expression or knockdown. LEMD3s interactions with Smad2/3
were negatively regulated by ECM stiffness and potentiated by disruption of the actin cy-
toskeleton, but these complexes were not potentiated by disruption of the LINC complex
or over-expression of the LEM domain. Furthermore, knockdown of YAP or TAZ reduced
Smad2/3-LEMD3 interactions by PLA and shifted the remaining interactions towards the
nucleus on soft substrates. We demonstrated cytosolic interactions between LEMD3 and
Smad2/3, which called into question basic assumptions about the current understanding
of LEMD3’s biology and its regulation of TGFβ. To understand these cytosolic events,
I identified and genetically localized N- and C-terminal LEMD3 fragments, which sepa-
rated LEMD3’s Smad-binding RRM and lamin-binding LEM domains. I established that
these fragments were created through post-translational proteolysis by a serine protease
and were differentially regulated by lamin integrity. Finally, I found correlates between
my in vitro findings and human lung tissue from idiopathic pulmonary fibrosis (IPF) and
non-IPF patients. Specifically, interactions between LEMD3 and Smad2/3 demonstrated
greater intra-patient/total variability in frequency and were more frequent in the cytoplasm
in human lung core biopsies from IPF patients relative to non-IPF tissues. Additionally, IPF
tissues had unique low-frequency LEMD3-Smad2/3 interaction regions, possibly indicative
of local fibrotic disease. My work demonstrates novel aspects of LEMD3 biology as well
as identifies a potential target for TGFβ antagonism relevant to fibrosis that complements
current medical management.
3.2 Methods
3.2.1 Primary Fibroblast Cultures and Transfection, Human Lung Biopsies, and Other
Reagents
Primary human foreskin fibroblasts (HFFs) were procured from ATCC (ATCC SCRC-
1041, ATCC, Manassas, VA) and routinely cultured in DMEM (ThermoFisher, Waltham,
MA) supplemented with 15% FBS and 1% penicillin/streptomycin (ThermoFisher, Waltham,
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MA) in 5% CO2 at 37C in a humified incubator to passage 13. CCL210s, a primary human
pulmonary fibroblast line, were procured from ATCC (ATCC CCD-19Lu, ATCC, Manas-
sas, VA) and routinely cultured in EMEM (ThermoFischer, Waltham, MA) supplemented
with 10% FBS and 1% penicillin/streptomycin (ThermoFisher, Waltham, MA). For DNA
transfections, 50,000 HFFs were resuspended in 10uL of Buffer R and electroporated using
a 1700V, 20ms pulse width, 1 pulse program with 1µg DNA in a Neon transfection sys-
tem (ThermoFisher, Waltham, MA). For siRNA transfections, 8,000-10,000 cells/cm2 were
treated with 25nM or 200nM siRNA with Lipofectamine2000 (ThermoFisher, Waltham,
MA) according to the manufacturer’s recommendations. IPF and non-IPF human lung core
biopsies were generously provided by Dr. Eric White and the Lung Tissue Research Con-
sortium (NHLBI: HHSN2682016000021). Selected cores all came from distal sections of
lung parenchyma. Human subjects approval for this tissue was obtained through the Uni-
versity of Michigan Institutional Review Board. This study abides with the Declaration
of Helsinki principles. For information on the oligos, antibodies, and uncommon chem-
icals used in this work, please refer to the Tables 3.1, 3.2, and 3.3 for supplier and use
information.
3.2.2 Generation of Recombinant Constructs
LEMD3 Constructs
LEMD3 constructs were derived from the pSVK3-FLAG-MAN1 construct, kindly pro-
vided by Dr. Howard Worman (Addgene plasmid # 26002). [156] Site directed muta-
genesis (SDM) was performed using the Q5 SDM kit (New England Biolabs, Ispwich,
MA) according to their protocol, including the use of ”NEB BaseChanger” applet to de-
sign primers and select PCR conditions. Primers and associated melting points for each




DN Kash and DN Control plasmids (pCDHEF1-MCS1-puro-mCherry-Nesprin-1αKASH
and pCDH-EF1-MCS1-puro-mCherry, respectively) were kindly provided by Dr. Jan Lam-
merding and are described in detail in [184]. The DN LEM construct was created by Gib-
son Assembly of the N-terminal LEM domain cDNA from LEMD3 (without FLAG) from
pSVK3-FLAG-MAN1 into the frame occupied by Nesprin-1αKASH in the pCDHEF1-
MCS1-puro-mCherry-Nesprin-1αKASH construct with primers and PCR conditions as de-
scribed in Table 3.1.
3.2.3 Western Blotting
For non-phospho-protein western blots
cell lysates from tissue culture plastic or from 2 or 25 kPa, 150cm Petrisoft dishes (Matri-
gen, Brea, CA) were either: harvested directly in 4X protein loading buffer (Licor, Lincoln,
NE) supplemented with protease and phosphatase inhibitors (#A32959, ThermoFisher,
Waltham, MA) according to the manufacturer’s instructions; or, processed with the NE-
PER compartment isolation kit (ThermoFisher, Waltham, MA) according to the manufac-
turer’s instructions. Lysates were treated with 0.3 µL of benzonuclease (ThermoFisher,
Waltham, MA) for 15 minutes at room temperature with vigorous shaking. Samples were
heated to 95C for 5 minutes and run on a 4-12% Bis-Tris gel in 1x MES buffer and run
for 70 minutes at 150V. The gel was then transferred to a nitrocellulose membrane using
the XCell Blot Module (ThermoFisher, Waltham, MA) at 25V for 65 minutes. Membranes
were air-dried for an hour, blocked with 5% non-fat milk in 1X PBS for an hour at room
temperature, and then incubated with primary antibodies as described in Table 3.2 in 1X
PBS-T with 1% milk for 16-24 hours at 4C. Near-IR or HRP conjugated secondaries as
described in Table 3.2 were then incubated with the blot and imaged subsequently on either
an Odyssey CLx system for near-IR dyes (Licor, Lincoln, NE) or a ChemiDoc MP system
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(Bio-Rad, Hercules, CA) with SuperSignal West Femto reagents (ThermoFisher, Waltham,
MA) for HRP secondaries according to the manufacturer’s instructions. Band analysis was
performed using the associated Licor or Biorad software.
For phospho-protein western blots
The procedure above was followed with the following changes: Cells were treated with
100pg/mL TGFβ 90 minutes before lysis. Membranes were incubated in and washed in
buffers formulated with TBS instead of PBS. Membranes were blocked in 5% BSA in 1X
TBS and all antibody incubations were done in 1% BSA in 1X TBS-T.
For recombinant LEMD3 western blots
Two samples of HFFs were prepared and electroporated as above and plated onto each plas-
tic or hydrogel surface for 12 hours (protease inhibitor experiments) or 24 hours (LEMD3
fragment abundance and deletion mutant experiments) before harvesting.
3.2.4 qPCR
RNA was isolated from cultured cells using RNEasy Plus Mini kits (Qiagen, Hilden, Ger-
many) according to the manufacturer’s instructions. cDNA libraries were constructed using
RT2 First Strand kit (Qiagen, Hilden, Germany) according to the manufacturer’s instruc-
tion. 25µL qPCR reactions were prepared using SYBR Green Master Mix (ThermoFisher,
Waltham, MA) with 250nM primers, listed in Table 3.1 and 10ng input cDNA. Reactions
were carried out on a StepOnePlus (ThermoFisher, Waltham, MA) for 40 cycles. Melt
curves were visually inspected after each run to confirm a single, defined peak in the
derivated intensity plot. Data from each run was imported into LinRegPCR, which per-
formed baseline correction and measured PCR efficiency by amplicon group as described
in [185]. The relative number of transcripts was calculated by dividing the Cq threshold by
the PCR efficiency for the reaction raised to the power of Cq, the cycle number at which
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the threshold is reached for a given target. For relative quantification between conditions,
LEMD3 transcripts were either: normalized for each condition to the mean of two refer-
ence genes, 18S and ACTB, if the samples were all from a single stiffness condition; or,
normalized to 18S alone if substrate stiffness was an experimental condition.
3.2.5 Smad-Driven Luciferase Assays
HFFs were transfected with Cignal Lenti Reporter virus (Qiagen, Hilden, Germany) with a
MOI of 40 and subsequently selected using 400 ng/mL puromycin until untransduced HFFs
died. Stably transfected HFFs, with or without additional LEMD3-focused genetic treat-
ments as described above, were plated at 10,000 cells/well on a HTS plate (Matrigen, Brea,
CA) containing glass surfaces and poly-acrylamide gels, which ranged in stiffness from 0.2
kPa to 50kPa, all functionalized with 10 µg/mL plasma-purified human fibronectin accord-
ing to the manufacturer’s instruction. Cells adhered to the surfaces for 4 hours in serum-
free DMEM supplemented with 1% BSA and 1% penicillin/streptomycin. Media was then
supplemented with the desired amounts of TGFβ and, when applicable, with cytoskeletal
agents as described in the results. HFFs were then incubated for 16 hours at 37C before
the luciferase reaction. Wells were supplemented to 2mM VivoGlo d-luciferin (Promega,
Madison, WI) using an plate reader controlled auto-injector system and light production
was subsequently quantified every 5 minutes for 30 minutes on a Synergy H4 plate reader
(BioTek, Winooski, VT). The raw luciferase signal was the median intensity measured over
this timecourse minus the intensity from luciferase-transfected cells not treated with TGFβ
to account for any TGFβ elaborated and activated by the cells in situ. Cells were then fixed
with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, and then stained with
1:10,000 Hoechst 33342 in 1X PBS for 30 minutes at room temperature (Thermo Fischer,
Waltham, MA). The raw luciferase signal was then normalized to the nuclear signal, which
was inside a linear standard curve form cells plated on glass and on polyacrylamide within
each plate. Data for each condition was then fit to a three-parameter logistic equation using
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a least-squares minimization fit in Prism (GraphPad, La Jolla, CA). For curves that did not
converge with this model, individual data points are shown with the standard error of the
mean to illustrate data heterogeneity. Otherwise, the trends across the maximal luciferase
signal (”Top” variable from the model) or the mid-transition point observed between ”Bot-
tom” and ”Top” signals (”EC50” variable from the model, called ”transition point” in text),
were statistically compared using an ANOVA with ”Test for Trends,” which restricts the
hypothesis testing to a particular order of the data-sets (e.g. max luciferase signal as a
function of increasing TGFβ dose or transition point as a function of increased LEMD3
expression). Each data point represents at least three biological replicates.
3.2.6 Proximity Ligation Assays
Ex vivo PLA
Lung biopsy samples were prepared by OCT embedding flash-frozen tissue (Tissue-Tek,
Sakura Finetek, Torrance, CA) and preparing 10 µm cryosections on a CryoStar NX70
(Thermo Fisher, Waltham, MA). Sections were fixed for 10 minutes at 4C in 2% paraformalde-
hyde in 1x PBS. Protein-protein proximity ligation assays (PLA) were performed with
antibody pairs listed in Table 3.2 as described previously in [186] with the following
modifications: all primary antibody incubations were done for 16-24 hours at 4C, sec-
tions were blocked in 0.5 % Tween-20, 0.1 % Triton X-100, 0.5 % gelatin, 5 % donkey
serum, 2 % bovine serum albumin (BSA), and 5 µg/mL poly dI-dC DNA in PBS, and
sections were actin counter-stained with 1:40 phalloidin-488 (Thermo Fischer, Waltham,
MA) for 30 minutes at room temperature following the PLA reaction using the IF protocol
recommended by Sigma’s PLA Resource Center. Slides were analyzed using a Axiovert
200M microscope (Carl Zeiss Microscopy, Jena, Germany) with an UltraVIEW spinning
disk (PerkinElmer, Waltham, MA) and Flash 4.0v2 cMOS camera (Hamamatsu Photon-
ics, Hamamatsu City, Japan). Low resolution images (20X) were collected using a 0.8NA
Plan-Apochromat, and high resolution images (63X) were collected using a 1.4NA Plan-
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Apochromat objective (Carl Zeiss Microscopy, Jena, Germany). Image acquisition and
analysis was performed in Volocity (PerkinElmer, Waltham, MA). To analyze the inci-
dence of LEMD3-Smad2/3 interactions between IPF and non-IPF biopsies at least 6 ran-
dom points were chosen by Volocity in each section and registered to a serial section of
the same tissue which was prepared as a no primary antibody PLA control. Tiled images
with 20% overlap were acquired at 20X, covering a 628 µm by 334 µm area with z-slices
acquired every 0.6 µm. The PLA signal was processed in Volocity using a consistent in-
tensity threshold to identify PLA puncta, which were then spatially filtered by excluding
PLA signal not associated with the actin or DAPI tissue-based signals. The remaining
PLA signal was processed using the “Subtract” function to remove tissue autofluorescence,
measured independently in an unused spectral window (615nm, width 70nm). The PLA
signal was then normalized to the measured nuclear volume in the image slice. Relative
PLA incidence between conditions was calculated by subtracting the normalized PLA sig-
nals between experimental and no primary antibody at each co-registered pair of points.
High resolution imaging (63X) of each tissue was preformed over at least 6 randomly cho-
sen areas, each 111 µm by 106 µm with z-slices acquired every 0.2 µm, to measure the
cytosolic and nuclear PLA compartments in tissue. Signal processing was similar to the
low-resolution processing described above except that the PLA signal was subdivided us-
ing the ”Exclude Non-Touching” function in Volocity to measure nuclear and non-nuclear
associated signal.
In vitro PLA
Protein-protein PLA was performed with antibody pairs listed in Table 3.2 as described in
[186] with the following modifications: cells were plated on FN-coated glass or hydrogels
(Matrigen, Brea, CA). All primary antibody incubations were performed for 16-24 hours
at 4C and cells were counter-stained with 1:40 phalloidin-488 or phalloidin-546 in 1X PBS
for 30 minutes at room temperature and/or further processed for IF imaging using the proce-
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dure recommended in Sigma’s PLA Resource Center. For all recombinant LEMD3 experi-
ments, HFFs were electroporated as above and allowed to culture for 24 hours on 10µg/mL
fibronectin coated glass or hydrogels before fixation. For LEMD3-phospho-Smad2/3 PLA
assays: cells were treated 90 minutes before fixation with 100pg/mL TGFβ. For FLAG
post-staining of PLA processed tissues, cells were blocked with unlabelled AffiniPure don-
key anti-rabbit antibodies (Jackson ImmunoResearch, West Grove, PA) at a 1:10 dilution in
1X PBS-T at room temperature for 1 hour before further IF processing with 1:1000 rabbit
anti-FLAG (#F7425, Sigma-Aldrich, Darmstadt, Germany) for 1 hour in PBS-T at room
temperature. Following three washes with PBS-T for 5 minutes, each sample was stained
with 1:500 goat anti-rabbit 546 in PBS-T for 1 hour at room temperature, washed again and
then counter-stained as above. For V5 post-staining of PLA processed samples, cells were
incubated with 1:200 647 labeled anti-V5 antibody (R&D Systems, Minneapolis, MN) di-
luted in PBS-T at room temperature for 1 hour before washing three times in PBS-T for
5 minutes each and then counter-stained as above. Imaging and analysis was performed
as described for high-resolution ex vivo PLA signals except that no tissue autofluorescence
signal was measured or needed to be subtracted and, when appropriate, other IF signal
(e.g. FLAG) were measured in parallel. For cells on Matrigen HTS plates (Figure 3.5c&d),
the confluence of cells prevented identifying individual cell boundaries. Instead, the PLA
signal was quantified as the PLA volume divided by the nuclear intensity for each image.
Each data point represents at least 3 unique surfaces with at least 12 cells measured per
surface.
3.2.7 Atomic Force Microscopy and Cell Morphology
Experiments were conducted on an MFP-3D atomic force microscope (AFM) (Asylum
Research, Santa Barbara, CA) on an inverted optical microscope (Nikon, Melville, NY).
MCLT O-10 cantilevers (Bruker Nano, Camarillo, CA) were functionalized manually with
4.47µm polystyrene beads. Probes were calibrated before each experiment using a com-
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bination of glass indention and thermal fluctuation measurements. Cellular and hydro-
gel measurements were acquired using a 2nN relative force trigger with a tip velocity of
2µm/s. Hydrogels were measured over a 400µm2 space without cells, sampled as a 4X4 ar-
ray. Young’s modulus was calculated using custom scripts in MATLAB (TheMathWorks,
Waltham, MA) that use a linearized Hertz approach for force-indentation measurements
40-60 nm into each surface. Cells and hydrogels were assumed to be incompressible (Pois-
son’s ratio, ν, = 0.5). After AFM analysis, cells were fixed in 4% PFA for 10 minutes and
stained with 1:40 Phalloidin-488 and 1:1000 Hoescht 33342 for 30 minutes. Cell spread
area and morphology were analyzed from images taken at 63X in Volocity (as above). Each
data point represents at least 3 unique surfaces with at least 10 cells per surface.
3.2.8 Mass Spectroscopy on LEMD3 Fragments
LEMD3 fragments were affinity purified from RIPA extracted lysates using FLAG (clone
M2, #A2220, Sigma-Aldrich, Darmstadt, Germany) or V5 (clone V5-10, #A7345, Sigma-
Aldrich, Darmstadt, Germany) affinity agarose according to the instructions of the man-
ufacturer. Purified fragments were separated by SDS-PAGE on a 4-12% Bis-Tris gel in
1x MES buffer and visualized by SimplyBlue staining (Thermo Fischer, Waltham, MA).
In gel digestion, nano-LC-MS/MS, and peptide identification was performed as previously
described [187] with the following modifications. Reverse phase chromatography was per-
formed using an in-house packed column (40 cm long X 75 µm ID X 360 OD, Dr. Maisch
GmbH ReproSil-Pur 120 C18-AQ 1.9 µm beads) and a 120 min. gradient. The Raw files
were searched using the Mascot algorithm (ver. 2.5.1) against a protein database con-
structed by combining the FASTA file for LEMD3 with a contaminant database (cRAP,
downloaded 11-21-16 from http://www.thegpm.org) via Proteome Discoverer 2.1. Only
peptide spectral matches with expectation value of less than 0.01 (High Confidence) were
used.
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Table 3.1: Oligos Used in this Chapter
Oligo Name 5’-3’ Sequence Purpose Tm Concentration Used Vendor Cat #
siLEMD1 GGAUAGAGCUGUUGACUUC siRNA anti-LEMD3 NA
Pooled to 200nM
Dharmacon siGENOME SMARTpool siRNA D-006306-01
siLEMD2 GAACUUCUCCAGCAAUUUA siRNA anti-LEMD3 NA Dharmacon siGENOME SMARTpool siRNA D-006306-02
siLEMD3 GGAAUAAGGUGUGUUGGUU siRNA anti-LEMD3 NA Dharmacon siGENOME SMARTpool siRNA D-006306-03
siLEMD4 CAAGGCAGAUGUAUGAUAU siRNA anti-LEMD3 NA Dharmacon siGENOME SMARTpool siRNA D-006306-04
siYAP (pool of 4 siRNAs) Not Disclosed siRNA anti-YAP NA 25nM Dharmacon SMARTpool siRNA M-012200-00-0005
siTAZ (pool of 3 siRNAs) Not Disclosed siRNA anti-TAZ NA 25nM Dharmacon siGENOME SMARTpool siRNA D-016083-04-0002; D-016083-02-0002; D-016083-01-0002;
siGFP CAAGCUGACCCUGAAGUUCUU siRNA Control NA 200nM IDT Gift From Dr. MG Finn’s Lab
insV5 For CTGCTGGGCCTGGATAGCACCTGAAAAGCTCGAGCTCGA
p.S931-Ter932insGKPIPNPLLGLDST in pSVK3-FLAG-LEMD3 68C
500nM IDT Custom
insV5 Rev CGGGTTCGGAATCGGTTTGCCGGAACTTCCTTGAGAATTGG 500nM IDT Custom
LEM GA For TTAAATGGATCCCCGCCACCATGGCGGCGGCA
DN LEM Construction from pCDH-EF1-MCS1-puro-KASH-mCherry
54C 500 nM IDT Custom
LEM GA Rev TGCTCACCATTCGATATTTCATGTAACGCAG 52C 500 nM IDT Custom
mCherry GA For GAAATATCGAATGGTGAGCAAGGGCGAG 58C 500 nM IDT Custom
mCherry GA Rev ATCCTTGCGGCCGCTCAC 62C 500 nM IDT Custom
del294-325 For CTGGAGACTTCAGTTCAGGGAG
p.delQ294-R325 in pSVK3-FLAG-LEMD3-V5 68C
500nM IDT Custom
del294-325 Rev TCTGCTGGAGGCCACGTC 500nM IDT Custom
del579-647 For TTTGTTACTGTAACTCACAG
p.delE579-A647 in pSVK3-FLAG-LEMD3-V5 57C
500nM IDT Custom
del579-647 Rev TTGAACAGAAAGCGTTCTTTG 500nM IDT Custom
del21-668 For CTGCGTTACATGAAATATCG
p.delM21-V668 in pSVK3-FLAG-LEMD3-V5 60C
500nM IDT Custom
del21-668 Rev TTTCTCGTCCGAATTCCTG 500nM IDT Custom
qLEMD3 For TTTCGACGTGCTTTTGTTACTG
RT-qPCR - Human LEMD3, Exons 6-7 60C
250nM IDT
Hs.PT.58.38449009
qLEMD3 Rev TGTTTCCTCCTCTTCTTTTGTCC 250nM IDT
q18S For GTAACCCGTTGAACCCCATT
RT-qPCR - Human 18S 60C
250nM IDT
Originally found in [188]
q18S Rev CCATCCAATCGGTAGTAGCG 250nM IDT
qACTB For AGGCACCAGGGCGTGAT
RT-qPCR - Human β-Actin 60C
250nM IDT
Originally found in [189]
qACTB Rev GCCCACATAGGAATCCTTCTGAC 250nM IDT




WB IF PLA Other
Primary
LEMD3 4E1 Mouse 1:1000 1:1000 (cells), 1:100 (tissue), used with EPR19557-4 & D27F4 LsBio LS-C114872
V5 V5-10 Mouse 1:1000 Sigma V8012
V5 Polyclonal Rabbit 1:2000, used with 18/Smad2/3 Abcam ab9116
647 labelled V5 1036H Rabbit 1:200 R&D Systems FAB8926R
Smad2/3 18/Samd2/3 Mouse 1:2000, used with Abcam ab9116 BD Bioscience 610842
Smad2/3 EPR19557-4 Rabbit 1:1000 (cells), 1:100 (tissue), used with 4E1 Abcam ab202445
phospho-Smad2/3 D27F4 Rabbit 1:1000 1:1000, used with 4E1 CST #8828
FLAG Polyclonal Rabbit 1:1000 1:1000 Sigma F7425
GAPDH D-6 Mouse 1:1000 Santa Cruz sc166545
Lamin A/C EPR4068 Rabbit 1:1000 Abcam ab108922
Secondary
Goat αMouse-HRP N/A Goat 1:15000 Abcam ab7023
Goat αRabbit-HRP N/A Goat 1:15000 ThermoFisher A-27036
Donkey αRabbit-IR680 N/A Donkey 1:20000 Licor 926-68073
Donkey αMouse-CW800 N/A Donkey 1:20000 Licor 926-32212
Goat αRabbit-546 N/A Goat 1:500 ThermoFisher A-11010
Blocking Donkey αRabbit N/A Donkey 1:10 Jackson ImmunoResearch 711-066-152
Table 3.3: Chemicals and Recombinant Proteins Used in this Chapter
Name CAS Working Concentration Solvent Use Vendor Cat #
Cytochalasin D 22144-77-0 2 µM DMSO Stablizes g-actin Sigma C8273
Blebbistatin 674289-55-5 2 µM DMSO Inhibits myosin II Sigma 203389
Jasplakinolide 102396-24-7 100-200 nM DMSO Stablizes f-actin Enzo ALX-350-275
E-64D 88321-09-9 2-40 µM DMSO Irreversible cystein protease inhibitor: calpain, papain, actinidase, cathepsins B, H, and L Sigma E8640
E-64 66701-25-5 10-100 µM DMSO Irreversible cystein protease inhibitor: calpain, papain, actinidase, cathepsins B, H, and L Sigma E3132
DCI 51050-59-0 10-100 µM DMSO Irreversible serine protease / esterase inihibitor: cathepsin G, elastase, thrombin, plasmin, factor Xa & X11a, granzymes A, B, and H Sigma D7910
MMPi III 927827-98-3 1-20 µM DMSO Reversible MMP inhibitor: MMP1, MMP2, MMP3, MMP7, MMP13 Millipore 444264
MG-132 133407-82-6 10 µM DMSO Inhibits 26S proteosome Sigma M7449
Roscotine 186692-46-6 0.1-35 µM DMSO Inhibits cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, cdk5/p35 Tocris 1332
TGFβ N/A 50-1000 pg/mL 4mM HCL with 10% BSA Recombinant human TGF-β R&D Systems 240-B
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3.3 Results
3.3.1 Fibroblast TGFβ Responsiveness is Potentiated by ECM Stiffness and Inhibited by
LEMD3 Expression
Dose-Dependent Stiffness Potentiation of TGFβ
I sought to validate that fibroblasts in our system displayed stiffness-dependent TGFβ re-
sponsiveness using primary human dermal fibroblasts (HFFs) stably transfected with a
Smad-driven luciferase. First, I characterized stiffness and morphology phenotypes as-
sociated with mechanotransduction using optical microscopy and atomic force microscopy
(AFM). With increasing stiffness, fibroblasts underwent cellular compliance matching (p=0.0022)
and increased their cell spread surface area (p=0.1801) and polarization (p=0.0263) as seen
in Figure 3.1a and Figure 3.2, respectively. Luciferase transfected HFFs showed a sig-
moidal responsiveness to recombinant human TGFβ (rhTGFβ) as a function of substrate
stiffness (Figure 3.1b). This stiffness potentiation was dose-dependent with increasing
pg/mL doses of rhTGFβ appearing to shift the transition point of the sigmoid towards
softer substrates (”soft-shift”, p=0.07). Transition points in the pg/mL dose-range occurred
at stiffness over a range from ≈ 1-4 kPa. These cells also showed the expected rhTGFβ
dose-response (increasing luminescence with increasing TGFβ dose) on stiff substrates
(p<0.0001, Figure 3.1b). Previous studies have also shown stiffness-dependent modula-
tion of TGFβ signaling, and our work improves the resolution of these results by more
finely probing the stiffness space across a range from 0.5 kPa to 50 kPa and the TGFβ
dose-dependence of this effect. [88, 89, 90, 91]
LEMD3 Modulation of Fibroblasts’ TGFβ-Stiffness Response
Having confirmed the TGFβ/stiffness phenotype, I tested how modulating LEMD3 al-
ters the stiffness responsiveness of fibroblasts using Lipofectamine 2000 delivered siRNA
against LEMD3 (“siLEMD3”) and electroporation with pFLAG-LEMD3-V5 (LEMD3 over-
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expression plasmid with N-terminal FLAG epitope tag and C-terminal V5 epitope tag).
Increasing LEMD3 expression (Figure 3.3a) induced a decrease in maximal luminescence
(p=0.04) and a “stiff-shift” in the stiffness response’s sigmoidal transition point (p<0.0001,
Figure 3.1c). There was a corresponding “soft-shift” in the transition point (p<0.0001)
and increase in maximal luminescence (p=0.04) when LEMD3 expression was decreased
through siRNA treatment (Figure 3.3b). There were no significant differences in either
maximal luminescence or the stiffness transition point of the sigmoid model between HFFs
treated with Lipofectamine2000, electroporated control HFFs (“Neon HFF”), or HFFs
treated with concentration matched siRNA against GFP (“siGFP”).
To connect LEMD3’s TGFβ antagonism seen in Figure 3.1c to Smad2/3’s activation,
I investigated the effect LEMD3’s modulation on Smad3 phosphorylation (Figure 3.4).
100pg/mL TGFβ treatment for 90 minutes increased the ratio of phospho-Smad3 to total
Smad3 relative to untreated HFFs (p=0.0506). Treatment with either Lipofectamine 2000
or electroporation reduced the phospho-Smad3/Smad3 ratio, but treatments with 25nM
and 200nM siRNA against LEMD3 increased the phospho-Smad3/Smad3 ratio relative to
siRNA against GFP (p=0.1103 and p=0.0057 for 25nM and 200nM siRNA groups, re-
spectively). Electroporation with pFLAG-LEMD3-V5 or a C-terminal fragment (pFLAG-
LEMD3p.∆21-669-V5, “CTF”), previously shown to be sufficient for Smad2/3 binding
and de-phosphorylation [166, 171, 169, 168, 190], decreased the pSmad3/Smad3 ratio;
however, as in Figure 3.1c, there was no difference between electroporation controls and
electroporation with any LEMD3 plasmids on tissue culture plastic. The stiffness-modulation
of LEMD3’s inhibition of TGFβ shown here is a novel finding, but the general inhibition
of TGFβ signaling [171, 161, 170, 165, 166] and Smad phosphorlation [168, 171, 169] by
LEMD3 (on stiff substrates) confirmed findings from previous reports.
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3.3.2 Cytoskeletal Determinants of TGFβ-Stiffness Response
To test which components of the cell’s microfilament cytoskeleton control the stiffness-
response of HFFs to rhTGFβ, I used chemical inhibition of the structural (cytochalasin
D, a g-actin stabilizer) and contractility machinery (blebbistatin, a myosin II inhibitor).
Stiffness-dependent TGFβ responses required actin polymerization but did not require cel-
lular contractility (Figure 3.1d). Treatment with 10 µM blebbistatin (a myosin II inhibitor)
did not significantly shift the transition point nor increase the maximal luminescence of
cells relative to HFFs treated with rhTGFβ alone. Cells treated with 2 µM cytochalasin
D showed a low, flat luminescent profile over increasing ECM stiffness, and the data did
not converge to a sigmoidal model. Curiously, siRNA against LEMD3 did not rescue the
cytochalasin D phenotype, though the degree of LEMD3 knockdown may not have been
sufficient (Figure 3.3b). These data indicate that the actin cytoskeleton, but not cellular
stress per se, is needed for stiffness-modulated TGFβ signaling.
3.3.3 LEMD3-SMAD2/3 Complexes are Inversely Correlated to Substrate Stiffness and
Occur Throughout the Cell
LEMD3-Smad2/3 Interactions Are Negatively Regulated by ECM Stiffness and Invariant to
TGFβ Dose
Given that LEMD3 modulated the stiffness response of fibroblasts to TGFβ, I used prox-
imity ligation assays (PLA, methodologically reviewed in [186]) to examine the stiffness
dependence of LEMD3-Smad2/3 interactions on hydrogels whose stiffness is represen-
tative of physiologic (1 kPa) and fibrotic (25kPa) lung tissue in humans. [4] LEMD3-
Smad2/3 interactions were negatively correlated with substrate stiffness in both the cy-
toplasm and the nucleus (Figure 3.5a&b). This negative correlation was independent of
rhTGFβ dosing (50pg/mL, inside the range of stiffness-responsive doses identified in 3.1b),
consistent with previous findings that LEMD3-Smad2/3 interactions are phosphorylation-
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independent. [171] While LEMD3-Smad2/3 interactions were unperturbed by TGFβ dos-
ing, I explicitly tested the ability of LEMD3 to bind phospho-Smad2/3 (Figure 3.6). I
found that HFFs treated with 100pg/mL TGFβ on glass had significantly higher LEMD3-
phospho-Smad2/3 interactions than untreated fibroblasts (p=0.0333) and that there was a
significant negative correlation between substrate stiffness and LEMD3-phospho-Smad2/3
interactions (p=0.0305). These data confirm and extend previous observations that LEMD3
can bind both phosphorylated and un-phosphorylated Smad2/3. [171]
I extended our findings by performing the PLA assay across a finer range of stiffness
with both HFFs and CCL210s, an adult, pulmonary-derived fibroblast line (Figure 3.5c).
Both CCL210s and HFFs showed a biphasic response to stiffness with peak values at 1
kPa. CCL210s demonstrated a greater dynamic range in response to stiffness as well as a
more gradual loss of PLA interactions on progressively stiffer substrates relative to HFFs.
Additionally, the abrupt loss of LEMD3-Smad2/3 interactions between 1 kPa and 4 kPa in
HFFs correlated with the stiffness dependence of the luciferase signal measured in Figure
3.1b.
LEMD3-Smad2/3 Interactions Occur in the Cytosol
Provocatively, I found that approximately half (≈ 50% and 42% on 1 kPa and 25 kPa
surfaces, respectively, in Figure 3.5a&b) of the PLA interactions on both substrates oc-
curred in the cytoplasm of the cells. Across a broader range of stiffness, I found that the
nuclear proportion of LEMD3-Smad2/3 interactions was inversely correlated to substrate
stiffness in both HFFs (p<0.0001) and CCL210s (p=0.0199), as seen in Figure 3.5d. Given
that LEMD3 is thought to be an integral protein of the inner nuclear membrane, I vali-
dated our findings through V5-Smad2/3 PLA in cells transfected with pFLAG-LEMD3-V5
(Figure 3.5e&f). Near identical trends were observed with this independent, recombinant
PLA reaction: a reduction in PLA frequency overall (p<0.0001), and reductions in both
the cytoplasm (p<0.0001) and nuclear (p=0.0018) compartments with increasing substrate
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stiffness. To control for the degree of recombinant LEMD3 expressed across stiffness con-
ditions, I found a significant difference in the linear regression between PLA puncta per
cell and the per-cell FLAG intensity in cells on both soft and stiff surfaces (p<0.0001)
(Figure 3.5g). The steeper slope observed for cells on soft substrates confirmed a higher
rate of LEMD3-Smad2/3 complex formation per arbitrary unit of LEMD3 expressed (as
measured by the fused FLAG epitope) relative to stiff substrates.
I also validated that our PLA methodology faithfully reported on sub-cellular interac-
tions between LEMD3 and lamin B1, a nuclear intermediate filament. 94.34% ± 0.005%
PLA interactions between LEMD3-lamin B1 were compartmentalized to the nucleus (Fig-
ure 3.7). There was not significant variation in this frequency across the biological repli-
cates. These data indicate that our PLA methodology and analysis techniques are sensitive
enough to determine the sub-cellular localization of LEMD3 interactions.
The C-terminal fragment of LEMD3 (pFLAG-LEMD3p.∆21-669-V5, “CTF”) I cloned
and described earlier has been shown to be sufficient for Smad2/3 binding [169, 171, 168,
190, 166] and lacks the necessary domains for nuclear localization [156, 168, 161]. I re-
peated these recombinant PLA experiments between the V5 epitope and Smad2/3 with
the CTF to ascertain 1) whether this fragment of LEMD3 was sufficient for generating
stiffness-dependent Smad2/3 interactions; and 2) whether these fragments were uniquely
localized to the cytoplasm. The CTF-expressing fibroblasts on 1 kPa hydrogels had signifi-
cantly more Smad2/3 interactions overall (p<0.0001), in the cytoplasm (p<0.0001), and in
the nucleus (p=0.0082) relative to CTF-expressing HFFs on 25kPa hydrogels (Figure 3.8a).
Transfected fibroblasts on 25 kPa hydrogels had significantly more overall CTF-Smad2/3
interactions than electroporation control fibroblasts (p=0.0227). To control for degree of
recombinant CTF expression we compared the V5 signal and the PLA interactions per cell
across each group. I found that fibroblasts on 1kPa hydrogels had a steeper slope (i.e. more
PLA per arbitrary unit of V5 expressed) than fibroblasts on 25 kPa hydrogels (p=0.1476,
Figure 3.8b). Unexpectedly, a significant fraction (≈ 40-55%, depending on stiffness) of
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CTF-Smad2/3 interactions took place in the nucleus. While the N-terminus of LEMD3 up
to the first transmembrane domain has been shown to be necessary for faithful localization
of full length LEMD3 to the nucleus [156, 161], the CTF has an independent ability to bind
both barrier-to-autointegration factor (BAF, a nuclear chromatin protein, [157]) and DNA
directly [190], which may allow for some partial enrichment of the CTF in the nucleus.
Overall, these V5-Smad2/3 PLA assays with recombinant LEMD3 proteins confirmed 1)
the negative stiffness correlation and cytoplasmic localization of LEMD3-Smad2/3 com-
plexes observed with endogenous protein antibodies; and 2) that the CTF is sufficient for
cytoplasmic LEMD3-Smad2/3 interactions.
3.3.4 Mechanism of LEMD3-Smad2/3 Stiffness Regulation
LINC Disruption Does Not Potentiate LEMD3-Smad2/3 Interactions
We hypothesized that the frequency of LEMD3-Smad2/3 complexes would be decreased
by transmission of ECM-driven cytoskeletal tension to LEMD3 through a two-part physical
linkage: 1) the nesprin-sun LINC complex joining the nuclear lamina and actin cytoskele-
ton; and, 2) through nuclear lamina-LEMD3 couping via the LEM domain. We tested
this hypothesis by disrupting the molecular linkages at either the level of the LINC com-
plex by expressing a previously validated dominant negative nesprin construct, DN-Kash-
mCherry, [184] or by disrupting LEMD3-lamin interactions by expressing a novel DN-
LEM-mCherry constructs and assessing complex formation by PLA. Neither DN Kash nor
DN LEM expression increased the LEMD3-Smad2/3 PLA frequency relative to mCherry-
only expressing fibroblasts on glass (Figure 3.9a&b). To assess if my findings were biased
by the degree of DN Kash or DN LEM expression, I correlated PLA puncta against the
mCherry expression of the fusion protein per cell (Figure 3.9c). None of the Pearson’s
coefficients (r=-0.251 and r=-0.087 for DN Kash and DN LEM, respectively) varied signif-
icantly from 0 (p=0.0579 and p=0.43 for DN-Kash and DN-LEM, respectively), indicating
that the degree of dominant-negative protein expression was not a likely explanation for my
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findings. These results also corroborated findings in Figure 3.1d, where cellular contrac-
tility inhibition, through blebbistatin antagonism of myosin II, did not significantly modify
the rhTGFβ stiffness-response of fibroblasts.
Actin Polymerization Negatively Regulates LEMD3-Smad2/3 Interactions
Because g-actin stabilizing agents did modify the fibroblast stiffness-response (Figure 3.1d),
I examined the effect of actin polymerization on LEMD3-Smad2/3 complex formation
by PLA. Actin polymerization was significantly, negatively correlated to the frequency
of LEMD3-Smad2/3 complexes (Figure 3.9d-f). Fibroblasts on glass treated with 2 µM
cytochalasin D for 90 minutes demonstrated an increase in the total frequency of LEMD3-
Smad2/3 complexes overall (p=0.0089). The frequency of LEMD3-Smad2/3 complexes
also increased in the cytosolic (p=0.0871) and nuclear compartments (p=0.5657). Con-
versely, f-actin stabilization through jasplakinolide treatment for 2 hours on 1 kPa hydro-
gels demonstrated a dose-dependent decrease in LEMD3-Smad2/3 interactions (p<0.0001
for vehicle/DMSO treated cells vs both 100nM and 200nM jasplakinolide, and p=0.0312
for 100nM vs 200nM jasplakinolide treatment, Figure 3.9f). Significant reductions in
LEMD3-Smad2/3 complex formation were observed in both the cytoplasm (p<0.0001
for DMSO treated cells vs. both 100nM and 200nM jasplakinolide) and in the nucleus
(p=0.0466 for DMSO treated cells vs. 100nM jasplakinolide and p=0.002 for DMSO
treated cells vs. 200nM jasplakinolide). Considered with the results in Figure 3.1a and
Figure 3.2, showing increased cell spreading, polarization and stiffness as a function of
substrate stiffness, these data suggested that actin polymerization in response to substrate
stiffness helps coordinate the LEMD3-dependent stiffness response of cells to TGFβ.
YAP/TAZ Knockdown Disrupts LEMD3-Smad2/3 Interactions
Neither LEMD3 nor Smad2/3 are known to bind actin directly, so I considered that other
actin-regulated, mechano-sensitive transcription factors might mediate this cytoskeletal
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effect. Yes-associated protein and Transcriptional Coactivator with PDZ-binding motif
(YAP/TAZ) are shuttled between the cytosol and nucleus in an actin-LATS1/2 dependent
fashion. [191, 15, 192] Moreover, YAP/TAZ bind Smad2/3 and have been shown to be
necessary for nuclear accumulation of Smad2/3 in response to TGFβ stimulus. [91, 152,
193, 194] TAZ, in particular, has been shown to bind to the MH1 domain of Smad2. [152]
I assessed the effect of YAP or TAZ knockdown by siRNA on LEMD3-Smad2/3 inter-
actions by PLA on 1 kPa hydrogels in HFFs (Figure 3.10). siRNA against YAP (“siYAP”)
reduced the interaction rate by 69.5% ± 2.4% (Figure 3.10b, <0.0001) while siRNA
against TAZ (“siTAZ”) reduced the interactions by 46.9% ± 5.6% (Figure 3.10b, p=0.0005).
While there was a significantly greater reduction of interactions with siYAP relative to
siTAZ (Figure 3.10b, p=0.0094), siYAP treatment was also more effective in knocking
down YAP expression relative to siTAZ knocking down TAZ expression (Figure 3.10e, ≈
85% and ≈ 72% reductions, respectively).
Treatment with either siYAP or siTAZ shifted the remaining LEMD3-Smad2/3 inter-
actions towards the nucleus (Figure 3.10c). siYAP treated HFFs had an increased nuclear
PLA fraction of 11.4% ± 2.9% relative to vehicle treated HFFs (p=0.0039), while siTAZ
treated cells had an increased nuclear PLA fraction of 8.4% ± 3% (p=0.0716) relative to
vehicle HFFs. These data together suggest that YAP and TAZ positively cooperatively reg-
ulate LEMD3’s binding to Smad2/3 but only in the cytosol, implicating phosphorylated,
quiescent YAP/TAZ in regulating LEMD3-Smad2/3 interactions.
3.3.5 LEMD3 Fragments are Generated by a Serine Protease and Differentially Regulated
by the Integrity of the Nuclear Lamina
Mass Spectroscopy and Genetic Perturbation of LEMD3 Fragments
I observed cytosolic LEMD3-Smad2/3 interactions with PLA antibody pairs against the na-
tive protein and against either the full length recombinant LEMD3 protein or a C-terminal
fragment of LEMD3, each expressing a V5 epitope tag. An ≈ 50 kDa LEMD3 frag-
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ment was also isolated from the cytosol in fractionated cell western blots using antibodies
against the native protein (Figure 3.11b). Additionally, these cytosolic interactions seemed
to be stiffness-regulated given their negative correlation with actin polymerization (Fig-
ure 3.9d-e). To understand how LEMD3 could interact with Smad2/3 in the cytosol, I
performed mass spectroscopy on lysates from cells transfected with pFLAG-LEMD3-V5
constructs (Figure 3.12a). Results from a FLAG-purified 60 kDa fragment showed two
transitions in the peptide spectral matches to LEMD3’s primary sequence - first at p.294-
325 and second at p.579-647 (these protein coordinates are offset by 20 amino acids in-
serted with the N-terminal FLAG tag in the pFLAG-LEMD3-V5 construct from the na-
tive protein sequence). The primary sequence relationship between these two regions and
other known domains of LEMD3 are shown in Figure 3.12b. Deletion mutants (pFLAG-
LEMD3p.∆294-325-V5 & pFLAG-LEMD3p.∆579-647-V5) exploring these two regions
showed differential fragment presentation in western blots which probed either the N-
terminal FLAG tag or C-terminal V5 tag of the recombinant protein (Figure 3.12c). Specifi-
cally, pFLAG-LEMD3p.∆294-325-V5 lysates lacked the 60kDa FLAG fragment (the FLAG
fragment at <50 kDa was also missing but was not consistently found in all blots) and the
46kDa V5 fragment. Suggestively, the 46kDa V5 fragment was similar in size to a cytoplas-
mically localized fragment of LEMD3 using a native antibody (Figure 3.11b). The pFLAG-
LEMD3p.∆579-647-V5 lysates did not appear to change the FLAG fragment presentation
but did eliminate V5 fragments at 60kDa and 85kDa. These genetic data suggested that the
protein was modified in at least two regions, one in the nucleoplasm (∆294-325) and one
in the peri-nuclear membrane space (∆579-647). Moreover, all the V5/C-terminal frag-
ments identified by my genetic mutations contained the CTF used in Figures 3.4 and 3.8,
indicating that they are sufficient for binding Smad2/3 in a stiffness-dependent fashion and
binding Smad2/3 in the cytoplasm.
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Proteolytic Degradation of LEMD3
Following the observation of cytoplasmic interactions with an intron-less LEMD3 cDNA
construct, I hypothesized that these fragments were generated proteolytically. I used west-
ern blots to determine the effects of several broad-spectrum protease inhibitors against cys-
teine (E64 & E64d), serine (3,4 dichloroisocoumarin, DCI) and matrix metallo-proteinases
(MMP inhibitor III - MMPi) as seen in Figure 3.12d&e. From fragments controlled by
the ∆294-325 region, the 60kDa FLAG fragment was reduced relative to the full length
protein in cells treated with DCI (p=0.0153), a known inhibitor of cathepsin G, elastase,
thrombin, plasmin, factors Xa & X11a, and granzymes A, B and H. [195] This fragment
was also reduced when cells were treated with MG-132 (p=0.0238), an inhibitor of the 26S
proteosome complex, an important regulator of overall protein homeostasis and particu-
larly critical for degrading ubitquinated proteins (reviewed recently in [196]). These same
trends were observed for the 46kDa V5 fragment (DCI: p<0.0001; MG-132: p=0.0238),
which is also controlled by the ∆294-325 region. Monash University’s PROSPER (Pro-
tease specificity Prediction Server as described in [197]) predicted only a single serine pro-
tease, cathepsin G, cleaving between p.V275-L276 (native protein coordinates, score=1.14)
in pFLAG-LEMD3p.∆294-325-V5’s deletion region. Using a more selective cathepsin G
inhibitor, I found a significant reduction in the 60 kDa FLAG fragment (p=0.0075) but no
significant trend with the 46 kDa V5 fragment. From the ∆579-647 region, the 60 kDa
V5 fragment was not significantly modified by any protease inhibitor treatments explored
here. Surprisingly, the 85 kDa fragment was only potentiated by MMPi (p=0.0004) and
E64d (p=0.0044) treatment. These fragment data together suggested that a serine protease,
possibly cathepsin G, operates in the ∆294-325-V5 region, with a distinct mechanism of
fragment generation occurring in the ∆579-647 region.
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Cell Cycle and Stiffness Regulation of LEMD3 Fragments
Because pFLAG-LEMD3p.∆579-647-V5’s deletion region lies in the peri-nuclear mem-
brane space, I hypothesized that this location might only be susceptible to degradation
during mitosis. Because LEMD3’s localization is controlled necessarily by its associa-
tion with the nuclear lamina through its LEM domain [161, 165, 158, 159, 160], I chose
roscovitine, a selective inhibitor of cdk1, which prevents cell cycle progression in part by
preventing lamin phosphorylation and disassembly. [198] Surprisingly, roscovitine only
modulated fragments associated with pFLAG-LEMD3p.∆294-325-V5 - significantly re-
ducing the generation of the 60kDa FLAG fragment (p=0.0051) and significantly increas-
ing the generation of the 46kDa fragment (p<0.0001).
Finally, Figure 3.5d showed that LEMD3-Smad2/3 interactions shifted towards the cy-
toplasm with increasing substrate stiffness. I tested whether this shift was driven by al-
terations in C-terminal LEMD3 fragment abundances as a function of substrate stiffness
with western blots assaying HFFs transfected with pFLAG-LEMD3-V5 (Figure 3.13a&b).
After 24 hours, cells grown on 1 kPa and 25 kPa hydrogels each had decreased proportions
of full length LEMD3 relative to fibroblasts cultured on tissue culture plastic (p=0.0062
and p=0.0031 for TC vs. 1 kPa and TC vs. 25 kPa, respectively). Lysates from 1 kPa and
25 kPa hydrogels had similar abundances of the 85 kDa and 60 kDa fragments, though the
45 kDa fragment was almost twice as abundant on 25kPa hydrogels as on 1 kPa hydrogels
(p=0.5196). I also found that full length native LEMD3’s abundance was not modulated
significantly by culture on 1 kPa or 25 kPa surfaces (Figure 3.14a) and that LEMD3’s
mRNA expression level was also invariant to culture on these surfaces (Figure 3.14b).
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3.3.6 LEMD3-SMAD2/3 Complexes are More Cytosolic and Their Frequencies are More
Varied in IPF Biopsies than non-IPF Biopsies
Subcellular Localization of Smad2/3-LEMD3 Interactions
I sought to validate our in vitro findings in human lung core biopsies from six patients
(three with and three without IPF). IPF patients had significantly more cytosolic LEMD3-
Smad2/3 interactions than non-IPF patients (p=0.0307, Figure 3.15a&c). These data are
compelling because they connect the cytoplasmic PLA localization trend seen with in-
creasing stiffness in in vitro in Figure 3.5d and the pattern observed in fibrotic relative to
non-fibrotic human tissue ex vivo. Additionally, these data directly demonstrated that extra-
nuclear LEMD3-Smad2/3 interactions occur in human lung tissue, which I also discovered
in Figure 3.5, indicating that extra-nuclear LEMD3 is not an artifact of in vitro culture.
Interaction Frequency Ex Vivo
Patients with IPF also had a slightly higher median frequency of LEMD3-Smad2/3 inter-
actions relative to patients without IPF (Figure 3.15d, p=0.5783). However, while each
non-IPF patient had a fairly consistent LEMD3-Smad2/3 interaction ”set-point,” IPF pa-
tients displayed a higher degree of intra-patient heterogeneity across their sampled tissue
regions (67% vs. 30% average coefficient of variance for IPF and non-IPF patients, respec-
tively). Overall, the whole IPF data set had a higher degree of kurtosis (4.765 vs. -0.1391
for IPF and non-IPF patients, respectively), indicating that more of the LEMD3-Smad2/3
variance in IPF tissue comes from extreme deviations in interaction frequency. In particu-
lar, ≈ 22% of tissue regions in IPF patients had uniquely low LEMD3-Smad2/3 interaction
rates (<25% the mean interaction frequency), which was not observed in non-IPF tissue.
Previous micro-mechanical investigations of IPF tissue revealed a high degree of spatial
heterogeneity to tissue stiffness in IPF lungs. [4] My findings were consistent with the
interpretation that spatially heterogeneous regions of fibrosis in the IPF tissue created both
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increased variability in the LEMD3-Samd2/3 interaction rate and regions of locally lower
LEMD3-Smad2/3 interactions. These data in aggregate suggested that LEMD3 regulation
of TGFβ through Smad2/3 is locally diminished in IPF tissue relative to non-IPF tissue and
that LEMD3’s role was not confined to the nucleus in human tissue.
3.4 Discussion
3.4.1 Relevance of LEMD3 to Pulmonary Fibrosis
The medical management of fibrotic diseases, such as pulmonary fibrosis, has enjoyed re-
cent success with the approval of pirfenidone, an anti-fibrotic agent, and nintedanib, an
inhibitor of multiple tyrosine kinase receptors after years of failed clinical trials with a va-
riety of other agents including anti-inflammatory and anti-oxidant drugs. [199, 10, 200,
9] Subsequent study of the mechanisms of pirfenidone has shown that pirfenidone antag-
onizes fibrotic progression in part by inhibiting the synthesis of TGFβ [126, 127], which
is preferentially activated in fibrotic matrices. [13, 150] While pirfenidone may success-
fully decrease the supply of TGFβ available in fibrotic pathology, my findings and others’
findings indicate that the fibrotic matrix also potentiates cellular responses (e.g. synthesis
of extracellular matrix and increased cellular contractility) to remaining TGFβ. [88, 89,
90, 91] I focused on the role of LEMD3 in this matrix-driven sensitization and a graph-
ical summary of our working model for LEMD3-Smad2/3 stiffness-driven interactions is
shown in Figure 3.16. We showed in vitro that LEMD3 over-expression antagonized TGFβ-
driven transcription and “stiff-shifts the responsiveness of these fibroblasts to TGFβ while
LEMD3 knockdown by siRNA “soft-shifts” the mechanical response to TGFβ and potenti-
ates TGFβ signaling. I also showed in vitro that LEMD3-Smad2/3 interactions are inhibited
and cytoplasmically shifted with increasing substrate stiffness and actin polymerization. Ex
vivo, I identified these same phenotypic correlates in IPF biopsies relative to non-IPF tis-
sue: IPF tissue had a pronounced cytoplasmic shift in PLA subcellular localization; and, ≈
22% of IPF tissue regions had a unique reduction in LEMD3-Smad2/3 interactions relative
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to non-IPF tissue and a higher degree of variation in the LEMD3-Smad2/3 interaction rate
across various tissue regions, both in individual patients and overall. These low interac-
tion regions in IPF are not likely attributable to changes in overall LEMD3 abundance in
pathology. My data, and others, showed that full length LEMD3 was not regulated by ECM
stiffness at the mRNA or protein level in vitro for endogenous LEMD3 (Figure 3.14) or for
recombinant LEMD3 (Figure 3.13). [12, 15] Moreover, IPF patients do not show evidence
of altered LEMD3 transcription in either microarray or NGS sequencing of IPF and control
patients. [201, 202, 203]
Supporting my discovery of LEMD3-Smad2/3 cytoplasmic interactions, I have discov-
ered here that LEMD3 was post-translationally cleaved at two sites and have implicated
serine proteases (possibly cathepsin G) in the generation of C-terminal fragments that lack
the necessary LEM domain for nuclear targeting. [204, 156, 157] I have also shown that a
C-terminal fragment of LEMD3 bound Smad2/3 throughout the cell. However, the under-
lying mechanism for a cytoplasmic shift in LEMD3-Smad2/3 interactions with increasing
substrate stiffness in vitro and in IPF patient ex vivo is not clear. In vivo, there is strong
evidence for an altered and generally more active serine [205], cysteine [206, 207], and ma-
trix metallo-proteinases [208, 209, 210, 211, 212] landscape in IPF tissue, though much of
the attention has focused on extra-cellular proteolysis. This more pronounced proteolytic
environment could contribute to the cytoplasmic shift seen in IPF patients in our study. In
vitro, I found that stiffness representative of scarred tissue in IPF (25 kPa) and physiologic
lung tissue (1 kPa) produced statistically similar abundances of all the LEMD3 fragments
I identified (Figure 3.13). However, the 46 kDa fragment was nearly twice as abundant
on 25 kPa matrices, prompting a need for further investigation. Overall, I have demon-
strated that LEMD3 sits at an promising intersection of mechanical and biochemical cues
in pulmonary fibrosis and LEMD3 expression may be a promising adjunctive avenue for
addressing fibrosis-driven cellular sensitivity to TGFβ in combination with pirfenidone.
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3.4.2 Mechanism of Stiffness Regulation of LEMD3
My original hypothesis for the stiffness regulation of LEMD3-Smad2/3 complexes was that
LEMD3s affinity for Smad2/3 would be negatively regulated by biophysical stress from
the actin network transmitted to LEMD3 through the LINC-lamina-LEM set of complexes.
However, this hypothesis requires critical re-evaluation in light of our discovery of cytosolic
LEMD3 fragments that bind Smad2/3 and the apparent lack of efficacy of cytosol-nuclear
and lamin-LEM disrupting constructs (DN-Kash and DN-LEM) in increasing LEMD3-
Smad2/3 complex formation in the nucleus. I have also observed that LEMD3-Smad2/3
complexes are negatively correlated to actin polymerization. However, it is not obvious
how actin polymerization itself would directly modulate LEMD3-Smad2/3 complex for-
mation given that neither LEMD3 nor Smad2/3 have a known direct association with
actin. One parsimonious explanation would be that LEMD3 competes for Smad2/3 binding
with other actin-regulated proteins, namely, yes-associated protein (YAP)/transcriptional
coactivator with PDZ-binding motif (TAZ). I have shown directly that LEMD3’s binding
of Smad2/3 is negatively regulated by knockdown of either YAP or TAZ. Interestingly,
YAP/TAZ and LEMD3 appear to bind different domains of Smad2/3. TAZ has been shown
to bind to the MH1 domain of Smad2 [152], while yeast two-hybrid assays indicate that
LEMD3 binds to the MH2 domain of both Smad2 and Smad3 [161]. While it is unclear
how YAP/TAZ regulate LEMD3 binding to Smad, YAP/TAZ have been shown to nega-
tively regulate the Smad binding of forkhead box protein H1 (FOXH1), which competes
for binding to Smad2/3’s MH2 domain with LEMD3 in embryonic stem cell CHIP assays
[213, 166], indicating that YAP/TAZ can regulate MH2 domain binding proteins.
While these data strongly indicate a role for YAP/TAZ in modulating LEMD3’s abil-
ity to bind Smad2/3 in an actin polymerization-dependent fashion, other actin-associated
proteins should also be considered. Rho-associated protein kinase (ROCK) has also been
shown to bind Smad2/3. [151] In particular, ROCK inhibition has been shown to mod-
ulate phosphorylation in Smad3s linker region (Ser203, Ser207, Ser212) [151] and could
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be an important alternative hypothesis for the stiffness-dependence of LEMD3-Smad2/3
interactions.
3.4.3 LEMD3 in Buschke-Ollendorff Syndrome
LEMD3 is directly implicated in the development of Buschke-Ollendorff syndrome (BOS)
with and without melorheostosis. My findings that LEMD3 was post-translationally pro-
cessed proteolytically and has cytosolic forms raises new questions regarding the pathogen-
esis of BOS. Many of the identified BOS patients possess nonsense or splice-site mutations
which eliminate the Smad-binding C-terminal end of LEMD3. [170, 173, 174, 175, 176,
177, 178, 179, 180] Promisingly, there are a five mis-sense mutations of unknown clinical
significance associated with BOS in NCBIs ClinVar database, which are associated with
one of the two deletion mutants (p.∆294-325 and p.∆579-647) identified in this study.1
[214] These mis-sense mutations suggest that alterations to the fragment controlling re-
gions of LEMD3 might play a role in the development of BOS. Additionally, our finding
that LEMD3 was processed by a serine protease and the 26S proteosome might suggest
additional targets/mechanisms in individuals with BOS who lack mutations in LEMD3.
[181]
3.4.4 Insights into Biology of Integral Nuclear Membrane Proteins
Finally, I have characterized several N- and C-terminal LEMD3 fragments and demon-
strated their varying sensitivities to: 1) genetic perturbation through deletion mutants; 2)
serine (DCI), cathepsin G and 26S proteosome (MG-132) inhibitors; 3) lamin integrity/disassembly
through cdk1 inhibition; and 4) substrate stiffness. One particular pair of fragments, the 60
kDa N-terminal FLAG and 46 kDa C-terminal V5 fragments, are particularly interesting
because they are both sensitive to the same mutation region (p.∆294-325), both fragments’
abundance is reduced with respect to DCI and MG-132 treatment, and they plausibly sum
1SCV000332734.2, SCV000341129.2, SCV000380866.2, SCV000380877.2, SCV000380879.2,
SCV000380878.2
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to the mass of full length LEMD3. However, these two fragments are differentially regu-
lated by integrity of the lamin network (following inhibition of cdk1 by roscovitine) and
by cathepsin G inhibition, making it less likely that these fragments are generated in a con-
certed proteolytic reaction. Additionally, I do not have a straight-forward explanation for
the position of our deletion mutations and the fragments’ sizes they seemingly control. It
is not possible to directly align our western blot fragment data and mass spec data because
of the unknown distributions of post-translational modifications in LEMD3; however, the
fragments’ relative masses controlled by either deletion mutant do not logically correspond
with expected size of products from cleavage in those areas.
This is, to my knowledge, the first report of an integral, inner nuclear membrane protein
processed proteolytically into cytosolic forms. However, my observations fit a broader pat-
tern of a more locationally dispersed role for nuclear envelope integral proteins. Several in-
tegral members of the nuclear membrane have alternative splice forms that both include and
omit their trans-membrane domain(s), including nesprin, lamina-associated polypeptide 2,
(LAP2), torsin-1a-interacting protein 1 (LAP1), and nurim. [215, 216, 217, 218] Moreover,
some localized elements of the nuclear envelope have been found dispersed throughout the
cytosol based on the cellular context. For example, nesprins, structural elements of the
outer nuclear membrane that link the cytoskeleton and nucleus are restricted to the nuclear
envelop in myoblasts but are not in differentiated myotubes [219, 220], and certain nesprin
isoforms are also de-compartmentalized during muscle regeneration in Duchenne muscular
dystrophy. [220] In addition, alternatively spliced, KASH-less nesprins, which lack the nu-
clear envelope anchoring domain, KASH, have recently been linked to a variety of cytosolic
locations, including focal adhesions and actin stress fibers [215], Golgi bodies, [221] and
RNA-processing bodies. [222, 223] My findings expand on the observed mechanisms that
regulate the localization of nuclear envelope proteins in the cell.
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3.5 Future Directions
3.5.1 LEMD3 as a Novel IPF Theraputic
The ability of LEMD3 over-expression to “stiff-shift” the stiffness potentiation of fibrob-
lasts to TGFβ signaling indicates that it is a viable avenue for addressing an unmet clinical
need in fibrosis. While pirfenidone has been shown to reduce the matrix stores of TGFβ
[127, 126], it has not been shown to reduce cellular sensitivity to any remaining TGFβ.
Clinically, pirfenidone has been shown to reduce the rate of loss of functional lung capac-
ity but only has a modest mortality benefit (≈ months of life extension). [10, 8] The ability
to address stiffness-dependent TGFβ sensitization through LEMD3 over-expression may
be an important synergistic treatment.
The work in this thesis indicates some important design considerations for the ther-
apeutic expression of LEMD3 in the lung. First, LEMD3 is a relatively large, double-
pass molecule with a theoretical molecular weight of 100 kDa. My work with a consen-
sus LEMD3 C-terminal fragment (“CTF”) indicates that smaller fragments (≈ 33 kDa) of
LEMD3 are just as effective as full length LEMD3 in dephosphorylating Smad3. Moreover,
this CTF also recapitulates the same stiffness-dependent binding phenotype as full-length
LEMD3 and, interestingly, this CTF may retain some degree of nuclear targeting through
its MSC domain. These findings indicate that the majority of LEMD3’s primary sequence
is dispensable for its function as a TGFβ inhibitor, but how much more of the CTF could be
trimmed and still retain this essential function is an open question. The annotated Smad-
binding domain of LEMD3 is comprised of the last 213 amino acids on the C-terminal
end and LEMD3’s binding of Smad1 can be completely abrogated by point mutations at
L703-I704 and Y835-V836. [171] Unfortunately, no similar, point-mutant mapping exists
for Smad2/3 binding to LEMD3. Finding this ”minimal LEMD3” may be important in
optimizing the ability to deliver it to the lung and in preventing the engagement of other bi-
ological processes (e.g. chromatin binding, cell cycle regulation, nuclear lamina structure),
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which LEMD3 has been shown to perform.
3.5.2 LEMD3 as a Biochemical Clutch Between YAP/TAZ and TGFβ
Understanding the regulation of LEMD3-Smad2/3 interaction by YAP/TAZ is of transla-
tional and scientific importance. YAP/TAZ have previously been shown to be necessary
for Smad2/3 translocation to the nucleus and contribute to the progression of fibrosis in
multiple organ systems. [152, 15] My work adds an important and contrasting view of
YAP/TAZ’s role in Smad/fibrosis biology - namely, that YAP/TAZ help coordinate an in-
hibitor of Smad2/3.
Resolving this apparent discrepancy might reveal additional therapeutic potential to
LEMD3-based approaches to fibrosis. My current hypothesis is that only phosphorylated,
inactive YAP/TAZ help to promote LEMD3-Smad2/3 interactions through direct binding to
Smad’s MH1 domain. If correct, it would be extremely intriguing to see if LEMD3 over-
expression has a reciprocal effect on YAP/TAZ-Smad2/3 interactions (i.e. does LEMD3
over-expression stabilize the cytosolic interactions between YAP/TAZ and Smad2/3?). By
understanding this mechanism more fully, we may learn that LEMD3 is not only antag-
onizing TGFβ-dependent signaling but also matrix-derived stiffness signaling, which has
been shown to be important to fibrosis. [15]
Important question to answer about this mechanism would be:
• How does YAP/TAZ knockdown change the stiffness profile of LEMD3-Smad2/3
interactions? Is the actin polyermiztion phenotype for LEMD3-Smad2/3 interac-
tions observed here dependent on YAP/TAZ expression? Is this a global or stiffness-
responsive inhibition? This question could be addressed by repeating PLA experi-
ments from this paper in YAP/TAZ knockdown (siRNA) and over-expression in vitro
systems.
• Is YAP/TAZ binding to the MH1 domain important for modulating LEMD3-Smad2/3
interactions or do PTMs in the MH1 domain confer this effect independent of YAP or
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TAZ actually being bound to Smad2/3? Experimentally, generating Smad2/3 recom-
binant mutants (deletion of Smad2/3’s MH1 domain versus point mutation of known
PTMs sites in Smad 2/3) for PLA-based assayes could answer whether these binding
events or PTMs modulate the ability of LEMD3 to associate with Smad2/3.
• Does YAP/TAZ’s phosphorylation state influence the potentiation of LEMD3-Smad2/3
binding? Generation of YAP/TAZ point mutants that cannot be phosphorylated and/or
inhibition of LATS1/2 could help address this particular question.
• Does LEMD3 expression modulate the interaction frequency of YAP/TAZ and Smad2/3?
If so, does LEMD3 expression modulate the translocation of YAP/TAZ to the nucleus
as a function of substrate stiffness and does that change the abundance of YAP/TAZ
associated transcripts? These questions could also be answered using a combination
of RT-qPCR, immunofluorescence, fractionated cell western blotting and PLA.
• Is the YAP/TAZ regulation of LEMD3-Smad2/3 binding recapitulated in vitro? For-
tunately, conditional YAP, TAZ, and YAP/TAZ floxed mice all exist and tissue PLA
approaches used in this paper could be adapted to answer this question directly. [224,
225, 226]
3.5.3 LEMD3 as a Novel mRNA Binding Protein
The discovery of a cytosolic role for LEMD3 and its previously annotated RNA-recognition
motif raise the intriguing possibility that LEMD3 or LEMD3 fragments are novel RNA reg-
ulatory proteins, much like recently identified nesprin splice variants. [222, 223] Currently
there is no clear understanding of transcriptional changes that accompany LEMD3 ex-
pression modulation. Understanding what, if any, mRNA species are affected by LEMD3
knockdown or over-expression would be a a critical first step in identifying potential targets
for post-transcriptional regulation. Given that LEMD3 does antagonize TGFβ and BMP
signaling, it would be important to determine if any unique mRNAs outside those signal-
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ing families are modulated by LEMD3 expression. Alternatively, the use of CLIP-based
assays could be employed to directly explore the role of LEMD3 in mRNA binding. If
LEMD3 is found to be an RNA binding protein, then the connection between some of the
novel LEMD3 biology identified in this thesis (e.g. LEMD3 fragmentation and proteolysis)
would be intriguing avenues to explore and connect.
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Figure 3.1: LEMD3 modifies the stiffness response of fibroblasts to activated TGFβ. A,
fibroblasts demonstrate mechano-sensitivity to ECM stiffness through cytoskeletal compli-
ance matching as measured by AFM on increasingly stiff matrices (p=0.001). B, fibroblasts
stably transfected with Smad-responsive luciferase demonstrate a dose-dependent, stiffness
modulation of their TGFβ responsiveness. Increasing doses of TGF β are associated with a
softer sigmoidal inflection point (p=0.07) and cells demonstrate a dose-response to TGFβ
on stiff surfaces (p<0.0001). C, LEMD3 expression is correlated with a stiffer transi-
tion point in TGFβ-stiffness responsiveness (p<0.0001) and with decreased luminescence
(p=0.04). D, cytoskeletal depolymerization, but not myosin II inhibition, is associated with
a decreased and flattened luminescent response of fibroblasts to TGFβ. LEMD3 KD does
not rescue actin-depolymerization phenotype. Treatments with cytochalasin D did not con-
verge to a sigmoidal model and the data are represented by the mean with standard error
of the mean to convey the heterogenity of the results. All cell stiffness/morphology phe-
notypes and stiffness model parameters were statistically analyzed using an ANOVA - Test
for Trends analysis.
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Figure 3.2: Fibroblasts spread and polarize in response to substrate stiffness A, fibrob-
lasts demonstrate mechano-sensitivity to ECM stiffness as demonstrated by increased cell
spreading (p=0.1801, ANOVA - Test for Trends) and polarization (p=0.0263, ANOVA -
Test for Trends).
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Figure 3.3: Over-expression and knockdown of LEMD3 using pFLAG-LEMD3-V5
and siRNA. A and B, representative western blots and quantification from plasmid over-
expression (A) and siRNA knockdown experiments (B). pFLAG-LEMD3-V5 electropo-
ration significantly increases full length LEMD3 (p=0.0018 for HFF vs. 1 µg pFLAG-
LEMD3-V5, p=0.0012 for Neon Only vs. 1 µg pFLAG-LEMD3-V5, ANOVA with
Tukey post-test). siLEMD3 delivered by Lipofectamine 2000 (L2K) significantly decreases
LEMD3 expression relative to siGFP control (p=0.0248, Student’s T-test).
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Figure 3.4: LEMD3 negatively regulates Smad3 phosphorylation. A, Phospho-Smad3
to Smad3 ratios were measured by western blot in HFFs on tissue culture plastic. HFFs
treated with 100 pg/mL TGFβ for 90 minutes had an increased pSmad3/Smad3 ratio rel-
ative to untreated fibroblasts (p=0.0506). HFFs treated with 100 pg/mL TGFβ and 25nM
or 200nM siRNA against LEMD3 (“siLEMD3”) had a higher pSmad3/Smad3 ratio than
cells treated with a concentration matched siRNA against GFP (“siGFP”; p=0.1103 and
p=0.0057 for 25nM and 200nM, respectively, Student’s T-test). TGFβ dosed HFFs electro-
porated with pFLAG-LEMD3-V5 (“FL-OE”) or pFLAG-LEMD3p.∆21-669-V5 (“CTF-
OE”) had diminished pSmad3/Smad3 ratios relative to TGFβ treated HFFs (p=0.0124 and
p=0.2116 for CTF-OE and FL-OE, respectively) but were not statistically different from
the electroporation-only (“Neon Only”) control. B, representative blots for Smad2/3 and
phospho-Smad2/3. Smad3 is the lower band at ≈ 50 kDa.
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Figure 3.5: LEMD3-Smad2/3 interactions are inversely correlated to substrate stiff-
ness and occur in the nucleus and cytoplasm. A, micrographs of LEMD3-Smad2/3 PLA
interactions on soft (top row, 1 kPa) and stiff (bottom row, 25 kPa) matrices (PLA in green,
f-actin in blue, nucleus in white). B, quantification of PLA interactions grouped by sub-
strate stiffness and by TGFβ dose. Total LEMD3-Smad2/3 interactions are negatively cor-
related to substrate stiffness (p<0.0001 for 1 kPa vs 25 kPa for both 0 pg/mL and 50 pg/mL
TGFβ) but are not correlated to TGFβ dose. Cytoplasmic (p=0.0164 for 0 pg/mL TGFβ,
p=0.0087 for 50 pg/mL TGFβ) and nuclear compartment (p = 0.0428 for 0 pg/mL TGFβ,
p=0.1228 for 50 pg/mL TGFβ) interactions are also negatively correlated to substrate stiff-
ness. C, total HFFs and CCL210s LEMD3-Smad2/3 interactions by PLA normalized to 0.5
kPa on surfaces with stiffness of 0.5, 1, 4, 8, 25 kPa and glass. Each fibroblast population
shows a biphasic trend, centered around a peak of LEMD3-Smad2/3 interactions at 1kPa.
CCL210 demonstrate greater dynamic range in interaction frequency and a slower loss of
interactions on stiffer substrates than HFFs. D, subcellular location of LEMD3-Smad2/3
PLA interactions in HFFs and CCL210s from (C). Each cell line demonstrates a cytoplas-
mic shift in location with increasing substrate stiffness (p<0.0001 and p=0.0199 for HFFs
and CCL210s, respectively; ANOVA - Test for trend). E, micrographs of V5-Smad2/3
PLA interactions with pFLAG-LEMD3-V5 on soft (top row) and stiff (bottom row) matri-
ces (PLA in green, f-actin in blue, FLAG in red, nucleus in white). F, V5-Smad2/3 PLA
interactions are also negatively correlated with substrate stiffness (for 1 kPa vs 25 kPa:
Total PLA - p<0.0001, Cytoplasmic PLA - p<0.0001, Nuclear PLA - p=0.0018) and also
occur in the cytoplasm. G, V5-Smad2/3 PLA interactions are significantly higher on soft
substrates independent of the degree of pFLAG-LEMD3-V5 expression (difference in lin-
ear regression slopes - p<0.0001). All PLA groups were statistically compared using a
2-way ANOVA with Tukey post-test unless noted. All scale bars are 10 µm.
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Figure 3.6: LEMD3 binds phospho-Smad2/3 in a stiffness-dependent fashion. PLA
interactions between phospho-Smad2/3 and LEMD3, normalized to HFFs on glass without
TGFβ treatment, are stiffness- and TGFβ dose-dependent. Fibroblasts on glass treated
with 100 pg/mL TGFβ have significantly more LEMD3-phospho-Smad2/3 interactions
than cells without TGFβ treatment. (p=0.0333, Student’s T-test). There is also a significant
decrease in interactions with increasing stiffness (p=0.0305, ANOVA-Test for trends).
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Figure 3.7: Lamin B1-LEMD3 PLA interactions are compartmentalized to the nu-
cleus. To assess whether PLA and our analysis methods could localize interactions to
particular subcellular compartments, we performed PLA between lamin B1, an integral el-
ement of the nuclear lamina, and LEMD3 on glass. A, micrographs of PLA interactions
between lamin B1 and LEMD3. B, quantification of the subcellular (nuclear) localization
of these interactions per cell. Across all biological replicates, 94.34 ± 0.005% of all lamin
B1-LEMD3 interactions were compartmentalized to the nucleus. There were no significant
deviations in nuclear PLA frequency across groups (all inter-group comparisons p≥ 0.48,
ANOVA).
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Figure 3.8: The C-terminal end of LEMD3 is sufficient for binding Smad2/3 in a
stiffness-dependent fashion. A, PLA interactions between the V5 tag of a C-terminal
fragment (“CTF”) of LEMD3 (pFLAG-LEMD3p.∆21-669-V5) and Smad2/3, normalized
to the total interactions observed on 1 kPa hydrogels. HFFs on 1 kPa hydrogels have signif-
icantly more interactions overall (p<0.0001), in the cytosol (p<0.0001), and in the nucleus
(p=0.0082) relative to fibroblasts on 25 kPa hydrogels. All transfected cells had more PLA
interactions than electroporation-only (”Neon”) populations (p<0.0001 and p<0.0227 for
1 kPa and 25 kPa hydrogels, respectively). B, the higher V5-Smad2/3 PLA frequencies
observed in fibroblasts on 1 kPa hydrogels is independent of the degree of V5 expression.
The slopes of individual cells’ PLA vs. V5 staining intensity were higher for cells on 1
kPa hydrogels than on 25 kPa hydrogels (p=0.1476, difference in slopes). All PLA groups
were statistically compared using a 2-way ANOVA with Tukey post-test unless noted.
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Figure 3.9: LEMD3-Smad2/3 interactions are negatively associated with actin poly-
merization but not nucleus-cytoplasm coupling or LEMD3-lamin coupling. A, mi-
crographs of LEMD3-Smad2/3 PLA in electroporated cells (top row), mCherry-DN LEM
expressing cells (2nd row), mCherry-DN Kash expressing cells (3rd row), or mCherry only
expressing cells (bottom row), all on glass (PLA in green, f-actin in blue, mCherry in red,
nucleus in white). B, no significant differences in PLA frequency are seen in the nucleus
or cytoplasm of cells expressing either DN LEM or DN Kash relative to mCherry control
cells. C, no correlation between DN LEM or DN Kash expression and PLA frequency
in transfected cells. D, micrographs of LEMD3-Smad2/3 PLA in cells treated with cy-
tochalasin D (top rows, g-actin stabilizer) on glass or jasplakinolide (bottom rows, f-actin
stabilizer) on 1 kPa gels (PLA in green, f-actin in blue, nucleus in white). E, cytochalasin
D treatment significantly increases the total frequency (p=0.0089) of PLA interactions per
cell on glass. F, jasplakinolide (“Jas”) treatment significantly decreases the total frequency
of LEMD3-Smad2/3 interactions in a dose-dependent fashion (p<0.0001 for DMSO vs.
100nM Jas or 200nM Jas, p=0.0312 for 100nM Jas vs. 200nM Jas), and decreases the
cytoplasmic (p<0.0001 for DMSO vs. 100nM Jas or 200nM Jas) and nuclear frequencies
(p=0.002 for DMSO vs. 200nM Jas, p=0.0466 for DMSO vs. 100nM Jas) of LEMD3-
Smad2/3 interactions on 1 kPa surfaces. All groups were statistically compared using a
2-way ANOVA with Tukey post-test. All scale bars are 10 µm.
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Figure 3.10: YAP and TAZ KDs by siRNA antagonize LEMD3-Smad2/3 interactions
and shift interactions towards the nucleus. A, representative micrographs of LEMD3-
Smad2/3 PLA interactions in HFFs on 1 kPa fibronectin hydrogels treated with 25nM
siRNA against YAP (“siYAP”, top row), 25nM siRNA against TAZ (“siTAZ”, middle row),
or L2K vehicle treatment (“L2K”, bottom row). B, quantification of PLA puncta per cell,
normalized to L2K condition, from at least two biological replicates per group. Signifi-
cant loss of LEMD3-Smad2/3 interactions are observed with either siTAZ (p=0.0005) or
siYAP (p<0.0001) treatment. SiTAZ treated samples also had significantly more LEMD3-
Smad2/3 interactions than siYAP samples (p=0.0094). C, loss of YAP (siYAP, p=0.0039)
or TAZ (siTAZ, p=0.0716) shifted remaining LEMD3-Smad2/3 interactions towards the
nucleus. All comparisons made using Kruskal-Wallis test with Dunn’s test for multiple
comparisons. D, representative western blots demonstrated YAP and TAZ KD by siRNA
using GAPDH as a loading control. E, quantification of YAP (left graph) and TAZ (right
graph) KD by siRNA from (D). Treatment with 25nM siYAP or 25nM siYAP and 25nM
siTAZ (“siYAPTAZ”) significantly reduced YAP levels relative to untreated HFFs (siYAP
p=0.0044, siYAPTAZ p=0.008). Similarly, 25nM siTAZ or 25nM siYAPTAZ reduced lev-
els of TAZ (siTAZ p=0.0081, siYAPTAZ p=0.0145). No significant reductions in either
protein are observed with vehicle alone (L2K), or siRNA against GFP (“siGFP”). All test-
ing done using ANOVA with Dunnett’s multiple comparison correction. All scale bars are
10µm.
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Figure 3.11: Full length LEMD3 is localized to the nucleus, but a 46kDa fragment is
localized to the cytoplasm. A, representative western blots of cytosolic (GAPDH) and
nuclear (LaminA/C) compartment markers from a fractionated lysate are shown. Cytosolic
markers are observed in the nucleus but no nuclear markers are observed in the cytosol. B,
LEMD3 western blot on whole cell lysate or enriched lysates for the cytoplasmic or nuclear
fractions. An ≈ 50 kDa native LEMD3 fragment is found in the cytoplasm and possibly
the nucleus, while full length LEMD3 is only found in the nucleus.
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Figure 3.12: LEMD3 is proteolytically modified by a serine protease. A, Peptide spec-
tral matches (PSMs) were normalized from a 60kDa FLAG fragment of LEMD3 by PSM
frequencies measured in full length LEMD3. Normalized PSM frequency revealed three
distinct zones: over-enriched (left shaded region), under-enriched (unshaded region), and
absent (right shaded region). B, LEMD3 cartoon showing relative position of the two dele-
tion mutants and known protein domains: LEM, transmemebrane (TMs 1&2), and RRM
domains, and FLAG and V5 epitope tags. C, western blots from full length and each dele-
tion mutant using N-terminal FLAG tag (top two blots) and C-terminal V5 tag (bottom two
blots) at 12 and 24 hours after electroporation. FLAG blots consistently produce a 60 kDa
fragment, while V5 blots produce 85 kDa, 60kDa, and 46 kDa fragments. D, representative
western blots for protease and cell cycle inhibitor experiments using N-terminal FLAG tag
(top two blots) and C-terminal V5 tag (bottom two blots). E, quantification of blots from
(D), showing that 60 kDa FLAG fragment is significantly reduced relative to the full-length
protein when cells are treated with DCI (p=0.0153), MG-132 (p=0.0238), Cathepsin-G in-
hibitor (p=0.0075), or roscovitine (p=0.0051). V5-tagged 46 kDa fragment are similar in
that DCI (p<0.0001) and MG-132 (p=0.0238) treatments decrease its abundance, but dis-
similar in that roscovitine increases its abundance (p<0.0001). V5-tagged 85kDa fragment
is increased with MMP inhibitor treatment (p=0.0004) and E64D treatment (p=0.0044). All
treatment groups, except MG-132, were tested statistically using ANOVA - Test for Trends
with a correction for multiple hypotheses using a False Discovery Rate (FDR) of α=0.05.
MG-132 was compared to DMSO treated lysates with a Mann-Whitney test and then also
corrected using the FDR approach above.
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Figure 3.13: LEMD3 C-terminal fragments are not significantly differentially abun-
dant in HFFs cultured on 1 and 25 kPa hydrogels. A, Fibroblasts transfected with
pFLAG-LEMD3-V5 were assayed by western blot for the relative abundance (fraction of
total V5 signal in that lane) of the full length protein or of the 85 kDa, 60 kDa, or 45 kDa
fragments after 24 hours on 1 kPa, 25 kPa hydrogels or tissue culture plastic. Fibroblasts
cultured on 1 kPa and 25 kPa hydrogels have significantly less full length LEMD3 than
cells cultured on tissue culture plastic (p=0.0062 and p=0.0031 for 1 kPa and 25 kPa hy-
drogels, respectively) but do not vary significantly in the abundance of any identified frag-
ment. Cells on 25 kPa hydrogels have nearly twice as much of the 45 kDa fragment than
cells from 1 kPa hydrogels (p=0.5196). B, representative blots of the experimental lysates.
All stiffness in a given protein mass group were statistically compared using ANOVA with
Tukey post-test. Data point represented by ”#” in Full Length, 1 kPa was determined to
be an outlier (Grubb’s method, α=0.05) and is plotted for completeness but excluded from
analysis.
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Figure 3.14: LEMD3 is not directly regulated by substrate stiffness at the mRNA or
protein level. A, representative western blots and quantification of LEMD3 protein from
soft (2 kPa) and stiff (25 kPa) hydrogels using GAPDH as a loading control. No significant
difference is observed between stiffness conditions. B, LEMD3 mRNA quantification from
cells on soft (2 kPa) or stiff (25 kPa) hydrogels using 18S as a house-keeping gene. No
significant difference is observed between stiffness conditions.
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Figure 3.15: LEMD3-Smad2/3 PLA interactions are more cytoplasmic and more var-
ied in frequency in IPF vs. non-IPF human lung tissue. A and B, LEMD3-Smad2/3
PLA frequency imaged at high-magnification (63X) (A) and low-magnification (20X) (B)
in non-IPF (top row) and IPF (bottom row) tissue (PLA in green, f-actin in blue, aut-
ofluorescence in red, nuclei in white). C, quantification of sub-cellular localization of
LEMD3-Smad2/3 PLA events from (A) showing cytoplasmic shift in PLA interactions in
IPF patients (p=0.0307, Mann-Whitney test), mirroring in vitro trends seen in Figure 3.5c.
D, quantification of total LEMD3-Smad2/3 PLA frequency from (B) showing similar fre-
quency of interactions between IPF and non-IPF patients (p=0.5783, Mann-Whitney test).
IPF tissue had a higher intra-patient variability (Coeff. of Variance = 67% and 30% for IPF
and non-IPF patients, respectively) and more extreme dispersion overall (kurtosis = 4.765
and -0.1391 for IPF and non-IPF patients, respectively). 22% of IPF tissue areas sampled
formed a unique low-interaction “tail” (<25% of the mean IPF interaction frequency, de-
noted by dotted line), which is absent in non-IPF tissues. All scale bars are 10 µM. Bars in
(C) and (D) represent grand medians.
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Figure 3.16: Summary Cartoon Mechanical cues from the extracellular matrix potentiate
TGFβ activation, which forms and translocates Smad2/3/4 complexes to Smad Response
Elements in the nucleus. LEMD3 antagonizes this TGFβ/Smad2/3 signaling by complex-
ing with Smad2/3 both in the nucleus and in the cytosol and shifts the mechanical re-
sponse of cells to TGFβ. Cytosolic LEMD3 fragments are post-translationally generated at
two sites, which separate the nuclear localizing LEM domain and the Smad2/3 interacting
RRM domain. Processing at the nucleoplasmic site (bottom red star) generates a LEM- and
RRM-containing fragment, which is inhibited by serine protease inhibitors, but has differ-
ential responses to lamin phosphorylation inhibitors. Both nuclear and cytosolic LEMD3-
Smad2/3 complexes are inhibited by actin polymerization, which is driven by mechanical
cues from the matrix, thereby connecting ECM mechanics to inhibition of an inhibitor of
Smad2/3. Inhibitory interactions are shown with red block-end arrows while activating sig-
nals are denoted with green arrows. Black arrows indicate translocation. Abbreviations:




TOOLS TO DISSECT THE THERMODYNAMIC LANDSCAPE OF THE
MURINE CARGOME
4.1 Introduction
4.1.1 Biophysically Targeting Disease and in vivo Stiffness Reporting
Alterations to tissue stiffness prompt a variety of temporal responses from cells. Many
of the short-term changes to a cell’s phenotypes are post-translationally regulated (e.g.
increased actin polymerization and contractility [14, 227], alterations to endocytosis and
intracellular transport [111], etc.). These short-term phenotypes, in turn, help to regulate
and are frequently reinforced by genetic programs that feedback into the mechanosensory
machinery of the cells and the matrix itself. [228, 12] These genetic programs drive many
of the long-term phenotypic changes (e.g. matrix metabolism [229, 230], cellular differ-
entiation [14], etc.) that arise from altered matrix stiffness. Provocatively, understanding
how mechanical information is filtered through the genome by measuring the stiffness-
response of key transcription factor families and charting the energy landscape in which
those transcription factor families operate over is important for two reasons: 1) it should
allow for the rational design of genetic therapies that selectively harness the cell’s intrinsic
mechanosensing potential, using stiffness as a stimulating cue for modular therapy; and,
2) it could provide a basis for therapeutic antagonism of gene sets that are specifically
activated in fibrosis.
A proof-of-concept study exploring the ability of stiffness-driven transgenes to biophys-
ically target metastatic breast cancer in the lung has recently been published. [231] This
work exploited 8x TEAD box driven transgenes, which are YAP/TAZ responsive, to drive
the therapeutic expression of a pro-drug converting enzyme from ex vivo modified mes-
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enchymal stem cells (MSCs). While their in vivo data did not show a theraputic benefit of
the stiffness-driven transgene relative to constitutively active expression of the converting
enzyme in MSCs, their in vitro data demonstrated a clear proof-of-concept: genetic expres-
sion using their system was driven in a stiffness-dependent fashion with marked increases
in transcription above 10kPa and was dependent on the intact focal adhesion and cytoskele-
tal activities of the cell. This demonstration is highly motivating to the work presented in
this chapter because it begs the question as to how mechanically regulated systems could
be designed rationally for specific stiffness performance criteria.
Here, I hypothesized that the stiffness-responsivity of mechanically-regulated trans-
genic promoters is based on the relative position of that promoter within the endogenous
energy landscape of the particular response element and the sensitivity of the system to me-
chanical activation. I focused my efforts on understanding the mechanical activation and
the underlying genetic structure of a model, stiffness-regulated transcription factor system
and on developing the tools necessary to make a unique measurement of its energy land-
scape.
4.1.2 Mechanically Sensitive Transcription Factor Systems
While there are a variety of mechano-sensitive transcription factor families, I have focused
on the activity of the myocardin related transcription factors (“MRTFs”) and serum re-
sponse factor (“SRF”) as a model mechanical system because a detailed understanding of
their mechanical regulation is already known and because of the relative simplicity of their
transcriptional activities. Following an introduction to the relevant biology of MRTF/SRF,
there is an overview of other mechanically sensitive transcription factor families that moti-
vate my choice of MRTF/SRF as a model mechanical-genetic system.
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Myocardin Related Transcription Factors
The myocardin related transcription factors A and B (“MRTF-A/MKL-1” and “MRTF-
B/MKL-2”) are actin sensitive transcription factors that regulate a variety of extracellu-
lar matrix components and mechno-sensing machinery of the cell primarily through co-
activation of serum response factor (SRF). [232, 233, 228] These proteins are structurally
similar to myocardin, a transcription factor largely restricted to the smooth muscle and the
cardiovascular lineage [127], and the MRTFs are found near ubiquitously throughout the
body in many cell types, including fibroblasts. [234, 228]
Mechanical Regulation of MRTF-A and MRTF-B
The activities of the MRTFs are controlled through their cytoplasm-nuclear shuttling. In
the cytosol, the MRTFs are bound and sequestered by g-actin. When the pool of free g-
actin drops during its polymerization to f-actin, MRTFs’ RPEL domain, which contains
cryptic nuclear localization sequences, is uncovered, allowing for rapid nuclear translation
in an importin-α/β dependent fashion. [233, 232, 235, 236, 237, 238] Once inside the
nucleus, nuclear export is regulated in a similar fashion - nuclear g-actin binds the MRTFs
and promotes their export to the cytoplasm. [239, 240] Only the nuclear compartments of
the MRTFs are transcriptionally relevant, acting as a necessary co-factor for SRF. [228]
The intimate connection between actin polymerization and substrate stiffness, medi-
ated by both Rho GTPases and formins, means that the nuclear localization of the MRTFs
is tightly correlated to the underlying substrate stiffness. [233, 241] However, this cor-
relation between localization and substrate stiffness can be modified by post-translational
phosphorylation of the MRTFs in a Rho- and serum/ERK-dependent fashion. While Rho-
phosphorylation generally inhibits the association of the MRTFs with nuclear actin (pro-
moting nuclear residency), MRTF phosphorylation by ERK has site specific effects - it can
both prevent g-actin-MRTF binding and promote nuclear export by increasing MRTF’s
affinity for g-actin. [242, 235] Additionally, the substrate-stiffness dependence of this
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process can be diminished by growth factor stimulation, which independently drives the
assembly of the actin cytoskeleton. [228, 14]
The CArGome and Transcriptional Activity of MRTF-A and MRTF-B
In the nucleus, MRTFs act as the co-activator of SRF and drives transcription at DNA re-
sponse elements called CArG boxes, which have a canonical sequence of 5’-CC(A/T)6GG-
3’. [243, 244, 245, 228] While SRF is able to be co-activated at 83 genetic loci in the
murine genome in a tertinary complex factor family-dependent fashion, the MRTFs con-
trol the activation of SRF at over 2295 genetic loci and are the dominant co-activators of
SRF. Moreover, SRF is co-precipitated at over 95% of all MRTFs’ loci and acts as the
main transcription factor partner for the MRTFs. [228] Genomically, while MRTF-A and
B appear to co-regulate many of the same loci, MRTF-B seems to have a larger indepen-
dent set of target loci relative to MRTF-A. CHIP seq studies of MRTF A and B reveal that
they co-precipitate at 1320 genomic loci while MRTF A has 75 unique loci not found with
MRTF-B, which has 1021 unique genetic loci. [228] Functionally, however, MRTF-A and
B appear to play redundant roles in the development of the cardiovascular system, implying
a strongly similar role for each in the regulation of SRF. [246]
The murine CArGome has been extensively characterized by CHIP-seq studies. It is
formed by over 2000 distinct SRF-MRTF regulated loci and regulates hundreds of genes.
[228] While the thermodynamic affinity of SRF with and without the MRTFs has been
reported for some “classic” CArG boxes (e.g. the CArG elements in the ACTA2 and cFOS
promoters), the energy landscape of the CArGome in rodents and humans remains largely
uncharacterized. [228, 247, 248]
Many of the genes in the CArGome feed directly back into the cell’s mechano-sensing
machinery and into the matrix itself. [228] Top ontological genetic categories of MRTF-
SRF targets for regulation are: cytoskeleton, actin cytoskeleton, focal adhesion, embry-
onic development, actomyosin, vasculature development, contractile fiber part, vesicle-
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mediated transport, cell projection, hypertropic cardiomyopathy, and cell junctions. “Ma-
trix organization” and “wound healing” ontological categories are also present in the SRF-
MRTFs gene set. [228] This system-level data complements findings from reports that
examine smaller, more disease focused genetic targets of MRTF/SRF. [229, 230, 14] These
data imply that MRTF/SRF is not only as mechano-sensitive but is part of an innate bio-
logical feedback loop between cells and their mechanical environment.
Other Mechanically Sensitive Transcription Factor Families
Yes Associated Protein/Transcriptional Co-activator with PDZ-binding motif
Yes Associated Protein/Transcriptional Co-activator with PDZ-binding motif (“YAP/TAZ”)
are conserved transcription factors from the Drosophila melanogaster Hippo pathway,
which regulate cell/tissue growth. They have been found to be mechano-sensitive transcrip-
tion factors implicated in the development of fibrosis in multiple organ systems. [15, 91]
Mechanically, YAP/TAZ are also regulated by actin: f-actin inhibits LATS1/2, which phos-
phorylates YAP/TAZ. Phosphorylated YAP/TAZ is retained in the cytosol, while unphos-
phorylated YAP/TAZ is able to translocate to the nucleus. While YAP/TAZ are regulated
through a similar, actin-dependent modulation of their nuclear transport, YAP/TAZ’s reg-
ulation by actin is more complex than MRTFs’ regulation. YAP/TAZ’s regulatory scheme
integrates cues from g-coupled protein receptors, Wnt signaling pathways, and adherens
junctions to lead to a net (inactivating) phosphorylation state. Phosphorylated or quiesced
YAP/TAZ is also subject to degradation through a 14-3-3 protein mediated complex, a
feature not observed in cytosolic MRTF biology. [192, 249, 250, 191]
Like the MRTFs, YAP/TAZ are co-activators and do not directly bind DNA. In contrast
to the MRTFs, YAP/TAZ are more promiscuous co-activators of other transcription factors,
including TEAD2, TEAD1, TEAD3, TEAD4, Smad2/3, RUNX, p73, and ErbB4 cytoplas-
mic domain. [251, 252] While there is near equivalent CHIP-seq information about the
architectural features of the YAP/TAZ genomic space [253, 254], the lack of specificity for
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a single co-activator makes it conceptually more difficult to understand the activity of YAP
and TAZ on a systems-based level.
Transforming Growth Factor β
TGFβ signaling is mechanically regulated both intra-cellularly and extra-cellularly. The
activation of TGFβ by cellular contractility is potentiated by substrate stiffness, which al-
lows for efficient transmission of force to the latent TGFβ complex and subsequent release
of TGFβ from the matrix. [13, 150] There is also strong in vitro evidence that cellular phe-
notypes in response to TGFβ are potentiated by substrate stiffness. [88, 89, 90, 91] Further
work exploring the intra-cellular regulation of TGFβ signaling is discussed at length in
Chapter 3 of this thesis.
TGFβ appears to acquire some of its mechano-sensitivity and to confer some me-
chanical phenotypes associated with it through physical interactions with both MRTFs
and YAP/TAZ. YAP/TAZ appear to have a potentiating effect on TGFβ signaling through
Smad2/3 - increasing substrate stiffness extends the nuclear residence of Smad2/3 in a
YAP/TAZ-dependent fashion. [91].
The effects of TGFβ signaling on MRTF biology focus on two distinct mechanisms:
(1) a RhoA/ROCK-dependent modulation of the cytoskeleton, which controls MRTF lo-
calization; and, (2) a Smad-dependent modulation of MRTF localization and transcrip-
tion through protein-protein interactions in the nucleus. For Smad-based regulation of
MRTF, Smad3 appears to impart a mechanical phenotype by inhibiting the activity of
MRTF-A at baseline, but not during TGFβ stimulation in the pulmonary vasculature. [153]
There is also evidence that TGFβ exerts a mechanical phenotype through MRTF-A in a
Smad-independent fashion. [154] TGFβ has also been shown to drive the polymeriza-
tion of the actin cytoskeleton in a RhoA/ROCK dependent fashion, driving epithelial-to-
mesenchymal transformation and the transcription of pathologic genes like α-smooth mus-
cle actin (“αSMA”). [255, 256, 257, 258, 259]. TGFβ also appears to negatively modulate
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cadherin-based cell-cell contacts, which help promote MRTF translocation in epithelial
cells. [258, 259]
4.2 Methods
4.2.1 Cell Culture and Transfection
Primary human foreskin fibroblasts (HFFs) were procured from ATCC (ATCC SCRC-
1041, ATCC, Manassas, VA) and routinely cultured in DMEM (ThermoFisher, Waltham,
MA) supplemented with 15% FBS and 1% penicillin/streptomycin (ThermoFisher, Waltham,
MA) in 5% CO2 at 37C in a humified incubator to passage 13. Human embryonic kidney
cell lines were procured from ATCC (ATCC CRL-3216, ATCC, Manassas, VA) and rou-
tinely cultured as above except with a 10% concentration of FBS, until passage 20. For
CArG sink delivery, 500,000 HFFs were resuspended in 100µL of Normal Human Dermal
Fibroblast buffer with supplement and DNA CArG probes and electroporated using pro-
gram U-023 in an Amaxa Nucleofector system according to the manufacturer’s instructions
(Lonza, Walkersville, MD). Alternatively, adherent, near confluent HFFs in 6 well plates
were incubated with CArG Probes resuspended in Lipofectamine 3000 using 1µL P3000
reagent and 1.5µL Lipofectamine 3000 reagent per well according to the manufacturer’s
protocol for at least 6 hours. HEK cells were also transfected with 2µg of pCGN-SRF
(Addgene, Cambridge, MA [260]) using Lipofectamine 3000 as above.
4.2.2 MRTF Translocation by Immunofluorescence
HFFs were plated in serum free media supplemented with 1% BSA in High-Throughput
Screening plates (Matrigen, Brea, CA), containing glass and stiffness-defined hydrogel
substrates, which were functionalized with 10µg/mL human fibronectin at a concentration
of 2000 cells/cm2. Cells were allowed to spread and mechanotransduce for 4 hours. Any
additional treatments indicated (50pg/mL TGFβ, 50pg/mL TGFβ with 10µM Y-27632,)
were added during the last 90 minutes of culture. Cells were then fixed in 4% paraformalde-
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hyde in 1X PBS for 10 minutes, permeablized with 0.1% Triton X-100 in 1X PBS for 5
minutes, and blocked for 60 minutes with 5% donkey and goat sera in 1X PBS. Cells
were incubated overnight with primary antibodies as indicated in Table 4.1 in PBS-T. After
washing, cells were incubated with secondary antibodies as indicated in Table 4.1, washed
again, and then counterstained with 1:1000 Hoescht 33342 and 1:40 Phalloidin-488 (Ther-
moFisher, Waltham, MA) and mounted with SlowFade Diamond (ThermoFisher, Waltham,
MA). Imaging was performed with a Axiovert 200M microscope (Carl Zeiss Microscopy,
Jena, Germany) with an UltraVIEW spinning disk (PerkinElmer, Waltham, MA) and Flash
4.0v2 cMOS camera (Hamamatsu Photonics, Hamamatsu City, Japan) using a 1.4NA Plan-
Apochromat 63X objective (Carl Zeiss Microscopy, Jena, Germany). Data analysis and
image acquisition were performed using Volocity (Perkin Elmer, Waltham, MA). Recom-
binant human TGFβ was procured commercially (R&D Biosystems, Minneapolis, MN)
while Y-27632 was a kind gift from Dr. Andres Garcia.
4.2.3 Fuzznuc Analysis of CHIP-Seq Data from Ensault et al. (2014)
Sequence data for CHIP-seq loci was obtained in FASTA format from UCSDs Genome
Viewer toolbox using BED genomic coordinates specified in Ensault et al. (2014). These
sequences were analyzed using the EMBOSS suites fuzznuc program with an input se-
quence of “C-C-W-W-W-W-W-W-G-G” to determine the number(s) and quality/qualities
(consensus, single and double mismatch) of CArG boxes present in the peaks. Custom
Matlab (TheMathWorks, Waltham, MA) scripts were used to extract the peak and peak
features associated with genes annotated in Ensault et al. (2014). Statistical analysis and
data representation was performed in Prism (Graphpad, La Jolla, CA).
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4.2.4 DNA Decoy Probe Construction and Labeling
Probe Construction or Purchase
Probe sequences are listed in the Appendix B of this thesis. All probes were order commer-
cially (Integrated DNA Technologies, Coralville, IA) except for synthetic, Biobrick derived
120 bp elements, which were cloned using restriction digest into the pSB1A3 vector (iGEM
Consortium, Boston, MA) and subsequently PCR amplified using Phusion polymerase ac-
cording to manufacturer’s instructions (New England Biolabs, Ipswich, MA) with VF2
and VR oligos from Table 4.2 and purified using PCR Cleanup Kits (Qiagen, Hilden, Ger-
many). Probes purchased from IDT incorporated a 5’ amine modified thymidine with a
6 carbon spacer for subsequent dye labeling. All commercially ordered probes were hy-
bridized in siRNA Resuspension Buffer (ThermoFisher, Waltham, MA) according to the
manufacturer’s protocol for siRNA hybridization.
Probe Labeling
Probes were labeled with a fluorescent intercalating dye for flow cytometry experiments
and covalently for sub-cellular localization experiments. For labeling with an intercalating
dye, probes were incubated for 30 minutes at room temperature with a 1:1000 solution
of SYBR Safe (ThermoFisher, Waltham, MA). Unconjugated dye was removed by spin
filtration using a 30kDa Amicon Ultra centrifugation filter (Sigma, Darmstadt, Germany)
according the manufacturer’s instructions. Covalent labeling with a monovalent Cy3b-
NHS-ester (GE Healthcare, Little Chalfont, United Kingdom) to the 5’ amine modified
thymidines on IDT probes was accomplished by resuspending the Cy3b ester in DMSO and
incubating it with probes at a 1:10 molar excess overnight, in a 0.1M sodium bicarbonate
buffer. Unconjugated dye was spin filtration using the 30kDa Amicon Ultra centrifugation
filters as above.
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4.2.5 RT-qPCR and qPCR
qPCR for Decoy Delivery
HFFs were electroporated with 140 fmol - 1.4 pmol of synthetic, 120bp double-stranded
αSMA CArG probes as above and allowed to recover in warm media for one hour. DNA
probes were then extracted from the cell using a modified Hirt extraction with subsequent
purification in Miniprep columns according to the procotol from [261]. The extracted
probes were assayed by qPCR with SYBR Green on a Step One Plus instrument (Applied
Biosystems, Foster City, CA) using primers VF2 and VR from Table 4.2 according to the
manufacturer’s instructions in quadruplicate. Quadruplicate doses ranging by an order of
magnitude from 100pg to 1fg were prepared and used as input template for standard curve
generation and run on the same plate as experimental samples. Derivative melt curves were
visually checked for single product peak. Raw amplification data were imported into Lin-
RegPCR (Heart Failure Research Center, Amsterdam, The Netherlands) where they were
baseline and efficiency corrected using linear regions of amplification for each amplicon.
Absolute levels of probes per cells were calculated using the standard curve to impute the
total number of probes delivered and dividing by the number of input cells. Statistical
analysis and data representation was performed in Prism (Graphpad, La Jolla, CA).
RT-qPCR for Endogenous Genes
HFFs were electroporated with 1.4-3.1 pmol of synthetic, 120bp double-stranded αSMA or
cFOS CArG probes as above and allowed to recover in warm media with full or low (1%)
for one hour. RNA was then extracted using an RNEasy kit and cDNA was prepared using
a RT2 First Strand cDNA kit according to the manufacturer’s protocol (Qiagen, Hilden,
Germany). RT-qPCR was performed using a Step One Plus instrument with SYBR-Green
chemistry and qPCR primers for GAPDH, XIAP, and Bcl-2 as described in Table 4.2 ac-
cording to recommendation from the manufacturer (Applied Biosystems, Foster City, CA)
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in technical quadruplicate. Derivative melt curves were visually checked for single prod-
uct peak. Raw amplification data was imported into LinRegPCR (Heart Failure Research
Center, Amsterdam, The Netherlands) where it was baseline and efficiency corrected us-
ing linear regions of amplification for each amplicon. ∆∆CT values were calculated by
normalizing apoptosis relevant gene N0’s to GAPDH and then normalizing to electropora-
tion only control cells. Statistical analysis and data representation was performed in Prism
(Graphpad, La Jolla, CA).
4.2.6 SRF Gel Shift Assays
EMSA assays were performed as described previously in [228]. Briefly, 20µL reactions
with Cy3b labeled probes were incubated with either 2µg of recombinant human SRF (Ori-
gene, Rockville, MD), 2µL of pCGN-SRF over-expressing HEK lysate, or no SRF source,
in 1mM EDTA, 10mM Tris HCl 7.9, 50mM NaCl, 50ug/mL BSA, 5mM spermidine, 5%
Ficoll 400, 0.5% (w/v) bromophenol blue with freshly added 3mM DTT and 25µg/mL poly
dIdC for 30 minutes at 37C. Samples were then mixed with 6X gel loading dye without SDS
(New England Biolabs, Ipswich, MA) and loaded on a 10% TBE gel in 1X TBE and run
at 100V at 4C until the gel front reached the end of the gel. The gel was post-stained with
1:10000 GelGreen (Biotium, Freemont, CA) for one hour at room temperature and imaged
on ChemiDoc MP system (Bio-Rad, Hercules, CA) with a Cy3 (probe) and a FITC filter
(ladder).
Table 4.1: Antibodies Used in this Chapter
Target Clone Host Concentration Vendor Cat. Number
Primary
SRF G-20 Rabbit 1:1000 Santa Cruz sc-335 (discontinuted)
MRTF-A Polyclonal Rabbit 1:1000 Sigma HPA030782
Smad2/3 Clone18 Mouse 1:1000 BD Biosciences 610842
Secondaries
Goat αRabbit 546 Polyclonal Goat 1:500 ThermoFisher A-11035
Goat αMouse 647 Polyclonal Goat 1:500 ThermoFisher A-21236
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Table 4.2: Oligos Used in this Chapter
Oligo Name 5’-3’ Sequence Purpose Tm Concentration Vendor Cat. Number
VF2 TGCCACCTGACGTCTAAGAA
Amplificaiton and qPCR of Synthetic, 120bp CArG Probes
60 250-500nM
IDT iGEM Primers




IDT Originally From [262]
GAPDH Rev CTGTTGCTGTAGCCAAATTCGT 60 250nM
XIAP For




XIAP Rev 60 250nM
Bcl2 For 60 250nM
Hs.PT.56a.654557.g
Bcl2 Rev 60 250nM
4.3 Results
4.3.1 Substrate Rigidity Translocates MRTF to the Nucleus with Peak Responsivity Over
8kPa
In order to map the initial stiffness-response of fibroblasts’ translocation of MRTF to the
nucleus as a function of substrate stiffness, HFFs were plated on poly-acrylamide hydrogel
surfaces functionalized with human fibronectin and assayed for MRTF localization by im-
munofluorescence. Because other fibrosis-relevant growth factors, like TGFβ, have been
shown to modulate the activity of MRTF in a ROCK-dependent fashion [255, 256, 258,
257, 259], MRTFs’ translocation was also examined with 50pg/mL TGFβ treatment and
with 50pg/mL TGFβ and 10µM Y-27632 treatment. Pharmacological treatment of fibrob-
lasts with 2µM latruculin B (“LatB”), a g-actin stabilizing agent and nuclear MRTF antag-
onist, demonstrated statistically significant alterations in fibroblast morphology and actin-
polymerization. Cell volumes were decreased (Figure 4.1B-upper left, p=0.035, p=0.074,
p<0.0001 for LatB vs. 0pg/mL TGFβ, vs. 50pg/mL TGFβ, and vs. 50pg/mL TGFβ +
10µM Y-27632, respectively) as were nuclear volumes (Figure 4.1B-upper right, p=0.0177,
p=0.1215, p<0.0001 for LatB vs. 0pg/mL TGFβ, vs. 50pg/mL TGFβ, and vs. 50pg/mL
TGFβ + 10µM Y-27632, respectively). Importantly, these changes in cell morphology
tracked with a decreased accumulation of MRTF in the nucleus of cells with LatB treat-
ment (Figure 4.1B-lower right, p=0.0089, p=0.0166, p=0.3615 for LatB vs. 0pg/mL TGFβ,
vs. 50pg/mL TGFβ, and vs. 50pg/mL TGFβ + 10µM Y-27632, respectively), indicating
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that the assay detected actin-polymerization dependent changes in MRTF localization.
TGFβ treatment with or without 10µM Y-27632 also significantly increased the nuclear
residence of Smad2/3 (Figure 4.1B-lower-left, p<0.0001 for any TGFβ treatment relative
to TGFβ untreated fibroblasts at any stiffness, except p=0.586 between 50pg/mL TGFβ
treated and untreated fibroblasts at 8kPa), indicating the activity of the TGFβ treatments
across all stiffness conditions. There were no significant differences in Smad2/3 transloca-
tion as a function of Y-27632 treatment at any stiffness (Figure 4.1B-lower left).
MRTF was imported into the nucleus in a stiffness-dependent fashion in all treatment
conditions (Figure 4.1B-lower-right, p<0.0001 for all groups). TGFβ and Y-27632 un-
treated fibroblasts demonstrated maximal sensitivity to substrate stiffness between 8 kPa
and 25 kPa with comparatively little stiffness-response between 0.5 kPa and 2kPa. Inter-
estingly, the treatment of fibroblasts with TGFβ or with TGFβ and Y-27632 did not consis-
tently modify the stiffness-responsive translocation of the MRTFs in HFFs. Qualitatively, it
appeared that TGFβ treatment shifted the mechanical sensitivity of the MRTF-translocation
phenotype to softer substrates and that this effect was rescued by ROCK inhibition by Y-
27632 treatment. These data collectively indicated that TGFβ treatment with or without
Y-27632 treatment did not significantly modulate the initial mechanical MRTF phenotype
of fibroblasts.
4.3.2 The Murine CArGome is Primarily Organized into Single Binding Domains Comprised
of 4-14, High Quality CArG Boxes
In order to understand the transcriptional activity of MRTFs/SRF after mechanical acti-
vation, the murine CArGome was architecturally characterized using publicly available
CHIP-seq and RNA-seq data from 3T3 fibroblasts. [228] SRF and MRTF localization to
CHIP peaks annotated to various genes were correlated to mRNA levels for those same
genes with or without serum stimulus as an activating cue for MRTF (Figure 4.2A). There
was a statistically significant correlation between SRF (Figure 4.2A-i), MRTF-A (Figure
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4.2A-ii) and MRTF-B (Figure 4.2A-iii) residence at a given CHIP peak and transcription of
the annotated gene both with and without serum stimulation (SRF: r=0.1361 and r=0.1940,
p<0.0001 for low and high serum, respectively; MRTF-A: r=0.08515 and r=0.1953 with
p=0.0004 and p<0.0001 for low and high serum, respectively; MRTF-B: r=0.1085 and
r=0.2172, p<0.0001 for low and high serum, respectively). While the increase in the cor-
relation coefficient between SRF and RNA with higher serum concentrations could indi-
cate the activation of SRF by MRTF by serum stimulation, the increase in the correlation
between MRTF-A and MRTF-B and RNA with serum stimulation was less clear. Never-
theless, the correlations between transcription factor residency and gene transcription was
an important proof-of-concept finding that validates further exploration of MRTF/SRF as a
driver of mechanical transcription.
In order to ascertain the number of SRF-binding regions associated with a given gene,
a histogram of CHIP-seq peaks per annotated gene was computed, revealing that the vast
majority of genes were regulated by a single SRF CHIP-seq peak, with ≈ 95% of all an-
notated genes regulated by one or two SRF peaks (Figure 4.2A-iv). Additionally, there
was a strong, positive correlation between the number of CHIP-seq peaks for a particular
gene and the residence of SRF at that particular gene (Figure 4.2A-v, r=.4901, p<0.0001).
These data demonstrated two important features of the CArGome: first, that individual
genes were often associated with a single SRF binding domain; and second, that there was
a positive association between SRF binding regions and SRF residency at a particular gene.
While characterization of the CArGome at the level of individual CHIP-seq peaks was
important in validating MRTF/SRF as a potential model system for mechanical transcrip-
tion generally, characterization of the number and quality (i.e. the inferred binding affinity
of the CArG box for SRF based on sequence homology to a canonical CArG box) was
performed to build a full architectural picture at the level of individual SRF binding ele-
ments inside these CHIP-seq peaks. From a fuzznuc-based analysis of all identified SRF
CHIP-seq peaks, individual CHIP peaks were found to contain an average of 8±4 CArG
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boxes, with a few peaks containing over 30 individual CArG boxes (Figure 4.2B-i, the
analysis searched for CArG boxes with up to two sequence mis-matches to the canonical
sequence). There was a statistically significant positive correlation between the number of
CArG boxes contained in an individual CHIP-seq peak and the residence of SRF at that
particular peak, averaged across serum stimulating conditions (r=0.222, p<0.0001). Addi-
tionally, there was a negative correlation between the degree of mis-match of the highest
quality CArG box in a peak and the residency of SRF at those peaks (Figure 4.2B-ii, r=-
0.2850, p<0.0001). The decision to not explore CArG boxes past a double mis-match was
further validated by these data, which indicated that only 7 CHIP-seq peaks did not contain
a double mis-match or higher quality CArG box. Together, these data indicated that CArG
box frequency and quality both contributed to the ability of an individual SRF-binding do-
main to recruit SRF. Finally, these data provided a baseline assessment of the features of the
CArG boxes in the murine genome that could be used for a first-pass design of CArG-based
promoter elements.
4.3.3 Decoy CArG Sinks Can Be Delivered on the Scale of the Endogenous CArGome
In order to construct a steady state, statistical mechanics-based model of the endogenous
CArGome to predict mechanically-driven transcription, thermodynamic measurements of
the endogenous CArGome will be required. While the tools to make cell-free measure-
ments of individual CArG box affinity for SRF have been established using an NGS-based
high-throughput EMSA approach (“Spec-Seq”) [263], the ability to perturb the affinity
landscape of the CArGome in vitro had not yet been developed. The delivery of double-
stranded, linear DNA elements containing CArG boxes (“CArG probes” or “CArG sinks”)
derived from the αSMA or cFOS promoters was characterized to ascertain the feasibility
of genomic-scale perturbations to the CArG landscape. DNA loads of 1.4 pmol of CArG
sinks, delivered to cells by electroporation, produced ≈ 25,000 CArG sinks per cells as
measured by absolute qPCR, which is on the scale of the endogenous ≈ 20,000 murine
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CArG boxes. The delivery of CArG probes to the cell was dose-dependent with 140 fmol
loads of CArG boxes delivering significantly fewer (≈ 10X fewer) CArG boxes per cell
(Figure 4.3A-iii, p=0.0053). Additionally, delivery of SYBR-labeled CArG sinks to cells
was assayed by flow cytometry both to characterize the relative delivery of CArG probes
per cell and to assess the ability to isolate fibroblasts with a specific intracellular load
of CArG sinks in future assays (Figure 4.3B-i&ii). Delivery of CArG sinks displayed a
dose-dependent shift in the median fluorescent intensity of individual cells (Figure 4.3B-
iii, p<0.0001), which correlated with the qPCR assayed number of probes per cell (Figure
4.3B-iv, r=0.9823, p=0.0005).
Because nuclear CArG sinks were required for competitive antagonism of SRF bind-
ing, the sub-cellular localization of these CArG probes was assayed using confocal mi-
croscopy (Figure 4.3C) across two delivery methods: electroporation and cationic lipid de-
livery (Lipofectamine3000). Electroporation was statistically more efficient in delivering
nuclear CArG sinks than Lipofectamine3000 (Figure 4.3D-i&iii, p<0.0001) though Lipo-
fectamine was capable of delivering statistically more CArG sinks to fibroblasts both in the
nucleus and in the cytoplasm (Figure 4.3D-ii, p<0.0001 for both compartments). These
data indicate that ≈ 50% of CArG sinks delivered to cells by electroporation ended up in
the nucleus, creating effective CArG sink loads on the same order of magnitude as the en-
dogenous murine CArGome. Additionally, these data indicated the feasibility of multiple
modes of delivery of CArG sinks to cells in vitro for future experiments.
4.3.4 CArG Sinks Do Not Modulate the Localization of SRF Nor Antangonize SRF
Transcription on Short Time Scales
In addition to their use as thermodynamic modulators of the CArGome, CArG sinks could
competitively antagonize SRF-transcription relevant to fibrosis. [14, 264] SRF transcrip-
tion could be perturbed either by either mis-localizing SRF to the cytoplasm or through
competitive antagonism of the sinks against the endogenous CArGome for SRF binding.
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The subcellular localization of SRF with and without CArG box delivery was assayed us-
ing confocal microscopy (Figure 4.4A). Delivery of 1.4pmol loads of cFOS CArG boxes
by electroporation did not induce a shift in the subcellular localization of SRF relative to
electroporation only controls (Figure 4.4B).
The ability of CArG sinks to perturb SRF transcription of fibrosis relevant SRF tran-
scripts one hour after delivery was assayed by RT-qPCR based on previous RT-qPCR ex-
perimental setups with serum stimulation. [228] CArG sinks of varying dose and varying
CArG box composition did not antagonize SRF transcription relative to CArG boxes with
a purine-pyrimidine substitution (“anti-CArG” sink). These data indicated that CArG box
delivery did not perturb the endogenous biological localization of SRF and was insufficient
at short time scales and at pmol loads of probe to antagonize SRF transcription.
4.3.5 Characterization of CArG Box Probe Design for SRF-Dependent Shift Assays
The ability to assay the thermodynamic landscape of the CArGome up to double mis-match
CArG boxes, in a cell-free system required the development of probes suitable for SRF shift
assays. I have characterized both naturally derived (Figure 4.5A, lanes 4-9 and Figure 4.5B,
lanes 3-4 and 7-8) and synthetically derived CArG probes (Figure 4.5A, lanes 2-3), CArG
probes with lengths between ≈120-400 bp (Figure 4.5A), and CArG probes with a single
CArG box or multiple CArG boxes per probe. Probes of various length from synthetic or
naturally derived sequences were all capable of binding SRF from over-expression HEK
lysates (Figure 4.5A). While several of these probes (Figure 4.5A, lanes 2-3, 6-7) con-
tained multiple consensus or mis-matched CArG boxes, no higher molecular shifts were
detected from additional SRF binding, most likely because the gel lacked spatial resolution
to see those multiple binding events. The integrity of the CArG box was necessary for SRF
gel shifts (Figure 4.5B). Anti-CArG probes, 120 bp probes containing a purine-pyrimidine
swap in the CArG box, were incapable of producing a shift when incubated with recom-
binant human SRF (Figure 4.5B, lane 6), while CArG probes based on the cFos or αSMA
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promoter were capable of SRF-shifting. These data indicated that there was a broad tol-
erance of the SRF gel shift assay to design parameters of the CArG box probes used and
that the assay was specific both for the presence of SRF and for the integrity of the CArG
sequence in the probe.
4.4 Discussion
4.4.1 Relevance to the Design of Mechanically Driven Transgenes
The characterization of the CArGome is translationally significant in terms of providing the
basis for a mechanistic understanding of how SRF-based stiffness promoters may function
and in informing the design of those promoters. The results in this Chapter demonstrated
the feasibility of such promoters by demonstrating correlations between the CArG number
and character in SRF CHIP-seq peaks and the recruitment of SRF to those peaks and by
demonstrating the correlation between SRF/MRTF occupancy at a particular genetic locus
and transcription of that gene. Additionally, these results suggested initial starting designs
based on the distribution of 8±4 CArG box per SRF peak found through out the genome.
Additionally, there may be data features of the CArGome that could be further considered
to help drive the development of CArGome based promoters, including characterizing the
inter-CArG box sequence spacing within peaks to optimize multiple SRF binding events,
and characterizing the quality composition of the CArG boxes in terms of percentages of
canonical, one and two mis-match boxes for deeper insight into the quality landscape of the
CArGome absent direct thermodynamic measurement. Finally, it may be useful to screen
for common sequence motifs in the interstitial sequences between CArG boxes to identify
other potential transcription factors that may be acting in concert with MRTF/SRF at en-
dogenous promoters. Identification and purposeful elimination of these sequences may be
useful in improving the specificity of synthetic promoter elements for MRTF/SRF signal-
ing. There are a number of computational techniques dedicated to the de novo discovery
of such motifs from CHIP-seq data [265, 266, 267] as well as open-source datasets of
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position-weighted matrices for known transcription factors binding sites, which could be
queried directly. [268]
The characterization of the CArGome may also contribute to the use of SRF-based
transgenes as reporters of cellular state beyond stiffness reporting / stiffness-targeting.
Other groups have used the α-SMA CArG-based promoter as a reporter of cell state, specif-
ically targeting myofibroblasts [269] and osteoblastic differentiation in stem cells. [270]
The ability to rationally fine tune the response of these cell-state reporters by modulating
their CArG box composition could be useful in identifying subpopulations of differentiat-
ing cells or in improving the specificity or sensitivity of the reporters to a particular cellular
state.
The characterization of MRTF’s translocation to the nucleus as a function of substrate
stiffness is also significant in terms of helping to predict the performance of CArG-based
transgenes. The greatest shift in MRTF localization occurred between stiffness of 8 and 25
kPa, which aligns well with pathological stiffness regimes in micro-mechanical character-
ization of lung biopsies from patients with pulmonary fibrosis. [4] While this sensitivity
might be useful in targeting pathology that is well separated from physiologic stiffness, as
in fibrosis, it indicates targeting stiffness states under 8 kPa (for other biological purposes
than therapeutic targeting of fibrosis) may be uniquely difficult and require more advanced
synthetic biology constructs, such as the use of bandpass terminator elements [271] or in-
terlaced high and low pass genetic regulatory schemes. [272, 273]
How do the results of this Chapter inform the choice of transcription factor family for
the construction of stiffness-driven transgenes? To date, a YAP/TAZ/TEAD box system
has been demonstrated as the only proof-of-concept stiffness-driven therapy with a focus
on treating metastatic disease in the lung. [231] Interestingly, there are some similarities
between that approach and the MRTF-based system explored here. Specifically, the peak
responsiveness of MRTF to stiffness over 8 kPa indicates that MRTF based transgenes may
perform similarly in vitro to YAP/TAZ-based TEAD box reporters, which demonstrated
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peak in vitro responsiveness over 10 kPa. [231] While there are no a priori reasons to
assume that the mechanical responses of MRTF and YAP/TAZ would be similar or differ-
ent, there may be reasons to suspect that the in vivo translation of these in vitro observa-
tions may be different for MRTF and YAP/TAZ. These differences are likely to arise from
the relative balance of other inputs, beyond the stiffness-mediated mechanisms, to nuclear
translocation for these two transcription factor systems. While MRTF is not wholly reg-
ulated by actin polymerization (e.g. MRTF can be phosphorylated in an ERK-dependent
fashion, which modifies its affinity to bind g-actin [242, 235]), YAP/TAZ appear to receive
a greater balance of non-stiffness mediated inputs into their biology. This is likely reflec-
tive of their dual role as a mechanical sensor and as a regulator of tissue/organ growth via
the Hippo pathway, as Wnt signaling, g-coupled protein receptor activation, and adherens
biology can direct the translocation of YAP/TAZ via its phosphorylation state. [192, 249,
250, 191]
Finally, conceptually, the CArGome is uniquely amenable to the analyses performed
in this chapter because of the unique molecular monogamy that exists between the me-
chanically regulated and necessary co-activator, MRTF, and the direct transcription factor,
SRF. [228] In comparison, YAP and TAZ appear to have coordinated but distinct tran-
scriptional profiles that necessarily intersect with several other DNA-binding transcription
factors. This would require a similar energy landscape profiling for each partnered tran-
scription factor, including TEAD1-4, Smad2/3, Runx, ErbB4 cytoplasmic domain, and p73,
leading to a significant increase in complexity of the model system. [251, 252]
4.4.2 MRTF Mechanobiology and Intersections with TGFβ Signaling
This chapter has reported on the stiffness-dependent translocation of MRTF to the nucleus
and the effects of TGFβ signaling on this translocation. The stiffness-mediated translo-
cation of MRTFs has been well reported in the literature [232, 233, 239, 240, 235], and,
indeed, makes MRTF/SRF an ideal model system for studying mechanical genetics; how-
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ever, this Chapter has expanded on those previous observations both by increasing the
stiffness-resolution of those measurements and, more importantly, by focusing on the role
of TGFβ signaling to modify this responsiveness in a ROCK-dependent fashion in the
initial mechanosensing of fibroblasts. Given the demonstrated experimental and clinical
importance of TGFβ signaling in fibrotic pathology [10, 119, 120, 274, 123] and the
Smad-dependent and -independent [153, 154, 255, 256, 258, 259] intersections between
TGFβ signaling and MRTF biology, understanding this connection is likely relevant to
understanding/predicting the behavior of CArG based transgenes in the setting of fibrotic
pathology.
Contrary to initial expectation based on the available literature and the result of model-
ing based on that literature by the Saucerman Lab at UVA, treatment with TGFβ or TGFβ
and a ROCK inhibitor, Y-27632, did not have consistent effects on modulating the MRTF-
stiffness phenotype of fibroblasts. However, there are several important differences be-
tween my findings and the reported literature, which may indicate a possible resolution of
this discrepancy. Many of the reports focusing on the connection of TGFβ signaling to
MRTF through RhoA/ROCK examine cells at extremely long time-scales (24-48 hours)
relative to the transcription activity of TGFβ and to the time-scale used in this Chapter (4
hours). Indeed, an increase in αSMA translation is usually interpreted as activity of alterna-
tion to MRTF/SRF biology in these systems. [256, 258, 259] My focus on relatively short
time scales is motivated by the dynamic activity of the cytoskeleton in response to substrate
mechanical cues during cell spreading, which in turn control the localization of MRTF.
[241, 14] Additionally, these long time-scales make it difficult to distinguish between activ-
ity by TGFβ signaling through the actin cytoskeleton and activity on the actin cytoskeleton
as it relates to the dynamics of MRTFs’ localization. [258, 257, 259] Furthermore, many
of these other studies employ active TGFβ concentration on the order of ng/mL, which is
above the physiologic range for many organs, like the liver, and is an order(s) of magni-
tude greater than the 50pg/mL dose used in this chapter. [275] One interpretation of these
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observations is that there may be some signaling threshold for TGFβ to directly act on the
cytoskeleton in order to drive TGFβ translocation. Finally, many other groups are specif-
ically interested in TGFβ’s ability to drive epithelial-to-mesenchymal transformation and
focus on epithelial cell population from various organs. [257, 256, 259] Given the basic
cytoskeletal and adherens junctions differences between these two cell types [276] and the
role of Wnt signaling [258] and cell-cell contacts [259] in the mechanisms proposed by
these groups, it is possible that different biological mechanisms are at play between fibrob-
lasts and epithelial cells. In short, there are important kinetic, dose and cell-type selection
biases between this work and the literature that may account for the seeming discrepancy
in MRTF translocation as a function of TGFβ dose.
Given the lack of effect of 50pg/mL TGFβ doses alone to modulate MRTF sub-cellular
localization, it is not surprising that Y-27632 treatment with TGFβ stimulation did not
have a clear statistical effect on modulating the TGFβ associated phenotype. This finding
is generally consistent with a report from the literature, which studied the effect of Y-
27632 dosing alone on MRTF translocation at a similar dose (10µM) and at relatively
short time-scales (12 hours) in aortic vascular endothelial cells. [277] This report found
no effect on MRTF translocation from Y-27632 dosing without a concomitant increase
in ERK-driven phosphorylation of MRTF, which modulates its affinity for g-actin. [242,
235] Fibroblasts in my system were plated in serum free media to maximize the effects of
mechanical signaling relative to soluble signaling on the cytoskeleton and are consistent
with this literature.
4.4.3 Impact of Mechanical Memory on Stiffness-Driven Transcription
The conceptual framework for organizing this thesis posits that the genome not only drives
transcriptional changes in response to mechanical stimuli but also evolves the state of the
cell in time to further stimulus. There is clear evidence that stiffness imparts an epigenetic
“memory” on the genome. Numerous groups have shown that fibroblasts cultured on either
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soft or stiff environments have phenotypic hysteresis when transitioning to a new mechan-
ical environment. The phenotypes explored are of direct relevance to fibrosis: myofibor-
blastic differentiation, activation of latent TGFβ, and cellular proliferation and contractility
[278] - as well as other pathologies, like cancer: metastatic potential, cell growth.[279]
The exact mechanism(s) of this mechanical memory is not clear. There is evidence that
persistent miRNA signaling through the MRTFs is critical to maintaining the mechanical
memory of mesenchymal stem cells, though the generality of this phenotype is unclear
since mesenchymal stem cells have a unique chromatin architecture due to their stem-ness.
[280] Other groups have found that persistent YAP signaling is critical to retaining memory
in epithelial cells undergoing collective or individual migration. [251] YAP in combination
with Runx signaling also appears to be critically regulated by substrate stiffness and im-
parts a memory phenotype in stem cells. [281] Some proposed mechanisms are not directly
related to substrate stiffness as the inciting cue, per se, but are the consequence of other
micro-environmental cues that converge on mechano-sensing pathways. The inflammation-
driven epigenetic hetero-chromatinization of the Thy-1 promoter by histone deacetylases
is an example of how biochemical stimuli can impart a distinct mechanical phenotype in-
dependent of changes to the actual matrix mechanical properties. [100, 282] While the sci-
ence around mechanical memory continues to evolve, considerations of how CArG-based
stiffness promoters interacts with the genome will have to contend with the environmental
memory imparted by previous culture and tissue conditions, specifically as these epigenetic
echoes converge on MRTF/SRF biology. [280]
4.5 Future Directions
4.5.1 Development of Statistical Mechanics-Based Model for Stiffness-Driven Transcription
The work in this Chapter has contributed to the development of logic-based differential
equation model of MRTF/SRF biology, where individual interactions are modeled using
normalized Hill functions with AND/OR logic gates, in collaboration with the Saucerman
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Group at UVA. This modeling allows for an understanding of how a MRTF/SRF/promoter
system may evolve in time. Currently the model focuses on the activation of MRTF by
mechanical cues and by TGFβ signaling. Important next steps in the development of this
model would be to link the architectural features of the CArGome into the down-stream
activity of MRTF/SRF to understand how they are transcriptionally titrated. The use of
statistical mechanics to model the steady state activity of transcription factors has been
demonstrated experimentally [283] and the theoretical framework for various promoter ar-
chitectures [284] and for coupled promoter architectures [285] have been previously estab-
lished.
A critical feature of these models are thermodynamic affinities for the various promoter
elements in the system. Thankfully, future work on this project is well positioned to survey
the thermodynamics of the CArGome in a cell free system by employing the experimen-
tal conditions found in this Chapter for CArG-SRF gel shift assays. The ability to profile
thousands of binding sequences for a given DNA-transcription factor pair has been demon-
strated by previous characterization of the lac operon and its various permutations, and
this approach is directly amenable to studying CArG degeneracies out to double mis-match
CArG boxes. [263] One important experimental condition to optimize before constructing
the necessary NGS libraries would be to optimize the CArG-SRF shift assay to incorporate
MRTF-A and MRTF-B into the complex since there is evidence that MRTFs can coopera-
tively regulate the affinity of SRF for CArG boxes. [228, 247]
4.5.2 Development of Second Generation CArG Sinks for Thermodynamic Measurements
and SRF Antagonism
In order to improve the effective delivery and the stability of CArG sinks both for ther-
modynamic measurements described above and for possible direct therapeutic action by
competitive antagonism of SRF-endogenous genomic interactions, a second generation of
the CArG sink should be developed. Important design considerations would be the incor-
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poration of a nuclear localization sequence to increase the effective delivery of these boxes.
NLS sequences have been profiled from viral, pro- and eukaryotic systems and there are
demonstrations of their effectiveness in increasing DNA delivery to the nucleus with mul-
tiple delivery systems. [286, 287, 288, 289]
Interestingly, one of the few negative reports on the use of NLS sequences to delivery
DNA efficiently to the nucleus focused on the delivery of short, linear double-stranded
DNA elements. This group found that the effect of the NLS was overwhelmed by the
aggressive activity of nucleases on the 3’ end of their fragments. [290] This observations
supports findings in this Chapter as CArG sinks, delivered on the order of the endogenous
CArGome, did not antagonize fibrosis-relevant SRF transcripts. One possible solution to
this problem is to incorporate modified nucleic acids into the 3’ and 5’ ends of the probes
to render them resistant to nuclease activity. In particular, the use of peptide nucleic acids
(nucleic acids with a peptide backbone instead of a phospho-diester backbone) to stabilize
competitive DNA sinks against NK-κ-B signaling has been reported and could be directly
incorporated into the probes used in this Chapter. [291, 292]
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Figure 4.1: Translocation of MRTF to the Nucleus at 4 Hours is Driven by Substrate
Stiffness but Not Modulated Consistently by TGFβ Treatment or ROCK Inhibition.
A, Representative micrographs of fibroblasts on soft, physiologic-representative (0.5 kPa)
hydrogels, on stiff, fibrotic-representative (25kPa) hydrogels, and on glass. Cells on glass
were treated with Latruculin B. MRTF and Smad2/3 subcellular localization was probed by
immunofluorescence in the presence or absence of 50pg/mL TGFβ or 50pg/mL TGFβ and
10µM Y-27632. B, Quantification of cellular volume (top right), nuclear volume (top left),
nuclear MRTF fraction (bottom right), and nuclear Smad2/3 fraction (bottom left). Treat-
ment of the cells with 2µM Latruculin B produced a reduction in measured cell volume
(p=0.035, p=0.074, p<0.0001 for Latruculin B vs. 0pg/mL TGFβ, vs. 50pg/mL TGFβ,
and vs. 50pg/mL TGFβ + 10µM Y-27632, respectively, ANOVA - Tukey post-test), a re-
duction in measured nuclear volume (p=0.0177, p=0.1215, p<0.0001 for Latruculin B vs.
0pg/mL TGFβ, vs. 50pg/mL TGFβ, and vs. 50pg/mL TGFβ + 10µM Y-27632, respec-
tively, ANOVA - Tukey post-test), and a reduction in nuclear MRTF (p=0.0089, p=0.0166,
p=0.3615 for Latruculin B vs. 0pg/mL TGFβ, vs. 50pg/mL TGFβ, and vs. 50pg/mL TGFβ
+ 10µM Y-27632, respectively, ANOVA - Tukey post-test). TGFβ treatment was associ-
ated with statistically increased nuclear localization of Smad2/3 (p<0.0001 for any TGFβ
treatment relative to TGFβ untreated fibroblasts at any stiffness, except between 50pg/mL
TGFβ treated and untreated fibroblasts at 8kPa, two-way ANOVA, simple column effect,
Tukey post-test). Stiffness was associated with increased nuclear MRTF in all treatment
conditions (p<0.0001 for all groups, ANOVA - Test for trends); additionally, treatment
with TGFβ or TGFβ and Y-27632 did not produce consistent, statistically significant alter-
ations in MRTF nuclear localization. All scale bars are 18µm.
127
Figure 4.2: Caption continued on next page.
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Figure 4.2: CHIP-peak and Sequence Based Characterization of the Endogenous
Murine CArGome A, Summary of CHIP-peak/gene level data from Esnault et al. (2014)
motivating the potential for SRF-MRTF based stiffness-driven transgenes. Panel i-iii) Cor-
relation plots of SRF (i), MRTF-A (ii), and MRTF-B (iii) occupancy at a given CHIP-seq
peak and the RNA reads associated with the annotated gene(s) of that peak in low serum
(0.2%) and high serum (15%), cultured fibroblasts. There was a statistically significant
correlation between SRF and RNA reads (r=0.1361 and r=0.1940, p<0.0001 for low and
high serum, respectively, Pearson’s correlation), MRTF-A and RNA reads (r=0.08515 and
r=0.1953 with p=0.0004 and p<0.0001 for low and high serum, respectively, Pearson’s cor-
relation) and MRTF-B (r=0.1085 and r=0.2172, p<0.0001 for low and high serum, respec-
tively, Pearson’s correlation). Panel iv) Frequency distribution of SRF peaks against anno-
tated genes demonstrated that ≈ 95% of all endogenous genes were associated with two or
fewer independent SRF peaks. Panel v) Correlation between the number of SRF peaks as-
sociated with a given gene and the occupancy of SRF at those particular loci demonstrated
that increasing numbers of independent SRF peaks statistically increased the relative abun-
dance of SRF occupancy at a given gene (r=0.4901, p<0.0001, Pearson’s correlation). B,
Individual CArG box identification and characterization by number and quality in Esnault
et al. (2014) CHIP-seq SRF peaks. Panel i) Frequency distribution of individual CArG el-
ements (up to double mismatch CArG boxes were analyzed) demonstrated that the average
number of CArG box elements per SRF peak was 8±4, with some SRF peaks containing
over 30 individual CArG boxes. There was a statistically significant correlation between
CArG box number in a CHIP-seq peak and SRF residency at that peak averaged across
serum conditions (r=0.222, p<0.0001, Pearson’s correlation). Panel ii) Decreasing qual-
ity, as indicated by number of mismatches from the canonical CArG box sequence, of the
highest quality CArG box in a given SRF peak was significantly inversely correlated with
occupancy of SRF in that CHIP-seq peak (r=-0.2850, p<0.0001, Pearson’s correlation) .
Collectively, the annotation of CArG box number and characterization of box quality up
to two mismatches (and beyond) described the thermodynamic architecture of the murine
CArGome as only 7 SRF CHIP peaks lack at least a double mismatch CArG box.
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Figure 4.3: Caption continued on next page.
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Figure 4.3: Characterization of the Delivery of CArG Probes by Electroporation and
Lipofectamine by Absolute qPCR, Flow Cytometry, and Confocal Microscopy A, pico-
mole loads of CArG sinks delivered CArG sink copies per cell on the order of magnitude
of the endogenous CArGome. Panel i) Representative qPCR amplification traces for the
quantification of probe delivery to cells. Panel ii) Standard curve of known input CArG
box load demonstrating the linearity of the measurement over multiple orders of magni-
tude (r2=0.9975). Panel iii) Delivery of 1.4 pmol of an 120 bp double stranded CArG sink
by electroporation to fibroblasts delivered ≈ 25,000 CArG sinks per cell, which is slightly
greater than the ≈ 20,000 CArG boxes present in the endogenous murine CArGome. There
was a statistically significant increase in CArG box delivery per cell with increasing input
CArG box load (p = 0.0053, Student’s T-Test). B, relative quantification of CArG boxes
probes by flow cytometry correlated strongly with qPCR derived results with single cell
resolution. Panels i and ii) Normalized flow histograms showed a single population shift
in the median fluorescent signal per cell in fibroblasts electroporated with 1.4 pmol (Panel
i) or 140 fmol (Panel ii) of labeled CArG sinks. Panel iii) Quantification of the shift in
per-cell median fluorescence as a function of CArG box load demonstrated a statistically
significant increase in fluorescence with increasing CArG box load (p<0.0001, ANOVA
- Test for Trends). Panel iv) Flow cytometry and qPCR quantification of delivered CArG
probes were significantly correlated (r = 0.9823 with p = 0.0005, Pearson’s correlation). C,
representative confocal micrographs demonstrating the subcellular compartmentalization
of CArG sinks delivered by electroporation (top row) or Lipofectamine3000 (bottom row).
The XY/XZ/YZ profile are shown in the right column, while the middle and left columns
highlight the cellularly constrained probe and the nuclearly localized probe, respectively.
D, quantification of subcellular delivery of CArG probes by electroporation or Lipofec-
tamine3000. Panel i) Relative nuclear delivery of CArG probes demonstrated that elec-
troporation was more efficient in delivering nuclearly localized probes than Lipofectamine
(p<0.0001, Student’s T-Test). Panel ii) Lipofectamine delivered greater abundances of
cellular and nuclear probes (p<0.0001 for both total and nuclear probes, Student’s T-test)
than electroporation based on relative quantification of probe fluorescent signal. Panel iii)
Scatter plot of nuclear probe signal versus total probe signal per cell demonstrated greater
efficiency of electroporation based delivery of CArG probes relative to Lipofectamine.
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Figure 4.4: CArG Sink Delivery by Electroporation Did Not Alter the Subcellular Lo-
calization of SRF Nor Antagonized SRF Transcripts Relevant to Pulmonary Fibrosis
A, Representative confocal microscopy images demonstrating the subcellular localization
of SRF after delivery of a 120 bp double stranded, linear probe containing a CArG box
based on the murine cFOS promoter. Panel i) Confocal images presented in XY/YZ/XZ
planes. Panel ii) Algorithmic detection of SRF based masked by the actin cytoskeleton
and nucleus. Panel iii) Algorithmic detection of nuclearly restricted SRF using a nuclear
mask. B, Quantification of SRF localization following 1.4pmol of a 120 bp cFOS CArG
probe relative to blank electroporation. There was no statistical difference or trend be-
tween the localization of SRF in cells with and without CArG probe delivery (p = 0.98
for Delivery 1 vs. Blank and p = 0.3523 for Delivery 2 vs. Blank, ANOVA with Dun-
nett’s post test). C, CArG sinks of varying dose and CArG box quality did not significantly
vary the transcription of disease relevant genes relative to “anti-CArG” (CArG boxes with
a purine/pyrimidines substitution) sinks. cFos CArG boxes were 120 bp double stranded,
linear probe containing a CArG box based on the murine cFOS promoter, while αSMA
probes were analogously based on the αSMA promoter, centered on the CArG-B box. All
electroporated conditions were plated in 15% serum. There was a statically significant de-
crease in XIAP transcripts in electroporation only control fibroblasts relative to fibroblasts
in 1% serum (p = 0.0364, ANOVA with Dunnett’s post-test), indicating that electroporation
itself may have a confounding effect on SRF transcription at short time-scales.
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Figure 4.5: Synthetic or Naturally-Derived Probe Shift in EMSA was Dependent on
CArG Integrity and SRF A, Synthetic and naturally-derived Cy3b-labelled CArG box
probes only demonstrated a mobility shift in the presence of HEK lystate enriched for SRF.
Lanes 2, 4, 6, and 8 did not contain any HEK lysate while lanes 3, 5, 7, and 9 contained
HFFs transfected with pCN-SRF. Lanes 2 and 3 use a ≈ 430 bp double stranded, linear se-
quence containing 16 CArG boxes designed synthetically. Lanes 4 and 5 contained a 300bp
double stranded, linear sequence containing CArG boxes from the murine cFOS promoter,
centered on the CArG box, while lanes 6 and 7 contained analogously constructed probes
centered on the αSMA CArG-B box. Lanes 8 and 9 contained a 120 bp double stranded,
linear sequence containing the CArG box from the cFOS promoter, centered on the CArG
box. Lane 1 was blank while Lane 10 was the DNA ladder. Gel shifts were observed with
all synthetic and naturally-derived probes, at all probe lengths between ≈ 100-400 bp and
with canonical and single mis-match CArG elements. No multiple binding events were
detected. B, Probe shift was specific to the integrity of the probe’s CArG box. Lanes 2-4
did not contain 2µg recombinant human SRF while lanes 5-8 did. Lanes 2 and 6 contained
an 120 bp double stranded, linear “anti-CArG” probe wherein the purines and pyrimidines
from the murine cFOS promoter’s CArG box have been swapped. The surround sequences
remained unmodified. Lanes 3 and 7 contained a 120 bp double stranded, linear CArG
probe based on the murine αSMA promoter and centered on the CArG-B box. Lanes 4
and 8 contained a 120 bp double stranded, linear CArG probe based on the murine cFOS
promoter and centered on its CArG box. Lane 5 contained SRF alone and Lane 1 was
the DNA ladder. These results demonstrated the specificity of the gel-shift response to the




This thesis has explored the ability of genetics and nucleic acids to intervene and under-
stand mechanotransduction and its pathologic consequences in pulmonary fibrosis. These
investigations follow the path of information from the surface of cells, through the mechan-
otranductory machinery of the cells, and finally in the genome itself. Each chapter has
summarized the implication of my findings with a focus on the state of the literature most
relevant to that particular project, and I have proposed future work specific to each of those
projects there. Here, I present interesting intersections between each of the projects and
explore their implications for proposed future work. Finally, I have summarized the state
of each project at the time of this thesis.
5.1 Future Work Inspired by Connections Between Chapters
5.1.1 Therapeutic Expression of C-Terminal LEMD3 Fragment by mRNA
In Chapter 3, I conclude by hypothesizing that C-terminal fragments of LEMD3 would be
of complementary clinical use to existing pulmonary fibrosis medical management, specif-
ically pirfenidone. This complementarity is motivated by the observations that pirfenidone
limits TGFβ synthesis and matrix deposition [127, 126] while LEMD3 de-sensitizes cells
to TGFβ signaling in a stiffness-dependent fashion as shown in Chapter 3. How best to
achieve the therapeutic translation of LEMD3 as an intracellular protein therapy remains
an open question. Literature from Chapter 2 reviews and highlights the challenges of deliv-
ering protein therapy to the lung, specifically in achieving delivery formulations sufficient
to reach the full extent of the airspace [110] and highlights engineering strategies to main-
tain therapeutic concentrations of the delivered cargo. [67, 64, 65, 68, 66, 69, 70] The use
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of mRNA to delivery pro-therapeutic transcripts of H5 and Thy-1 constructs in Chapter 2
provides a novel approach to solve this problem. The delivery of the C-terminal fragment
as mRNA should be modularly adaptable with the techniques characterized and developed
in Chapter 2 since these mRNA cargoes are seemingly equivalent in terms of length/size
and composition. Future work in this area should focus directly on the therapeutic efficacy
of C-terminal fragments of LEMD3 in bleomycin models of fibrosis.
5.1.2 Understanding Mechanotransductive Feedback After Thy-1 or H5 Expression with
MRTF Translocation Models
In Chapter 4, time-variant model of MRTF translocation to the nucleus as a function of
substrate stiffness were expanded to include the short-term effects of TGFβ signaling, con-
necting the work between Chapters 3 and 4. These models should be extended to incorpo-
rate the mechanical effects of cell-ECM interactions through integrin modulation motivated
in Chapter 2. Thy-1, in particular, may be an especially compelling and important node in
these models since Thy-1 is an endogenous protein, whose loss is associated with the de-
velopment of fibrosis in humans [72, 80], and whose mechanism of action converges on the
cytoskeleton through focal adhesion and Rho kinase modulation. [78, 79, 81, 30] More-
over, the ability to modulate Thy-1 expression, summarized in the conclusion of Chapter 2,
would provide important tools to test this model and its conclusions. The development of a
more complete model of MRTF translocation could be especially beneficial in its eventual
application to fibrosis where the mechanical machinery of the cell is perturbed, specifically
through loss of Thy-1. [73, 72]
5.1.3 mRNA-Based Stiffness Sensors
The use of promoter elements to drive stiffness expression has been demonstrated in a
proof-of-concept fashion by others using a YAP/TAZ/TEAD box system in a model of
metastatic disease in the lung. [231] In Chapter 4, I’ve characterized the genomic architec-
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ture and tools necessary to permit rational design of similar promoter elements based on
MRTF/SRF biology. Interestingly, the general biological system of control for both tran-
scription factor systems is the same - stiffness, through the actin cytoskeleton, regulates
the sub-cellular compartmentalization of the activating transcription factor. [192, 249, 250,
191, 233, 241, 242, 235] A novel synthesis of the approaches from Chapters 2 and 4 would
be to develop mRNA-based stiffness sensors, which could potentially have complementary
stiffness-sensitivity relative to DNA-based stiffness sensors. I hypothesize that therapeutic
mRNA conjugated to the RPEL domains of MRTF (MRTF’s actin-sensitive nuclear local-
ization domains) would be localized to the nucleus in an actin-polymerization, stiffness-
dependent fashion. Since mRNA’s translational potential is controlled by its access to
ribosomes outside the nucleus, this translocation would theoretically be an inactivating,
rather than potentiating event. The consequences of this switch from stiffness-activation
to stiffness-quiescence would be an ability to drive stiffness-dependent translation specifi-
cally on soft substrates, which from the model of MRTF translocation developed in Chapter
4, may be difficult to uniquely target using DNA-based approaches. Additionally the use
of mRNA based therapeutics may lower the regulatory burden of future clinical transla-
tion since mRNA-based therapies do not have the same safety concerns as DNA based
therapeutics. [55, 54] The RPEL domains and their interaction with actin have been pre-
viously crystallized [236], giving strong a priori guidance as to how to design the neces-
sary protein domains that would control this translocation. Moreover, biologically-inspired
mRNA-protein conjugation strategies through the MS2 phage coat protein have been pre-
viously developed and characterized. [293] Future work in this area should focus on a
proof-of-concept demonstration of this mechanism and the ability to titrate the transloca-
tion of mRNA by modulating the copy number of the conjugated RPEL domains and in
exploring point mutations in the nuclear localization and actin binding domains of RPEL.
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5.2 Current State of Projects
Considerable work has occurred in each Chapter - the state of each project is briefly sum-
marized below:
• Chapter 2: Contextual Antagonism of αVβ3 Integrin with a FN-Strain Specific scFv,
H5: In vitro work demonstrating the surface expression and efficacy of the GPI
and CD8 linked H5 mRNA constructs is complete. Colocalization with αVβ3 by
PLA and confocal microscopy is underway as is a parallel experiment analyzing
these clustering events using dSTORM super-resolution microscopy. Additionally,
the modulation of focal adhesion number and location relative to cell centroid by
these H5 constructs has been experimentally completed and the PLA images are be-
ing analyzed. The effects of these linkers on the global phosphorylation state of
key focal adhesion molecules (FAK and the Src family of kinases) are complete.
Focal adhesion pulldowns to assay specific competition between H5 and αVβ3 as
well as fyn localization are underway. I have performed morphological mechano-
transduction experiments to characterize the net effect of H5 expression to fibrob-
lasts’ mechanosensitivity. These experiments have been completed.
Parallel experiments to validate the expression of a positive control mRNA express-
ing Thy-1 are also underway. The use of PLA to validate Thy-1’s association with
αVβ3 have been completed and are in analysis. Additionally focal adhesion western
blotting experiments similar to those with H5 constructs have also been performed
and are in analysis.
In vivo, I have validated the expression of these constructs out to day 8 in healthy
mice and developed the techniques and mRNA constructs necessary for rapid assess-
ment of mRNA expression in a bleomycin model of fibrosis.
• Chapter 3: Matrix-Stiffness Regulation of Transforming Growth Factor-β by Inner
Nuclear Membrane Protein 3: This project has been submitted to the Journal of
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Biological Chemistry and has come back from review twice. After our first round of
review, we were left with only one reviewer with concerns, which we have addressed
experimentally. These experiments have been conducted but not yet analyzed. After
analysis, the paper will be re-written and re-submitted.
• Chapter 4: Tools to Dissect the Thermodynamic Landscape of the Murine CArGome:
The characterization of the transfer function between substrate stiffness and MRTF is
complete. Modeling the evolution of the stiffness response through MRTF with the
Saucerman Group at UVA is underway with the first generation of the model com-
pleted and in preparation for a manuscript. The characterization of the CArGome
architecturally is complete. Experimentally, we are ready to conduct NGS SpecSeq
experiments to characterize the CArG-SRF interactions and further optimization to
assay CArG-SRF-MRTF complexes are planned for work at UVA. A second genera-
tion of CArG sinks with NLS and peptide nucleic acids have been planned and their






CHAPTER 2: SEQUENCES FOR THERAPUTIC MRNA
These sequence contains the ORF for each of the mRNA used in Chapter 2. The V5 tag or
nanoLuc enzymes attached to each mRNA are separately annotated. The protein transla-

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CHAPTER 4: SEQUENCES FOR CARG BOX PROBES
These are the sequences for the synthetic and naturally derived CArG box element used in
Chapter 4. Each CArG box element present is annotated, though other features useful in




Synthetic 120bp aSMA CArG Box Probe (121 bp)
TGCCACCTGACGTCTAAGAAAACGCTAGCGGATGTACATCTGGATACATCTGGATGTCCCTATATGGACATCTGGATGTACATCTGGATACATCTAGATCTGCTCAC
ACGGTGGACTGCAGATTCTTTTGCGATCGCCTACATGTAGACCTATGTAGACCTACAGGGATATACCTGTAGACCTACATGTAGACCTATGTAGATCTAGACGAGTG









Synthetic 120bp cFOS CArG Box Probe (121 bp)
TGCCACCTGACGTCTAAGAAAACGCTAGCGGATGTACATCTGGATACATCTGGATGTCCATATTAGGACATCTGGATGTACATCTGGATACATCTAGATCTGCTCAC
ACGGTGGACTGCAGATTCTTTTGCGATCGCCTACATGTAGACCTATGTAGACCTACAGGTATAATCCTGTAGACCTACATGTAGACCTATGTAGATCTAGACGAGTG









Synthetic 16X cFOS CArG Box Probe (433 bp)
TAAACGCTAGCGGATGTCCATATTAGGTGGGAGTGGTTGATGCCCATATTAGGTCTATACTCCATTTGGCCATATTAGGCGCGATAGGCTGACAACCATATTAGGGG
ATTTGCGATCGCCTACAGGTATAATCCACCCTCACCAACTACGGGTATAATCCAGATATGAGGTAAACCGGTATAATCCGCGCTATCCGACTGTTGGTATAATCCCC
20 40 60 80 100
GTTTAACATTGAATCCATATTAGGAGCAAGGCACTTCCGGCCATATTAGGGGTATGGGAGGATCAACCATATTAGGCTTCTCCCTCACTCGCCCATATTAGGAACAA
CAAATTGTAACTTAGGTATAATCCTCGTTCCGTGAAGGCCGGTATAATCCCCATACCCTCCTAGTTGGTATAATCCGAAGAGGGAGTGAGCGGGTATAATCCTTGTT
120 140 160 180 200
TGGTTACTACACCATATTAGGTCGATACGTGAAACATCCATATTAGGGTCCAACGGTTGCCCACCATATTAGGAAGTGTTAAGTGTCTACCATATTAGGTCACCCCT
ACCAATGATGTGGTATAATCCAGCTATGCACTTTGTAGGTATAATCCCAGGTTGCCAACGGGTGGTATAATCCTTCACAATTCACAGATGGTATAATCCAGTGGGGA
220 240 260 280 300 320
AGGGCCGTCCATATTAGGTTCCCGGATATAAACGCCATATTAGGCCAGGTTGAATCCGCACCATATTAGGTTTGAAGCTACCATGGCCATATTAGGACATCTAGATC
TCCCGGCAGGTATAATCCAAGGGCCTATATTTGCGGTATAATCCGGTCCAACTTAGGCGTGGTATAATCCAAACTTCGATGGTACCGGTATAATCCTGTAGATCTAG




Figure B.3: Synthetically Designed 430bp CArG Box Probe with 16 repeats of a cFOS-
derived CArG Element. These interstitial sequences were generated randomly but




120bp aSMA CArG Box Probe (121 bp)
GCTTCCCAAACAAGGAGCAAAGACGGGCTGAAGCTGGCCGTTCACTCTAACACAACCATATAGGGACCTCAGCACAAAACTCTCTAATCTGGGTGGCCAGAGGCCTG
CGAAGGGTTTGTTCCTCGTTTCTGCCCGACTTCGACCGGCAAGTGAGATTGTGTTGGTATATCCCTGGAGTCGTGTTTTGAGAGATTAGACCCACCGGTCTCCGGAC










120bp cFOS CArG Box Probe (121 bp)
TGGCTGCAGCCGGCGAGCTGTTCCCGTCAATCCCTCCCTCCTTTACACAGGATGTCCATATTAGGACATCTGCGTCAGCAGGTTTCCACGGCCGGTCCCTGTTGTTC
ACCGACGTCGGCCGCTCGACAAGGGCAGTTAGGGAGGGAGGAAATGTGTCCTACAGGTATAATCCTGTAGACGCAGTCGTCCAAAGGTGCCGGCCAGGGACAACAAG









300bp aSMA CArG Box Probe (301 bp)
GGCTGGGCTTCTCCACTCTGGGTGGGTGGTGTCCCGGGAGGCTGAACGCTGAAGGGTTATATAGCCCCTTGCTCTGATCCCCTCCCACTCGCTTCCCAAACAAGGAG
CCGACCCGAAGAGGTGAGACCCACCCACCACAGGGCCCTCCGACTTGCGACTTCCCAATATATCGGGGAACGAGACTAGGGGAGGGTGAGCGAAGGGTTTGTTCCTC




120 140 160 180 200
TCCTCTGTTCTGCTCCCGAAACAGGAGGCAGCTCAGCTGCTTATGGGGATAAACATCCTAAGCCCTCAGAACAACTGCTCAAATGCC
AGGAGACAAGACGAGGGCTTTGTCCTCCGTCGAGTCGACGAATACCCCTATTTGTAGGATTCGGGAGTCTTGTTGACGAGTTTACGG
220 230 240 250 260 270 280 290 300





300bp cFOS CArG Box Probe (301 bp)
GTGCGAATGTTCGCTCGCCTTCTCTGCCTTTCCCGCCTCCCCTCCCCCGGCCGCGGCCCCGGTTCCCCCCCTGCGCTGCACCCTCAGAGTTGGCTGCAGCCGGCGAG
CACGCTTACAAGCGAGCGGAAGAGACGGAAAGGGCGGAGGGGAGGGGGCCGGCGCCGGGGCCAAGGGGGGGACGCGACGTGGGAGTCTCAACCGACGTCGGCCGCTC
20 40 60 80 100
CTGTTCCCGTCAATCCCTCCCTCCTTTACACAGGATGTCCATATTAGGACATCTGCGTCAGCAGGTTTCCACGGCCGGTCCCTGTTGTTCTGGGGGGGGGACCATCT
GACAAGGGCAGTTAGGGAGGGAGGAAATGTGTCCTACAGGTATAATCCTGTAGACGCAGTCGTCCAAAGGTGCCGGCCAGGGACAACAAGACCCCCCCCCTGGTAGA
120 140 160 180 200
CCGAAATCCTACACGCGGAAGGTCTAGGAGACCCCCTAAGATCCCAAATGTGAACACTCATAGGTGAAAGATGTATGCCAAGACGGG
GGCTTTAGGATGTGCGCCTTCCAGATCCTCTGGGGGATTCTAGGGTTTACACTTGTGAGTATCCACTTTCTACATACGGTTCTGCCC
220 230 240 250 260 270 280 290 300
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